

# AUTHOR INDEX

*Arthritis & Rheumatism*, Volume 46, Numbers 1-12, 2002

## A

- Aaron SL, 766  
Aarset H, 2816  
Abad LW, 2574  
Abatangelo G, 2262  
Abbal M, 1754  
Abbud-Lozoya K, 2260  
Abe Y, 1067  
Abeles M, 2983  
Abraham DJ, 1857  
Abramovicz D, 2121  
Abramson SB, 2831  
Abu-Shakra M, 1399  
Adams BS, 3340  
Adams ME, 1536  
Aganna E, 245, 2445  
Ahern MJ, 2538  
Ahmed S, 2079  
Ahn CW, 1714, 2990  
Aigner T, 1986, 2648  
Aita T, 2578  
Akagi M, 2486  
Akahoshi T, 2504  
Åkerström B, 259  
Åksentijevich I, 3340  
Al-Matar MJ, 2708  
Ala-Kokko L, 1086  
Alarcón GS, 561, 1413, 1969  
Albani S, 1937, 2721, 3015  
Albert DA, 1651, 1968  
Alcocer-Varela J, 1885  
Aliabadi P, 946, 1217  
Alibert O, 2039  
Allahabadia A, 3109  
Allam F, 175  
Alldersea J, 640  
Allegrì F, 1399  
Allotey RA, 245  
Alourfi Z, 2402  
Alten R, 1470  
Altman RD, 694  
Amano H, 1410  
American College of  
Rheumatology Audiovisual  
Aids Subcommittee, 1160  
American College of  
Rheumatology Subcommittee  
on Rheumatoid Arthritis  
Guidelines, 328  
Ames PRJ, 2686  
Amital H, 1689  
Amoura Z, 281, 1123  
Andersen GN, 1324  
Anderson JJ, 2410  
Anderson LG, 3103  
Andersson U, 2598  
André M, 2181  
Andreassen K, 1270  
Andrejevic S, 278  
Andresen J, 1965  
Andrews B, 2983  
Andriacchi TP, 2884  
Antonen J, 1696  
Antoniou J, 2087  
Aota K, 1585  
Appelboom T, 1470, 2249, 3301  
Apple R, 2320  
Aractingi S, 1039  
Arai K, 1683  
Arbel G, 3240  
Arbogast PG, 2195  
Arend WP, 3065  
Årlestig L, 3096  
Arlet Ph, 2762  
Arnaud M, 2051  
Arnesen E, 1270  
Arnett FC, 2678, 2829, 2928,  
2990  
Arntz OJ, 1661  
Arroyo RA, 1480  
Arrue P, 2762  
Asano M, 533  
Ashida Y, 1585  
Askanaase AD, 269, 2377  
Aslam A, 2827  
Assmann KJM, 1691  
Astudillo L, 2762  
Auger I, 929  
Auger M, 847  
Auleley GR, 1693  
Aurich M, 2903  
Austin F, 3340  
Austin HA, 995  
Aymard G, 1123  
Ayral X, 2613  
Azuma M, 1585  
Azzi A, 2262  
Babin-Chevaye C, 522  
Baca S, 1309  
Bacarese-Hamilton I, 2059  
Baccarani M, 2252  
Badley EM, 3331  
Badreddine R, 1410  
Bae EY, 1109  
Baeten D, 755, 2826  
Baethge BA, 1460  
Baggott JE, 1413  
Bajocchi GL, 3099  
Baker S, 2917  
Bakker AC, 1379, 1661  
Balada E, 1974  
Baldassare A, 2020  
Balestrieri G, 1399  
Baleva M, 1019  
Balow JE, 995, 1981, 3340  
Bambara LM, 451  
Banda NK, 3065  
Bank RA, 114  
Banki K, 175  
Bansal V, 2132  
Barbone F, 451  
Bardin T, 1643, 2039  
Bárdos T, 2207, 2465  
Bardy P, 1694  
Barnum SR, 934  
Baron G, 1693  
Baron JA, 2436  
Barozzi L, 2964  
Barr WE, 2917, 2983  
Barrett EM, 2010  
Barrett JH, 557, 632  
Barron K, 3340  
Barry F, 704  
Bartnik E, 2648  
Bartolomé MJ, 3290  
Barton A, 632  
Basel-Vanagaite L, 245  
Bathon JM, 1443  
Battafarano DF, 1480  
Bau B, 2648  
Baumann I, 191  
Baumer B, 1217  
Baynes JW, 114  
Bear MB, 614, 2838  
Beck S, 704  
Becker JC, 1470  
Behney KM, 2235  
Bélisle P, 3327  
Bell J, 632  
Bell P, 2410  
Ben Hadj Hmida Y, 280  
Ben Zaken C, 114  
Bendahian D, 774  
Bendele A, 3065  
Bendixsen S, 1270  
Bennett PH, 1729  
Bennett R, 1344  
Benson LL, 250  
Berckmans RJ, 2857  
Bergin I, 2524  
Bergman GA, 2884  
Bernabeu C, 1857, 2830  
Bernert RA, 1698  
Beroukas D, 202  
Berry C, 3015  
Bessard G, 1319  
Bessard J, 1319  
Bethel KJ, 2537  
Betta A, 451  
Bettica P, 3178  
Beuf O, 385  
Bevan MA, 2251  
Bezemer PD, 564  
Bianchi DW, 2538  
Biasi D, 451  
Biasini C, 1126  
Biedermann T, 2392  
Bienvenu J, 2181  
Bienvenu T, 2181  
Biggs J, 2301  
Bijlsma JWW, 114, 1784, 2893  
Billinghurst RC, 2087  
Bingham S, 837  
Bird H, 3143  
Bird L, 2972  
Bistoni F, 806  
Biswal S, 2884  
Bizri AR, 850  
Black C, 1857  
Blades MC, 824, 2109  
Blades S, 1210  
Blakely K, 1164  
Blanco-Gelaz MA, 2968  
Blank M, 1399, 1689  
Blaser S, 1291  
Blau E, 3041  
Bloch DA, 1014  
Block JA, 2020, 3185  
Block SR, 1162, 3102  
Blockmans D, 2121  
Blumenfeld Z, 2542  
Blüthner M, 1866  
Bodo M, 1086  
Boehnke M, 1620  
Boers M, 347, 899, 913, 2818,  
2847  
Boffa MC, 1019  
Bohland P, 2255  
Boiardi L, 3099  
Boileau C, 2637  
Boing AN, 2857  
Boivin GP, 1102  
Bollen ELEM, 2665  
Bollow M, 2392  
Bolon B, 1926, 2604, 3121  
Bombardier C, 436  
Bombardieri S, 1019  
Bona CA, 2748  
Bonaci-Nikolic B, 278  
Bonavita G, 3041  
Böni J, 2811  
Bonifacio S, 445  
Boomsma MM, 849  
Boonen A, 347, 913, 2847  
Booth DR, 245, 2445  
Boothby M, 514  
Borghi MO, 1602  
Bork D, 1309  
Borzi RM, 3201  
Bos JD, 2776  
Bos PK, 976  
Bosma GPTH, 2665  
Botstein GR, 1460  
Boumpas DT, 995  
Bourgeois P, 1408  
Bovenzi M, 451  
Bowman SJ, 209  
Bowness P, 2972  
Boyle DL, 3076  
Boyle WJ, 3121  
Bozonnat MC, 559  
Bradbury L, 1629  
Bradley JD, 100, 202, 1572  
Bramlage C, 149  
Brand DD, 1086  
Brandt KD, 100, 109, 1223

## B

- Brassard N, 2695  
 Braud VM, 2972  
 Bräuer R, 64  
 Braun J, 319, 841, 2822  
 Braun MM, 2565, 3151  
 Braun-Benjamin O, 114  
 Breban M, 840, 1405  
 Breedveld FC, 357, 366, 899, 1155, 2857  
 Bremme K, 1233  
 Brennan FM, 31  
 Bresnihan B, 574, 913, 2838  
 Breur GJ, 1947  
 Bridges SL Jr., 2045  
 Brinckerhoff CE, 13  
 Brinkman DMC, 1121  
 Briskin MJ, 874  
 British Paediatric Rheumatology Study Group, 2402, 2716, 3304  
 Brömme D, 663  
 Brooks P, 2301  
 Brooks SA, 1362  
 Brooks WH, 1412  
 Brophy S, 1629  
 Brorson SH, 2816  
 Brown J, 714  
 Brown MA, 632, 1629  
 Brown S, 420  
 Brown SL, 2565, 3151  
 Brown VB, 1390  
 Brown WM, 2132  
 Brownfield A, 640  
 Bruce B, 2320  
 Bruhlmann P, 2808  
 Brummendorf TH, 2911  
 Bruner GR, 428  
 Brunner HI, 436  
 Brush M, 2917  
 Bruynesteyn K, 913  
 Bryant LR, 1698  
 Bucher W, 2543  
 Buckley C, 2109  
 Bucknall RC, 1351  
 Buckner JH, 5, 238  
 Buckwalter KA, 109  
 Budde M, 976  
 Budgen A, 3168  
 Budhai L, 1554  
 Bugawan T, 2320  
 Bukhari M, 906  
 Bukilica M, 278  
 Bultink IEM, 848  
 Bunce M, 209  
 Burant CJ, 2429  
 Burgos-Vargas R, 1885  
 Burkhardt H, 2339  
 Burma M, 83  
 Burmester GR, 149, 2160  
 Burt RK, 2917  
 Burwinkle T, 714  
 Busby WH Jr., 694  
 Bush KA, 802  
 Buskila D, 845  
 Busso N, 1371, 2268  
 Buurman SWM, 2794  
 Buyon JP, 202, 269, 1127, 1572, 2377  
 Buzio C, 1595
- C**
- Cabral DA, 2708  
 Cachot S, 1319  
 Cacoub P, 2828, 3317  
 Cahue S, 2632  
 Caidahl K, 1324  
 Cailleau-Moindrault S, 2039  
 Calabrese LH, 585, 1309, 2020  
 Caldwell J, 1460, 2020  
 Calin A, 1629  
 Cáliz R, 556  
 Callan MFC, 1763  
 Callebert J, 1643  
 Cambon-Thomsen A, 1754  
 Cambridge G, 2673  
 Campagnuolo G, 1926, 3121  
 Camps MT, 1019  
 Cannell P, 2301  
 Cannon GW, 1075, 1443, 2225  
 Cantagrel A, 1754, 2051  
 Cantini F, 2964, 3099  
 Cantor RM, 2678, 2928  
 Carlson CS, 1956, 2349  
 Carlson P, 250  
 Carmody EE, 1298  
 Carmona L, 1415  
 Carpentier PH, 1319  
 Carr A, 1780  
 Carreiro M, 2762  
 Carrero H, 3340  
 Carson DA, 2867  
 Casali B, 3099  
 Casciola-Rosen L, 1873  
 Case JP, 3185  
 Caspi D, 2264, 2571  
 Catanoso MG, 3099  
 Caterson B, 124, 1544, 2658  
 Cattani D, 2181  
 Cattaneo R, 2121  
 Cattini L, 3201  
 Cavill D, 1572  
 Cawston TE, 961  
 Çeliker MY, 3361  
 Cerejo R, 2632  
 Cerhan JR, 83, 3104  
 Cernanec J, 968  
 Ceruti R, 1416  
 Cervera R, 1019, 2121, 3283  
 Cha S, 1390  
 Chae JJ, 3340  
 Champy R, 1643  
 Chan EKL, 726  
 Chan KW, 1003  
 Chang DM, 2924  
 Chang L, 818  
 Chang YH, 276  
 Channin D, 2632  
 Chapman K, 1519, 1780  
 Chapuy-Regaud S, 2051  
 Charles P, 1693, 2259  
 Charlionet R, 1196  
 Chauvet E, 2762  
 Chen AC, 3212  
 Chen CJ, 2678, 2928  
 Chen J, 514  
 Chen M, 2486  
 Chen Q, 130  
 Chen Y, 514, 1857  
 Cherin P, 467  
 Cheung N, 3143  
 Chiorazzi N, 2598  
 Chiou HL, 276  
 Chiu P, 766  
 Chizzolin C, 1602  
 Cho CS, 42, 1109, 1202  
 Cho H, 793  
 Cho ML, 42, 1202  
 Choi HK, 1309, 1714  
 Choy EHS, 3143  
 Christgau S, 21, 2613, 2847  
 Christian HC, 2765  
 Chu WS, 2189  
 Chung JB, 1651, 1968  
 Chung M, 1536  
 Churchill M, 1164  
 Ciancio G, 553, 2964  
 Cicuttini FM, 2065  
 Cid MC, 1309  
 Ciesielski CJ, 31  
 Cisternas M, 3107  
 Clague R, 837  
 Clark IM, 961  
 Clarke AE, 3327  
 Clarke S, 640  
 Clauw DJ, 1136, 1333  
 Clements PJ, 2983  
 Clemmons DR, 694  
 Cline G, 3178  
 Coblyn J, 3136  
 Cohen H, 845  
 Cohen P, 1309  
 Cohen PL, 1840  
 Cohen S, 614, 748, 1470  
 Cohen Tervaert JW, 849, 1894  
 Coimbra IB, 404  
 Colden-Stanfield M, 545  
 Cole AA, 2349, 2903  
 Collier DH, 2410, 2983  
 Conaghan PG, 1970, 1971  
 Condemi JJ, 748  
 Confort-Gouny S, 774  
 Connolly JE, 1362  
 Connolly MK, 1857  
 Conrad K, 1185  
 Constantin A, 1754  
 Conti F, 3110  
 Coon CI, 3230  
 Cooper GS, 1830, 1840  
 Cornélis F, 2039  
 Corps AN, 3034  
 Corr M, 2867  
 Cortés F, 1974  
 Costedoat-Chalumeau N, 1123  
 Costouros N, 3015  
 Cosyns JP, 2121  
 Cotter FE, 2445  
 Coxon A, 2604  
 Coyte PC, 3331  
 Cozzone PJ, 774  
 Cracowski JL, 1319  
 Crane AM, 1629  
 Crane M, 995  
 Cremer MA, 1086  
 Criswell LA, 83, 3104  
 Crofford LJ, 1136, 1980  
 Croft D, 2059  
 Croft JD Jr., 1407  
 Cronin C, 92  
 Crosby MB, 598  
 Crowl RM, 404  
 Crowson CS, 625, 2287, 2294  
 Csernok E, 2384  
 Csuka ME, 2410  
 Cuchacovich R, 1973  
 Cueto P, 1416  
 Cummings SR, 1773  
 Cupples LA, 946  
 Cupps TR, 3108  
 Currie MG, 1789  
 Curry VA, 3034  
 Curtis CL, 124, 1544  
 Cush J, 614
- D**
- D'Agostino MA, 840  
 Dahlqvist SR, 3096  
 Dal Cin E, 3378  
 Dalbeth N, 1763  
 Dale K, 986  
 Dalgin P, 748  
 Damoiseaux J, 849  
 Danielli MG, 2121  
 Daniels M, 92  
 Danning CL, 995  
 Darbois Y, 1123  
 Daurès JP, 559  
 David CS, 2465  
 Davidson A, 1554  
 Davidson B, 209  
 Davies KA, 1028  
 Davies ML, 209  
 Davis JC Jr., 3251  
 Davis JM III, 2257  
 Davis MDP, 2257  
 Davis P, 766  
 Dawes PT, 640  
 Day MJ, 1671  
 Dayer JM, 574, 1602  
 D'Cruz DP, 2121, 3392  
 De Bandt M, 522  
 De Benedetti F, 232, 2402, 2721, 3015  
 De Candia A, 2029  
 de Groot PG, 1019  
 de Jong Z, 274  
 de Keyser F, 606, 755, 1185, 2826  
 de Kleer I, 3015  
 De Luigi J, 1416  
 de Ramon Garrido E, 2121  
 de Rie MA, 2776  
 de Toma C, 2039  
 De Vita S, 2029, 2252  
 de Vries N, 921  
 de Vries RRP, 899  
 Deeb J, 1410  
 DeGroot J, 114, 976, 3212

- Dekker J, 1784, 2816  
 Del Carlo M Jr., 394, 1528, 2349  
 Del Papa N, 1602  
 del Rincón I, 1480  
 Delgado Alves J, 2686  
 Delisle MB, 2762  
 Dell'Antonio G, 3378  
 Delmas PD, 21, 2613  
 Deloria LB, 2495  
 Delpech M, 2181  
 Delporte C, 2249  
 Demaille J, 2785  
 DeMarco PJ, 2983  
 Dement JM, 1840  
 Demissie S, 946  
 Demols P, 3301  
 den Broeder AA, 1691  
 Dent CM, 1544  
 Dent P, 3340  
 Deodhar A, 1344  
 Depresseux G, 2121  
 Derksen RHWM, 1019  
 Dermer ME, 1123  
 Di Battista JA, 494  
 Dias AAM, 2453  
 Dickler H, 1309  
 Didelot MN, 2785  
 Diegel RJ, 1362  
 Dietz F, 1460, 2020  
 Dieudé M, 2695  
 Dieudé P, 2039  
 Dijkmans BAC, 347, 564, 848, 2776  
 Dijkstra bloem HM, 1125, 1242  
 Dillingham MF, 2884  
 Dinant HJ, 2776  
 Direskeneli H, 2121  
 Distler O, 1978  
 Dixon K, 704  
 Dobbins DE, 1075, 2225  
 Dodé C, 2181  
 Doherty M, 3386  
 Donn RP, 2402, 2716, 3304  
 Donohue S, 2686  
 Dooley MA, 1830, 1840  
 Doran MF, 625, 2287, 2294  
 Dörner T, 1233, 2160  
 Dou X, 1857  
 Dougados M, 840, 1693, 2613  
 Dowling B, 1519, 1780  
 Downie-Doyle S, 1694  
 Doyle DV, 92  
 Dracheva SV, 2225  
 Driss F, 522  
 Dryburgh N, 2476  
 Duhaut P, 3317  
 Dunlop DD, 2632  
 Dunn G, 1729  
 Dunstan CR, 785  
 Durante E, 553  
 Duryea D, 2604  
 Duthilleul P, 1127  
 Dziewczopolski W, 1744
- E**
- Easley KA, 1309  
 Eberhardt K, 2310
- Ebstein RP, 845  
 Echols J, 934  
 Eckhoff PJ, 1164  
 Eckstein F, 2073  
 Edberg JC, 2132  
 Edmonds J, 913  
 Edwards DR, 961, 1789  
 Edwards ET, 2565, 3151  
 Edwards JCW, 1210, 2673, 3105  
 Edwards SW, 1351  
 Egeland T, 986  
 Eguchi K, 1411  
 Ehrenstein MR, 2673  
 Eisen G, 2195  
 Eisenstein SM, 2658  
 El-Gabalawy H, 2587  
 El-Shabrawi Y, 2821  
 Elkayam O, 2571  
 Elkon KB, 1504  
 Elliott SF, 3230  
 Ellman MH, 844, 2410  
 Emery P, 366, 489, 557, 837, 1470, 1970, 1971, 2034, 2814, 3168, 3349, 3398  
 Emmi L, 445  
 Emons V, 3026  
 Endo N, 1683  
 Ene-Stroescu D, 844  
 English A, 3349  
 Englund P, 1044  
 Engström A, 2339  
 Enyedy EJ, 163  
 Enzer I, 1729  
 EPISER Study Group, 1415  
 Erkan D, 1127  
 Erlandsson Harris H, 2598  
 Erlich H, 2320  
 Eronen M, 562  
 Escalante A, 1480  
 Escolar G, 3283  
 Espehaug B, 675  
 Espinola RG, 545  
 Espinosa G, 3283  
 Espinoza LR, 1973  
 Estrada E, 250  
 Estrada J, 2604  
 Ettlinger R, 1460  
 European Consortium on Rheumatoid Arthritis Families, 2039  
 European Group of Clinical Investigators, 2838  
 Euro-Phospholipid Project Group, 1019  
 Eymard B, 467  
 Eyre S, 632  
 Eystathioy T, 726
- F**
- Fabian D, 704  
 Facchini A, 1602, 3201  
 Fahmi H, 494  
 Fairlie DP, 2476  
 Falch JA, 1720  
 Falkenberg C, 259  
 Fan FZ, 1735  
 Fanin R, 2029, 2252
- Faour WH, 494  
 Fardellone P, 1196  
 Farmer KM, 802  
 Farnetti E, 3099  
 Farrow S, 3143  
 Fasanmade AA, 1451  
 Fass DN, 279  
 Fauré S, 2039  
 Faust J, 3083  
 Fautrel B, 1408  
 Fava RA, 1362  
 FcγRIIIa-SLE Meta-Analysis Investigators, 1563  
 Fearon U, 837  
 Feige U, 1926, 2604, 3121  
 Feighery C, 2445  
 Feist E, 2160  
 Feldman A, 704  
 Feldman BM, 436  
 Feldmann M, 31  
 Fellenberg J, 2911  
 Felson DT, 779, 946, 1217, 1773, 2817  
 Felt J, 1164  
 Fenwick SA, 3034  
 Ferland D, 1309, 3327  
 Fermor B, 968  
 Fernandez A, 1164  
 Fernández-Morera JL, 2968  
 Fernández-Nebro A, 1019  
 Ferraccioli G, 2029, 2252  
 Ferrara GB, 553  
 Ferrero ME, 3378  
 Ferri C, 2262  
 Ferro D, 3110  
 Fesmire J, 2957  
 Fessler BJ, 1309  
 Feussner JR, 2265  
 Fiehn C, 2255  
 Fife M, 75  
 Fife R, 748  
 Figarella-Branger D, 774, 2535  
 Filipowicz-Sosnowska A, 1744  
 Finck BK, 21, 1443  
 Findell PR, 1857  
 Fink C, 420  
 Finlay DR, 1857  
 FIN-RACo Trial Group, 894  
 Firestein GS, 298, 818, 859, 3076, 3106  
 Fisher CU, 163  
 Fisher J, 640  
 Fisher S, 75  
 Fitzgerald AA, 766  
 Flamm SD, 1634  
 Flannery CR, 124, 1544  
 Flatø B, 986  
 Fleck M, 934  
 Fleischmann RM, 1443, 2020  
 Flores JA, 2545  
 Florey O, 3026  
 Flower RJ, 2765  
 Flugsrud GB, 675  
 Flynn JA, 1309  
 Foecking MF, 1264  
 Folsom AR, 83  
 Foltz V, 1408
- Fonseca JE, 1210  
 Font J, 1019, 2121, 3283  
 Ford DK, 2259  
 Førre Ø, 986, 1614  
 Forsyth CB, 2368  
 Fortin PR, 1309, 2695, 3327  
 Fossati G, 1351  
 Fossel AH, 2436, 3327  
 Fournié B, 2051  
 Foxall H, 3109  
 Foxwell BMJ, 31  
 Frances C, 1408  
 Franklyn JA, 3109  
 Franssen CFM, 1894  
 Franzen P, 894  
 Fraser P, 1171, 2280  
 Frassi M, 1126  
 Frauscher F, 647  
 Freed LE, 2524  
 Frémeaux-Bacchi V, 2828  
 French Hereditary Recurrent Inflammatory Disorder Study Group, 2181  
 Frenkel J, 2794  
 Fries JF, 2320  
 Fryer AA, 640  
 Fukazawa T, 1242  
 Fulgenzi A, 3378  
 Funa K, 507  
 Furie R, 1554, 2598  
 Furst DE, 1460, 2020, 2410, 2983  
 Furumitsu Y, 1489  
 Furuya T, 2225
- G**
- Gabriel SE, 625, 2287, 2294  
 Gabrielli A, 1602  
 Gaipl U, 191  
 Gál I, 2207  
 Gale D, 1217  
 Galeazzi M, 1019, 2121  
 Gallart T, 3283  
 Galle PR, 3083  
 Garcia Kutzbach A, 1885  
 Garcia-De La Torre I, 1885  
 Garmong A, 694  
 Garner P, 21, 2613, 2847  
 Garred P, 555  
 Garrod T, 3143  
 Gatti R, 1595, 3201  
 Gaudet R, 2445  
 Gaudiano C, 553  
 Gay RE, 1512, 2811  
 Gay S, 52, 64, 934, 1413, 1512, 1978, 2811  
 Gaydos CA, 1056  
 Gebe J, 5  
 Gebhard PM, 2648  
 Gelber AC, 1873  
 Genereau T, 467  
 Genina O, 1689  
 Genot E, 2059  
 Genovese MC, 1014, 1443  
 Genth E, 1866  
 George AJT, 2109  
 Gepstein A, 3240

- Gergely P Jr., 175  
 Gershon SK, 2565, 3151  
 Gervais R, 1980  
 Getting SJ, 2765  
 Geusens P, 2847  
 Gharavi AE, 545, 850  
 Gherardi RK, 2535  
 Ghillani P, 3317  
 Ghosh S, 385  
 Giacosa R, 1595  
 Giannini EH, 1851  
 Giannoni F, 2721  
 Gibbon WW, 366, 489, 1970  
 Gibbs JP, 1460  
 Gibofsky A, 1163  
 Gilbert D, 1196  
 Gilburd B, 1399  
 Gilkeson GS, 598, 1830, 1840  
 Gillaspay E, 3386  
 Gilliland WR, 163  
 Gilson G, 280  
 Gineyts E, 21  
 Ginzler EM, 1820, 2678, 2928  
 Girschick HJ, 1255  
 Giuggioli D, 2262  
 GL701 Lupus Study Group, 1820  
 Glant TT, 2207, 2465  
 Glass DN, 1851  
 Glass J, 1980  
 Glazier RH, 3331  
 Gluck O, 748  
 Glück T, 2255  
 Goater JJ, 2095, 2514  
 Goedkoop AY, 2776  
 Goldbach-Mansky R, 3340  
 Goldberg VM, 2079  
 Golden HE, 1460  
 Goldenberg D, 2546  
 Goldring MB, 2095  
 Goldring SR, 663, 3055  
 Goldsmith D, 3340  
 Goldstein R, 2678, 2928  
 Golmia RP, 3390  
 González S, 2968  
 Goodson NJ, 2010  
 Gøransson L, 1228  
 Gordon C, 209, 3109  
 Gordon TP, 202, 1572, 1694  
 Gorelick KJ, 1820  
 Gorla R, 1126  
 Goronzy JJ, 457, 3113  
 Goto H, 1489  
 Gough SCL, 3109  
 Goulding NJ, 1210  
 Gourley MF, 995  
 Gracely RH, 1333  
 Grammer AC, 1255, 1417  
 Granfors K, 606, 2172  
 Grant EP, 874  
 Grasland A, 277  
 Gratacós J, 3392  
 Grateau G, 2181  
 Graudal HK, 555  
 Graudal NA, 555  
 Gravalles EM, 663, 1171, 3055  
 Gray-McGuire C, 428  
 Green P, 31  
 Green WR, 1056  
 Greene JM, 3103  
 Greene MH, 3151  
 Greenstein AS, 2814  
 Greenwald R, 3361  
 Gregersen PK, 582  
 Greidinger EL, 1264  
 Griffin M, 2195  
 Griffith JF, 1914  
 Griffiths B, 557, 913  
 Griffiths MM, 1075, 2225  
 Gripenberg-Gahmberg M, 894  
 Gris JC, 1019  
 Grodzinsky A, 2524  
 Grom AA, 3010  
 Gromnica-Ihle E, 64, 1019  
 Gross G, 149  
 Gross WL, 1309, 2384  
 Grossin M, 522  
 Grossman C, 175  
 Grossman JM, 2678, 2928  
 Grote LA, 1947  
 G'Sell P, 100  
 Guadagnoli E, 2436  
 Guilak F, 420, 968  
 Guillemin L, 1309  
 Guis S, 774, 2535  
 Gül A, 2121  
 Gulko PS, 1075, 2225  
 Gursel I, 2219  
 Gutierrez-Ramos JC, 874  
 Gutsch D, 1282
- ## H
- Haag J, 2648  
 Hachulla E, 1019, 1039  
 Hack CE, 2857  
 Hadley S, 1164  
 Hahn BH, 565, 2678, 2928  
 Hahn W, 793  
 Haire C, 1164  
 Haisch A, 149  
 Hakendorf P, 2538  
 Häkkinen A, 274  
 Hale G, 1974  
 Halpern E, 647  
 Halse JJ, 1720  
 Ham KD, 1956  
 Hamburger MI, 2543  
 Hamel JC, 726  
 Hamilton JA, 2268  
 Han J, 250  
 Han Z, 818  
 Handel M, 2301  
 Hanly JG, 2695  
 Hannonen P, 274, 894  
 Hansen A, 2160  
 Hanyu T, 1683  
 Haqqi TM, 2079  
 Haralambous S, 785  
 Hardy MM, 1789  
 Harley JB, 428, 2132, 2678, 2937  
 Harrall RL, 3034  
 Harris EN, 545  
 Harris MD, 1698  
 Harris RE, 2020  
 Harrison BJ, 906, 3312  
 Hart CJ, 92  
 Hart DA, 2495  
 Hart DJ, 3178  
 Harvey B, 3331  
 Harwood JL, 1544  
 Hase K, 2330  
 Hasegawa J, 2878  
 Hashimoto H, 735, 1242, 1410, 2946  
 Hashiramoto A, 2225  
 Haskard DO, 3026  
 Hastie T, 2884  
 Hatta Y, 1242  
 Haugeberg G, 1720  
 Häupl T, 149  
 Hausfater P, 2181  
 Havelin LI, 675  
 Hawker GA, 3331  
 Hawkins PN, 245, 2445, 2571  
 Hayashi Y, 1585  
 Hayashida K, 2878  
 Hayer S, 785  
 Hayes AL, 31  
 Hays E, 3230  
 Hazes JMW, 274, 357, 899  
 Hazleman BL, 1974, 3034, 3143  
 He QW, 494  
 He X, 3369  
 Heaton T, 1671  
 Heberer M, 2524  
 Heilman DK, 100  
 Helliwell PS, 3098, 3168  
 Hellmann DB, 1056, 1309  
 Hellmich B, 2384  
 Helsen MMA, 1379  
 Helve T, 894  
 Helweg G, 647  
 Henmi Y, 1489  
 Hepkema BG, 1125  
 Herlyn K, 2410  
 Hermann J, 2821  
 Hernández-Rodríguez J, 1309  
 Hernanz S, 1974  
 Herold M, 647  
 Herrick AL, 3312  
 Herrmann M, 191  
 Herson S, 467  
 Herssens A, 755  
 Heuvelmans-Jacobs M, 1379  
 Heward JM, 3109  
 Hider SL, 2245, 3312  
 Hill CL, 779  
 Hill M, 2828  
 Hillson J, 1997  
 Hilton RC, 2245  
 Hirata D, 3388  
 Hirata G, 379  
 Hirose J, 3218  
 Hirsch BE, 3168  
 Hirsch R, 1102  
 Hirst TR, 1671  
 Hiscock J, 202, 1572  
 Hitchon C, 2587  
 Hitman GA, 245, 2445  
 Ho CTK, 1003  
 Ho SH, 793  
 Hochberg MC, 1773  
 Hodler J, 2808  
 Hoffman DB, 1309  
 Hoffman GS, 1309, 1634  
 Hoffman H, 3340  
 Hoffman RW, 1264  
 Hofmann SR, 3340  
 Hogan A, 961  
 Hokonohara M, 2539  
 Holers VM, 3065  
 Holman AJ, 3390  
 Holmberg CL, 2172  
 Holmdahl R, 259, 2339  
 Holmes A, 1857  
 Holmes T, 2320  
 Homik J, 766  
 Hong DLT, 1123  
 Hoppin JA, 1840  
 Horai R, 533  
 Horiuchi H, 1922  
 Horiuchi T, 3259  
 Hoshikawa H, 2486  
 Hou WS, 663  
 Houben H, 913  
 Houssiau FA, 1019, 2121  
 Houten SM, 2794  
 Howell DS, 694  
 Hsia EC, 1651  
 Hsieh YH, 1056  
 Hu YL, 2604  
 Huang D, 1536  
 Huang L, 2330  
 Huang W, 1554  
 Hübscher O, 561  
 Huebner JL, 420  
 Hughes CE, 124, 1544  
 Hughes GRV, 1019, 3283, 3392  
 Hugot JP, 1405  
 Hui ACF, 1914  
 Huitema MG, 1894  
 Huizinga TWJ, 899, 1125, 1155, 2665, 3107  
 Hukkanen M, 953  
 Hulkkonen J, 1696  
 Hull KM, 2189  
 Hülsemann JL, 1965  
 Humbel RL, 280, 1185  
 Humphreys-Beher MG, 1390  
 Hunder GG, 1309  
 Hurd E, 614, 2020  
 Hurme M, 1696  
 Hurwitz EL, 2983  
 Husby G, 1228, 2816  
 Husni ME, 1171  
 Hutchinson C, 2245  
 Hutchinson D, 640  
 Huynh LH, 3065  
 Hwang SY, 1109, 1202  
 Hynds DL, 2658
- ## I
- Ibrahim SA, 2429  
 Ida H, 1411  
 IDEC-131 Lupus Study Group, 3251  
 Ihn H, 2421



Ikeda K, 2946  
Ikeda Y, 2148  
Illei GG, 995  
Ilonen J, 894  
Imagawa T, 1102  
Imai T, 2878  
Imamura K, 3273  
Imanaka H, 2539  
Imbert B, 1319  
In BH, 1714  
Inaba M, 1489  
Ingegnoli F, 824  
Ingelmo M, 1019, 3283  
Inobe M, 1094  
Inohara N, 3041  
Inoue H, 735  
Inoue M, 2504  
International Network for the  
Study of Systemic  
Vasculitides (INSSYS), 1309  
Inui K, 1489  
Ioannidis JPA, 741, 1563  
Ioannou Y, 3143  
Isaacs JD, 557, 837, 1974  
Isenberg DA, 1997, 2673, 2686,  
3143  
Ishii KJ, 2219  
Ishimura E, 1489  
Islam N, 2079  
Ito H, 2105  
Iuliano L, 3110  
Iwahashi M, 2578  
Iwakura Y, 533  
Iwamoto M, 3388  
Iwamoto Y, 379

## J

Jablonska S, 1978  
Jack A, 3349  
Jackman JK, 1857  
Jacobelli S, 3107  
Jacobi AM, 2160  
Jacobs JP, 3136  
Jacobs P, 347  
Jacobsen S, 1019  
Jacobsson L, 1729  
James JA, 2937  
James WH, 563  
Janin A, 1039  
Jansen MD, 1125, 1242  
Jara LJ, 1885  
Jawaheer D, 582  
Jendro MC, 1965, 2260  
Jenq G, 2045  
Jeong JG, 793  
Jhangri GS, 766  
Jiang Y, 3361  
Jiménez SA, 404, 683, 2410  
Joe B, 1075, 2225  
John S, 632  
Johnson DA, 3103  
Johnson KL, 2538  
Johnson RW, 1976  
Johnson WEB, 2658  
Johnston V, 986  
Jolivet M, 2051  
Jones EA, 3349

Jones J, 3340  
Jones KD, 1344  
Jones RA, 3349  
Jones SA, 124  
Jönsson L, 2310  
Joosten LAB, 1379, 1661, 3055  
Jordan JM, 2280  
Jorgensen C, 559  
Joseph L, 3327  
Joske D, 2301  
Jouglard J, 774  
Jouzeau JY, 2637  
Joven B, 3392  
Joyal SV, 2545  
Judex M, 52, 934  
Julkunen H, 562  
Jun JB, 1504  
Jundt G, 2524  
Jurik AG, 555  
Jüsten HP, 52

## K

Kaburaki J, 2148  
Kahn C, 2546  
Kaine J, 2020  
Kaipiainen-Seppänen O, 894  
Kaiser M, 457  
Kaiser MJ, 559  
Kajihara M, 2148  
Kalajdzic T, 494  
Kalden JR, 191, 2339  
Kalla AA, 1407  
Kallenberg CGM, 1125, 1242,  
1894  
Kalsbeek-Batenburg EM, 1498  
Kalsi J, 2678  
Kalunian KC, 1309, 2678, 2928,  
3251  
Kamath RV, 2207  
Kammer GM, 1139  
Kamogawa J, 1067  
Kanamaru Y, 735  
Kanbe K, 130  
Kaneda K, 2946  
Kaneko M, 373  
Kang AH, 1086, 3369  
Kaplan M, 1282  
Kaplanski G, 2535  
Kaps C, 149  
Karassa FB, 1563  
Karenko L, 1061  
Karim Z, 1971  
Karin M, 818  
Karlson E, 2280  
Karr R, 694  
Kastner DL, 2189, 3340  
Katakura S, 1102  
Katholi M, 269, 2377  
Kato H, 1242  
Katz BP, 100, 109, 1223  
Katz JN, 2436, 3136, 3327  
Kaufman KM, 2132  
Kaufman S, 2604  
Kautiainen H, 894  
Kavanaugh A, 1451, 2547  
Kawai S, 2504, 3159  
Kawakami Y, 2148, 2742  
Kawanaka N, 2578  
Kawashima M, 2541, 2578  
Kazzam E, 1324  
Kehayias JJ, 2574  
Keijsers V, 1125  
Kekow J, 843  
Kelley VR, 3083  
Kellner U, 843  
Kelly JA, 2132, 2937  
Kelly MA, 3109  
Kent PD, 2257  
Keystone EC, 1443, 1451  
Keyszer G, 663  
Khalil I, 850  
Khalkhali-Ellis Z, 2263  
Khamashta MA, 1019, 3283,  
3392  
Khan MA, 606  
Khanna D, 565  
Kikuchi Y, 3259  
Kilpatrick J, 2937  
Kim G, 1504  
Kim HA, 1986  
Kim HY, 42, 1109, 1202  
Kim J, 1109  
Kim JM, 793  
Kim S, 793  
Kim SH, 1109, 1202  
Kim SK, 2928  
Kim WU, 42, 1109, 1202  
Kimberly RP, 2132  
Kimoto M, 3259  
Kimura K, 2742  
King JB, 420  
Kington R, 2280  
Kinsey SE, 3349  
Kirchner T, 191  
Kirdaite G, 1371  
Kirkham BW, 802  
Kishimoto T, 3143  
Kissin EY, 3000  
Kitasato H, 2504  
Kjeldsen E, 1270  
Klareskog L, 1044  
Klashman D, 1309  
Klassen L, 1164  
Klauser A, 647  
Klein MJ, 663, 2453  
Klinman DM, 2219  
Klintland N, 1324  
Klippel JH, 995  
Kluve-Beckerman B, 1905  
Knecht H, 2073  
Knight TS, 714  
Knijff-Dutmer EAJ, 1498  
Knorr T, 2648  
Knowler WC, 1729  
Koarada S, 3259  
Kobayashi H, 1094  
Kobayashi S, 1922  
Kobelt G, 2310  
Kodera T, 2748  
Koeleman BPC, 1614  
Koerts J, 1498  
Kogure T, 2946  
Kojima K, 3273  
Koki A, 1789

Kokkola R, 2598  
Kolb SA, 2811  
Koldingsnes W, 1228  
Koller T, 2339  
Kollias G, 785  
Kollnberger S, 2972  
Kolowos W, 191  
Komarow H, 3340  
Kon S, 1094  
Koné-Paut I, 2785  
Kontopoulou-Griva I, 1019  
Kontinen YT, 953  
Koopman WJ, 1413  
Korn JH, 2410, 3000  
Korpela M, 894  
Koshino T, 1813  
Koshy PJT, 961  
Koski J, 894  
Kosmorsky G, 1309  
Kostenuik PJ, 3121  
Kouri JB, 2260  
Kovacs B, 276  
Kowal-Bielecka O, 1978  
Kowalczewski J, 1744  
Koyama A, 2141  
Kozak-Ribbens G, 774  
Kraan MC, 366, 1121, 2034,  
2776, 2857  
Kraetsch HG, 2339  
Kramer IJM, 2059  
Kraus D, 3065  
Kraus VB, 420  
Krause A, 1177  
Kremer JM, 614, 2257  
Kriegsmann J, 3083  
Krishnan S, 163  
Kruithof E, 755  
Kubo M, 2421  
Kucera P, 1371  
Kuchen S, 1413  
Kuenzler P, 1512  
Kuettner KE, 2903  
Kuffner T, 2045  
Kuipers JG, 2260  
Kuis W, 2794  
Kuivaniemi H, 3041  
Kullmann F, 52, 934  
Kumeda Y, 1489  
Kunz A, 1820  
Kuo TM, 276  
Kuroiwa T, 995  
Kurowska M, 1744  
Küster RM, 1620  
Kusunoki N, 3159  
Kuwana M, 2148, 2742  
Kvien TK, 1720  
Kwiatk R, 1129  
Kwiatkowski D, 3304  
Kwok CK, 2429, 3103  
Kwok WW, 5, 238  
Kyogoku C, 1242

## L

La Cava A, 2721, 3015  
La Tourette AM, 3136  
Laasonen L, 894  
Labrador M, 1974, 3290

- Labrador-Horrillo M, 2547  
 Lachmann HJ, 2445, 2571  
 Lafeber FPJG, 114, 2893  
 Laforet P, 467  
 Lafyatis R, 3000  
 Lagerstedt A, 1061  
 Lahat N, 3240  
 Lahita RG, 1133, 1820  
 Laippala P, 1696  
 Lajeunesse D, 1804  
 Lakos G, 1019  
 Lally E, 2983  
 Lamb R, 2402  
 Lan JL, 2924  
 Lanchbury J, 75  
 Landewé RBM, 347, 2847  
 Landis RC, 3026  
 Lane KA, 109, 1223  
 Lane NE, 1, 385, 1292, 1773  
 Lang P, 2884  
 Lang S, 785  
 Lang T, 1292  
 Lange C, 1196  
 Lange N, 1371  
 Langefeld CD, 2132  
 Langford CA, 2254  
 Langlands B, 2301  
 Lard LR, 899, 3107  
 Larsson A, 259  
 Larsson P, 1233  
 Lasbleiz S, 2039  
 Lassus J, 953  
 Lau CS, 556, 1003, 2678, 2928  
 Laufer S, 1804  
 Launay D, 1039  
 Lauterbach K, 2867  
 Lauwers-Cancès V, 1754  
 Laval S, 632  
 LaValley MP, 779  
 Lawrence R, 2280  
 Lawson TM, 2251  
 Laxer RM, 1291  
 Le T, 3015  
 le Cessie S, 357  
 Le Danff C, 1039  
 Le Fur Y, 774  
 Le Loët X, 1196  
 Leandro MJ, 2673  
 Leask A, 1857  
 LeClercq S, 766  
 Lecron JC, 2181  
 Lee CG, 2235  
 Lee D, 632  
 Lee HC, 1714  
 Lee JH, 2565  
 Lee L, 2109  
 Lee LA, 2377  
 Lee RB, 3190  
 Lee SH, 42, 1714  
 Lee SK, 1714  
 Lee SS, 1202  
 Lee WK, 1109  
 Lee YL, 276  
 Lee YW, 793  
 Leff R, 1164  
 Leger JM, 3317  
 Lehman TJA, 845  
 Leirisalo-Repo M, 654, 894  
 LeLorier J, 3046  
 Lemaire R, 3000  
 Lems WF, 848  
 Leon M, 1470  
 Lepecuchel L, 929  
 Lesage S, 1405  
 Lester S, 1694  
 Letourneur O, 2051  
 Levy D, 946  
 Levy R, 663  
 Levy Y, 1689, 2121  
 Lewis C, 75  
 Li J, 2598  
 Li TF, 953  
 Li W, 663, 1217  
 Liang MH, 2280, 3327  
 Lidove O, 3317  
 Lie BA, 1614  
 Lien G, 986  
 Liepnieks JJ, 1905  
 Liljeström M, 953  
 Limaye V, 1694  
 Limburg PC, 1894  
 Lin HY, 2924  
 Lindal S, 1228  
 Linde HJ, 2255  
 Lindgren BR, 1956  
 Lindgren P, 2310  
 Lindsley H, 1460  
 Lingard EA, 2436  
 Linghult S, 3096  
 Link TM, 385  
 Linn-Rasker S, 3107  
 Lioté F, 1643  
 Liotta M, 3015  
 Lipnick R, 3340  
 Lipsky PE, 1155, 1255, 1417, 1735, 2160, 2817, 2820  
 Listing J, 2392  
 Little CB, 124, 1544  
 Liu G, 404  
 Liu X, 545  
 Livne E, 3240  
 Lizak MJ, 2219  
 Lloyd MS, 2537  
 Lo Scocco G, 3099  
 Locker GA, 1309  
 Lockshin MD, 1127, 2542  
 Loeser RF, 394, 1528, 1956, 2349, 2368  
 Lopez-Ben R, 1969  
 López-Escribano H, 3290  
 López-Hoyos M, 3290  
 López-Larrea C, 2968  
 Lopez-Soto A, 1309  
 López-Vázquez A, 2968  
 Lorig K, 2280  
 Losina E, 2436  
 Loughlin J, 1519, 1780  
 Lovell DJ, 3340  
 Low PS, 1947  
 Lu Q, 1282  
 Lubberts E, 1379, 3055  
 Ludivico C, 1309  
 Luggen M, 1470  
 Lugtenberg D, 3266  
 Lui LY, 1773  
 Lundberg IE, 1044  
 Lundgren NT, 2574  
 Lundy CJ, 961  
 Lunt M, 906, 2010, 2402  
 Luo SF, 2924  
 Luqmani RA, 1309  
 Luross JA, 1671  
 Luszczkiewicz G, 1744  
 Lyttle D, 2587  
  
**M**  
 Ma D, 2301  
 Ma G, 2587  
 Macardle PJ, 1572  
 Macchioni PL, 3099  
 Macfarlane GJ, 1130  
 Machold KP, 1155  
 Machour N, 1196  
 MacKay K, 632  
 Madsen HO, 555  
 Maeda T, 379  
 Maeno N, 2539  
 Magagnoli G, 3201  
 Maggi E, 445  
 Magliano M, 1997  
 Magni-Manzoni S, 232  
 Mahler M, 1866  
 Mahomed N, 3327  
 Maier AL, 785, 1171  
 Maini RN, 507, 1693, 1973, 2259, 2817, 2820  
 Maisonnobe T, 467, 3317  
 Majumdar S, 385  
 Makino H, 2541, 2578  
 Maksymowych WP, 766  
 Mallah M, 3340  
 Mallek J, 1164  
 Malleson PN, 2708  
 Malley JD, 1885  
 Mallone R, 1602  
 Maloney MD, 2095  
 Manaloor JJ, 1905  
 Mandelin J, 953  
 Mandell BF, 1309  
 Mandy SHL, 2794  
 Manger B, 191  
 Mangra N, 3340  
 Manning PT, 1789, 2637  
 Manzo A, 824  
 Margules KR, 2547  
 Margulis A, 2903  
 Mariette X, 1039  
 Marijnissen ACA, 2893  
 Marinova-Mutafchieva L, 507  
 Markenson J, 1443  
 Märker-Hermann E, 606  
 Markham AF, 557, 3349  
 Markusse HM, 347  
 Maroudas A, 114  
 Martel-Pelletier J, 494, 1804, 2637  
 Martens PB, 847, 2544  
 Martin I, 2524  
 Martin J, 556  
 Martin RW, 1443, 2410, 2983  
 Martin V, 2377  
 Martinez M, 2039  
 Martínez-Borra J, 2968  
 Martini A, 232, 2721, 3015  
 Martinon F, 2445  
 Marvin L, 1196  
 Marzo-Ortega H, 489, 2814, 3098, 3398  
 Masaki T, 2486  
 Mascha E, 1634  
 Masciandaro S, 553  
 Maslinski W, 1744  
 Mason JC, 3026  
 Massa M, 2721, 3015  
 Massicotte F, 1804  
 Masuda I, 3218  
 Masuhara K, 2625  
 Matarán L, 556  
 Mathieu A, 2121  
 Matsuda H, 735  
 Matsudaira R, 2946  
 Matsumoto A, 2020  
 Matsumura R, 2141  
 Matsushita M, 2946  
 Mattei JP, 774, 2535  
 Matteson EL, 2257  
 Matthey DL, 640  
 Matsushima K, 735  
 Matyas JR, 1536  
 Mau U, 3041  
 Mayer P, 1177  
 Mayes MD, 2410, 2983  
 Mayet WJ, 3083  
 Mayton L, 2514  
 Mazières B, 1754  
 Mazzetti I, 3201  
 Mazzoli F, 2721, 3015  
 Mazzuca SA, 109, 1223  
 McBeth J, 1130  
 McCabe D, 614, 2838  
 McColl G, 862, 2301  
 McDermott MF, 245, 1061, 2445  
 McGaha TL, 2748  
 McGonagle D, 489, 837, 1970, 2814, 3349, 3398  
 McGovern DPB, 1629  
 McGrath H Jr., 3104  
 McIntyre P, 2059  
 McKay K, 75  
 McLaughlin GE, 1460  
 McMichael A, 2972  
 McNicholl J, 2045  
 McRorie E, 1309  
 Mease PJ, 1171  
 Meazza C, 232, 2402  
 Medsger TA Jr., 2410, 2983  
 Meheus L, 1185  
 Meignin V, 1039  
 Mellgren SI, 1228  
 Mengshol JA, 13  
 Menke J, 3083  
 Menon Y, 1973  
 Meredith DM, 3349  
 Merkel PA, 1309, 2410  
 Merlino LA, 83, 3104  
 Meroni PL, 1019, 1399, 1595, 1602  
 Merrill JT, 1127, 1820, 3251

Mesecke-von Rheinaben I, 1177  
 Metzger G, 1177  
 Meunier A, 1643  
 Meyer HE, 675  
 Meyer J, 3178  
 Miceli-Richard C, 1405  
 Michel BA, 1512, 2808, 2811  
 Michelutti A, 2252  
 Middelkoop HAM, 2665  
 Mielants H, 755  
 Mierau R, 1866  
 Miida T, 1683  
 Mijares-Boeckh-Behrens T, 2547  
 Mijiyawa M, 2968  
 Mikecz K, 2207, 2465  
 Miki T, 1489  
 Mikuls TR, 83, 3104  
 Milewicz DM, 2990  
 Milicic A, 632  
 Miller DL, 1291  
 Miller FW, 1885  
 Miller ML, 1160  
 Milliken S, 2301  
 Mima T, 1094  
 Min DJ, 42, 1202  
 Min JK, 42, 1202  
 Min SY, 42, 1109, 1202  
 Minambres E, 3290  
 Mincheva-Nilsson L, 1324  
 Minden K, 2392  
 Mindrescu C, 2453  
 Miner A, 2436  
 Minota S, 3388  
 Miranda-Carus ME, 269  
 Misbah SA, 2827  
 Mitsuhashi S, 1813  
 Mix KS, 13  
 Miyake K, 3259  
 Miyasaka N, 2878  
 Miyata K, 2539  
 Miyazaki H, 2148  
 Miyazaki K, 2105  
 Mizrahi J, 114  
 Mizuki S, 1067  
 Modin G, 1292  
 Mody GM, 1407  
 Moens U, 1270  
 Moereels H, 1185  
 Mohan N, 3108  
 Mok CC, 1003  
 Moldovan F, 2637  
 Mollenhauer C, 2903  
 Monneaux F, 1430  
 Moore G, 1164  
 Moore J, 2301, 3076  
 Moore TL, 3340  
 Moots RJ, 1351  
 Morales TI, 2358  
 Moran M, 2045  
 Moreland LW, 614, 1443, 1460, 1470, 1969, 2020, 2553, 2983  
 Morgan AW, 557  
 Morgan G, 837  
 Morgan SL, 1413  
 Mori A, 2105  
 Mori S, 1067

Morimoto K, 1067  
 Morimoto S, 1410  
 Morita Y, 2578  
 Morito F, 3259  
 Moro L, 553  
 Morony S, 3121  
 Morris S, 1873  
 Mort JS, 2207  
 Mosca M, 1019  
 Mosci P, 806  
 Moser KL, 428, 2132  
 Motegi K, 1585  
 Möttönen T, 894  
 Mountz JD, 934  
 Moutsopoulos HM, 215, 741, 2248  
 Moxley G, 250  
 Mudano AS, 83  
 Mukai S, 2486  
 Müller GA, 1177  
 Muller S, 1430  
 Müller-Ladner U, 52, 934, 2255  
 Munechika E, 735  
 Munford RS, 1661  
 Munneke M, 274  
 Munster T, 1460  
 Murad YM, 2207  
 Murai T, 1683  
 Murakami A, 3273  
 Murakami Y, 2504  
 Murata H, 2141  
 Murphy FT, 1480  
 Murphy JM, 704  
 Musset L, 281  
 Mustafa Z, 1519, 1780  
 Mutkus L, 3041  
 Myers B, 1014  
 Myers LK, 1086, 3369  
 Myers R, 946  
 Myers RP, 3317  
 Myerscough, 632  
 Myllykangas-Luosujärvi R, 894

## N

Nagamine R, 379  
 Nagasaka K, 2878  
 Nagasawa K, 3259  
 Nagashima H, 1390  
 Nagata M, 1489  
 Naides SJ, 2263  
 Nakagawa T, 2486  
 Nakai T, 2625  
 Nakamura T, 2486  
 Nakamura Y, 1067  
 Nakase T, 373  
 Nakashima Y, 379  
 Nakatsuru S, 1067  
 Nakayama Y, 2105  
 Nam CM, 1714  
 Nambiar MP, 163  
 Namjou B, 2937  
 Nandakumar KS, 2339  
 Nanki T, 1255, 2878  
 Nara H, 3388  
 Narita T, 2105  
 Nash JT, 1028  
 Nath SK, 2937

Nauseef WM, 1127  
 Navaux F, 1754  
 Nawata M, 2946  
 Neale MC, 250  
 Neame RL, 847  
 Neidel J, 1620  
 Neidhart M, 1413, 2811  
 Nelson JL, 291, 2538  
 Nennesmo I, 1044  
 Nepom GT, 5  
 Netter P, 2637  
 Neuhuber WL, 191  
 Neumann E, 52, 934  
 Neumann L, 845  
 Neupane H, 175  
 Nevala H, 1061  
 Nevitt MC, 1, 1217, 1773  
 Newitt DC, 385  
 Newman J, 1554  
 Newton J, 75  
 Ng DM, 3212  
 Niccoli L, 2964  
 Nicoli D, 3099  
 Nicoli F, 2535  
 Niermann KJ, 475  
 Nieto A, 556  
 Nieuwland R, 1498, 2857  
 Nieva DRC, 2263  
 Niewerth M, 2392  
 Nikolic MM, 278  
 Niland B, 175  
 Nishihara M, 1067  
 Nishimoto N, 3143, 3388  
 Nishioka K, 1094  
 Nishizawa Y, 1489  
 Nissila M, 894  
 Nixon NB, 640  
 Nogueira L, 2051  
 Nomura S, 1094  
 Nomura Y, 2539  
 Nonomura Y, 2878  
 Noorouz-Zadeh J, 2686  
 Nordquist N, 259  
 Nordsletten L, 675  
 Norsworthy P, 1028  
 Nose M, 1067  
 Notarnicola C, 2785  
 Novak EJ, 5  
 Nowak M, 3340  
 Nozawa K, 1410  
 Nuamah I, 1470  
 Nuki G, 1309, 2838  
 Nunez G, 3041  
 Nyberg G, 1324  
 Nylander-French LA, 1840

## O

Oates JC, 598  
 O'Callaghan J, 2301  
 Ochi T, 373  
 O'Connor PJ, 366, 489, 1970, 1971, 2814, 3168  
 O'Dell JR, 283, 1164, 2553, 3103  
 Odendahl M, 2160  
 Oegema TR Jr., 2495  
 Oehlert J, 1014

O'Fallon WM, 625, 2287, 2294  
 Ogawa H, 2330  
 Ogawa N, 2730  
 Oglesby RJ, 163, 1416  
 O'Hanlon TP, 1885  
 Ohlsson M, 202  
 Ohmoto Y, 2578  
 Ohsawa K, 2486  
 Ohshima S, 1094, 2811  
 Ohta A, 3259  
 Ohya K, 3273  
 Okamoto A, 2578  
 Okazaki Y, 2148  
 O'Keefe RJ, 1298, 2095  
 Oksmann F, 2762  
 Okumura K, 735  
 Olivieri I, 553, 2964, 3396  
 Ollier WER, 75, 632, 2402, 2716, 2721, 3304  
 Olofsson P, 259  
 Olsen NJ, 475  
 Olson JM, 428  
 Olszewski RJ, 2453  
 Omdal R, 1228  
 Oppers-Walgreen B, 3055  
 Ordinas A, 3283  
 Ordi-Ros J, 1974  
 Orefici G, 806  
 Orlandini G, 1595, 3201  
 Ørstavik R, 1720  
 O'Shea JJ, 3340  
 Osorio J, 2039  
 Ota H, 1922  
 Ottaviani R, 1399  
 Otterness IG, 1544  
 Otto T, 2543  
 Overman SS, 1171  
 Oyama Y, 2917

## P

Pablos JL, 3102  
 Pacheco E, 2604  
 Pachman LM, 3015  
 Padula A, 553, 2964, 3396  
 Paimela L, 654  
 Paiva ES, 1344  
 Palangio M, 2545  
 Pallwein L, 647  
 Palmblad K, 2598  
 Palmer W, 1164  
 Panayi GS, 824, 2109, 3143  
 Pandey JP, 1885  
 Pando J, 995  
 Panfilo S, 2262  
 Paoletti S, 3201  
 Paoli JR, 2762  
 Pap T, 843  
 Paredes Y, 1804  
 Park DC, 1980  
 Park EJ, 793  
 Park JH, 475  
 Park JS, 1109  
 Park SH, 42, 1109, 1202  
 Park YB, 1714  
 Parkin D, 995  
 Parks CG, 1840  
 Parsch D, 2911

Pascual M, 556  
 Pasquier C, 522  
 Passalia M, 2721  
 Passeullo F, 2301  
 Pasternack A, 1696  
 Patel DD, 1984  
 Paulos CM, 1947  
 Paulsen G, 1164  
 Paulus H, 913  
 Pazdur J, 1744  
 Pease C, 489  
 Pêcheux C, 2181  
 Peck AB, 1390  
 Peebles CL, 726  
 Peeters AJ, 347  
 Pelletier JP, 494, 1804, 2535, 2637  
 Pelletier S, 467  
 Pellissier JF, 2535  
 Peloso P, 913  
 Peltomaa R, 654  
 Pennington D, 1857  
 Penrod JR, 3327  
 Penttinen MA, 2172  
 Perl A, 175, 1139  
 Perretti M, 824, 2765  
 Pertovaara M, 1696  
 Petera P, 2121  
 Peters AM, 1028  
 Peterson CE, 844  
 Peterson P, 1061  
 Petersson AS, 1324  
 Petit E, 2039  
 Petri MA, 1820  
 Petrone D, 748  
 Petroustos G, 2248  
 Petrovic R, 2121  
 Petrow P, 64  
 Pettersson T, 1061  
 Pettersson U, 259  
 Pettit AR, 3055  
 Pettitt D, 3046  
 Petty RE, 2708  
 Petzke F, 1333  
 Philippidis P, 3026  
 Phillips CB, 2436, 3327  
 Phillips PE, 175  
 Piccinni MP, 445  
 Pickard MD, 874  
 Pidoux I, 2087  
 Pierangeli SS, 545  
 Piera-Velazquez S, 404, 683  
 Pierlot C, 2039  
 Pietschmann P, 785  
 Piette JC, 281, 1019, 1123, 2181, 3317  
 Pignatti P, 232, 2721  
 Pihlajamaa T, 1086  
 Pile KD, 1694  
 Pincemail J, 522  
 Pines M, 1689, 2748  
 Ping L, 2730  
 Pino M, 3283  
 Pisa FE, 451  
 Pischel KD, 2537  
 Pisetsky DS, 859, 968, 1409  
 Pitsillides AA, 2059

Pitzalis C, 824, 2109  
 Platsoucas CD, 3112  
 Ploski R, 1614  
 Polihronis M, 215  
 Pollard JN, 1699  
 Polley A, 75  
 Pond GR, 625, 2287, 2294  
 Ponticos M, 1857  
 Poole AR, 138, 2087, 2549, 2903  
 Popa ER, 1894  
 Popovic R, 2121  
 Porter S, 961  
 Posthuma D, 250  
 Pottel H, 1185  
 Pouchot J, 277  
 Poveda JD, 1130  
 Pozzi S, 553  
 Prahalad S, 1851  
 Prakken BJ, 1937  
 Prayson R, 1309  
 Price J, 514  
 Price R, 3143  
 Prudhommeaux F, 1643  
 Pruijn GJM, 3266  
 Prum B, 2039  
 Puéchal X, 1130, 1309  
 Pulai JJ, 1528, 2368  
 Puliti M, 806  
 Puskas F, 175  
 Puzas JE, 1298

## Q

Qin M, 1773  
 Quattrini A, 3378  
 Quéré I, 1019  
 Quinn MA, 1971  
 Quinn TC, 1056  
 Quintero-Del-Rio AI, 2957

## R

Raatikainen M, 1061  
 Radjenovic A, 366  
 Radzikowska A, 1744  
 Rahme E, 3046  
 Rall LC, 2574  
 Ramamurthy N, 3361  
 Ramsey-Goldman R, 3115  
 Ranatunga S, 1264  
 Ranki A, 1061  
 Rantapää-Dahlqvist S, 1324  
 Raschi E, 1595, 1602  
 Rattan A, 2604  
 Rau R, 2804  
 Rauch J, 2695  
 Rauta J, 1061  
 Ravelli A, 232, 3015  
 Ravirajan C, 2686  
 Ray D, 1282, 2402  
 Ray D, 1282  
 Ray NB, 2263  
 Ray WA, 2195  
 Raymond Y, 2695  
 Reay N, 3168  
 Reddy B, 1554  
 Redlich K, 785  
 Reece RJ, 366, 489, 837, 2034

Reed J, 2587  
 Rees SG, 1544  
 Reeves WH, 2235  
 Regan MJ, 1056  
 Rehman Q, 1292  
 Reichlin M, 2957  
 Reichlin S, 2574  
 Reichstetter S, 5  
 Reid J, 2937  
 Reid RC, 2476  
 Reifert J, 2867  
 Reijonen H, 5  
 Reilly CM, 598  
 Reiner A, 2903  
 Reinert P, 2181  
 Reis LFL, 2453  
 Reiter K, 2160  
 Rekvig OP, 1270  
 Rell-Bakalarska M, 1744  
 Remmers EF, 1075, 2225, 3340  
 Réseau Rhumato Study Group, 1130  
 Rethage J, 1413  
 Retiere C, 2972  
 Reumaux D, 1127  
 Reuss-Borst MA, 565, 1177  
 Reveille JD, 1976, 2829, 2990  
 Reverter JC, 3283  
 Reviron D, 2535  
 Rex K, 2604  
 Rezzonico R, 1602  
 Riboni M, 1399  
 Rich SS, 2132  
 Rich WJ, 614  
 Richards CD, 1379  
 Richards HB, 2235  
 Richardson A, 3304  
 Richardson BC, 1139, 1282  
 Richter W, 2911  
 Rider LG, 1885  
 Ridgway JP, 366  
 Riemekasten G, 2678  
 Ries M, 385  
 Rigby WFC, 1362  
 Rijkers GT, 2794  
 Riley GP, 3034  
 Rischmueller M, 1694  
 Robbins ML, 3103  
 Roberts S, 2658  
 Roberts WN, 1460, 3103  
 Roberts-Thomson PJ, 2538  
 Robinson WH, 885  
 Robson MG, 1028  
 Roch B, 1019  
 Rodriguez J, 2917  
 Rolland D, 2051  
 Romagnani S, 445  
 Romeo L, 451  
 Romera M, 847  
 Romero-Merino E, 2547  
 Romijn FPHTM, 2857  
 Ronda N, 1595  
 Rood MJ, 2665  
 Rooney TW, 1460  
 Roord S, 1937, 3015  
 Roos D, 1127  
 Rosa RM, 2917

Rosen A, 1873  
 Rosenbaum JT, 309  
 Rosenberg HF, 3340  
 Rosenthal A, 75  
 Rosenzweig S, 3340  
 Rosier RN, 1298  
 Rosloniec EF, 514, 3369  
 Ross JB, 2445  
 Rost H, 1177  
 Roth BE, 565  
 Rothfield NF, 2410  
 Rothschild B, 1460, 3113  
 Roubenoff R, 2574  
 Roudier J, 929, 2535  
 Roughley PJ, 2207  
 Rousseau JC, 2613  
 Rowan AD, 961  
 Rozenberg S, 1408  
 Rubin JS, 2867  
 Rubin L, 1629  
 Rudwaleit M, 319  
 Rule S, 2301  
 Russell AS, 766, 1980, 2547  
 Russell KA, 279  
 Russo D, 2252  
 Russo R, 3340  
 Ruzsiewicz P, 277  
 Rutstein J, 2020  
 Ryan LM, 3218  
 Ryoo JW, 1109

## S

Saag KG, 83, 2020, 3104  
 Sacco S, 2029  
 Sack M, 1460, 2020  
 Saeki Y, 1094  
 Sah RL, 3212  
 Said-Nahal R, 840, 1405  
 Saijo S, 533  
 Sailler L, 2762  
 Saito N, 1922  
 Saito T, 1813  
 Sakkas LI, 3112  
 Sakurai Y, 3369  
 Salazar-Paramo M, 1885  
 Salido M, 3392  
 Salmon JE, 2132  
 Salo J, 953  
 Salomonsson S, 1233  
 Salstrom JL, 2225  
 Salvarani C, 2964, 3099  
 Samayoa EA, 1885  
 Sammaritano LR, 1127, 2542  
 Samodal R, 2721  
 Sandell LJ, 2613  
 Sanderson WT, 1840  
 Sandhu T, 2546  
 Sandy JD, 2207, 2495  
 Santavirta S, 953  
 Sany J, 559  
 Saraux A, 1130  
 Sasaguri Y, 2625  
 Sato M, 1585  
 Satoh M, 2235  
 Satoi Y, 2020  
 Saudan A, 913  
 Saulot V, 1196



- Savitz DA, 1840  
 Sawamura T, 2486  
 Scaletti C, 445  
 Scarano E, 2964, 3396  
 Schachna L, 1873  
 Schaefer D, 2524  
 Schaevebeke T, 1130  
 Schaible T, 1451  
 Schalkwijk CG, 114  
 Schatz H, 2384  
 Schedel J, 1512  
 Scheel AK, 1177  
 Scheetz RJ, 1309  
 Scheinberg MA, 3390  
 Schenk W, 2893  
 Schett G, 785  
 Schiff MH, 614, 1443, 1820, 2020  
 Schikler K, 3340  
 Schiltz C, 1643  
 Schindler A, 2808  
 Schirmer M, 647  
 Schmit P, 280  
 Schnabel A, 2384  
 Schnarr S, 2260  
 Schned E, 1309  
 Schnitzer T, 2020  
 Schölmerich J, 52, 654, 934, 2255  
 Scholze J, 2160  
 Schöntube M, 2392  
 Schousboe J, 1309  
 Schreuder GMT, 899  
 Schroeder ML, 2708  
 Schultz DR, 694  
 Schulze-Westhoff C, 64  
 Schüpbach J, 2811  
 Schwartzman PR, 1634  
 Schwarting A, 3083  
 Schwartz JS, 1651  
 Schwartz KE, 1820  
 Schwartzman S, 2542  
 Schwarz EM, 1298, 2095, 2514  
 Schwieterman WD, 2565  
 Scleroderma Clinical Trials Consortium, 2410  
 Scott DGI, 906  
 Scott DL, 286  
 Scully S, 2604  
 Sebastiani GD, 2121  
 Sebastiani M, 2262  
 Sebba AI, 1460  
 Sebbag M, 2051  
 Seemayer CA, 1413, 1512, 2811  
 Seftor EA, 2263  
 Segal AM, 1309  
 Seguret F, 2785  
 Seibert K, 1789  
 Seibold JR, 2410, 2983  
 Seid M, 714  
 Seidel J, 2524  
 Selva-O'Callaghan A, 2547  
 Sen M, 2867  
 Senécal JL, 2695  
 Senter RG, 2020  
 Serre G, 1185, 2051  
 Servan J, 3317  
 Shah C, 75  
 Shaheen VM, 2235  
 Shakoor N, 3185  
 Shalhoub V, 3121  
 Shamim EA, 1885  
 Shapiro S, 3240  
 Sharma L, 2632  
 Shear ES, 1851  
 Shelley E, 2402  
 Shen D, 1460  
 Shen N, 2928  
 Shergy W, 1470  
 Sherrer Y, 1309, 2020  
 Shi K, 373  
 Shi YE, 3361  
 Shiao MY, 276  
 Shibatomi K, 1411  
 Shibuya K, 2141  
 Shiels IA, 2476  
 Shimizu T, 2330  
 Shinomiya F, 2330  
 Shirato I, 735  
 Shi-Wen X, 1857  
 Shoenfeld Y, 1019, 1399, 1689  
 Shoham NG, 3340  
 Shoji T, 1489  
 Sholter D, 766  
 Shott S, 3185  
 Shuto T, 379  
 Sibilia J, 1039, 1130  
 Sibley RK, 1014  
 Siegel JN, 2565  
 Sieper J, 319, 841, 2822  
 Sigal LH, 1439  
 Sikström C, 3096  
 Silman AJ, 579, 632, 906, 1130, 1729, 2010, 3312  
 Silver RM, 2564  
 Silverman ED, 436  
 Siminoff LA, 2429  
 Siminovich KA, 1629  
 Simmen B, 1512  
 Simmonds MJ, 3109  
 Simms RW, 2410, 3103  
 Simon A, 467  
 Simon RA, 2201  
 Singh R, 1973, 2079  
 Singh RR, 2235  
 Sinha J, 1554  
 Sinico RA, 2121  
 Sistonen L, 2172  
 Sittlinger M, 149  
 Skeith KJ, 766  
 Skjesol A, 1228  
 Skopouli FN, 2248  
 Sledge C, 3327  
 Slifman NR, 2565  
 Smalley W, 2195  
 Smeets TJM, 1121, 2034, 2776, 2824  
 Smerdel A, 986, 1614  
 Smith JR, 309  
 Smith MD, 2538  
 Smolen JS, 785, 1155  
 Smolian H, 149  
 Snaddon J, 2065  
 Sneller MC, 1309  
 Snow DM, 2658  
 Snowden JA, 837, 2301  
 Snyderman L, 2574  
 So A, 1371  
 Søballe K, 2095  
 Sokka T, 274  
 Solans-Laqué R, 2547  
 Solomon DH, 2436, 3136  
 Sone S, 2330  
 Song J, 2632  
 Sonthheimer RD, 1697  
 Sopena-Sisquella JM, 2547  
 Sorkin LS, 3076  
 Sørskaar D, 986  
 Soubrier M, 1309  
 Sousa BDB, 3390  
 Southam L, 1780  
 Spaepen A, 2073  
 Specks U, 279  
 Spector TD, 92, 3178, 3386  
 Spencer-Green G, 1443  
 Spiera H, 2748  
 Spreckley K, 3386  
 St. Clair EW, 1451, 1830, 1840  
 St-Pierre Y, 3327  
 Stadheim TA, 3230  
 Stamler DA, 2020  
 Stan AC, 2748  
 Stanke-Labesque F, 1319  
 Stanyer L, 2686  
 Staud R, 564  
 Steen V, 2983  
 Steer S, 75  
 Stegeman CA, 849  
 Stein CM, 282, 428, 2020, 2195  
 Stein L, 3340  
 Steinbach L, 385  
 Steinberg AD, 995  
 Steiner G, 785, 1185  
 Steinfeld SD, 2249, 3301  
 Steinman L, 885  
 Steultjens MPM, 1784  
 Stevens A, 2402  
 Stevenson DD, 2201  
 Stjernberg S, 1061  
 Stokes DG, 404, 683  
 Stone JH, 1056, 1309  
 Stoner J, 1164  
 Strachan AJ, 2476  
 Strand V, 1820, 2836  
 Strange RC, 640  
 Straszynski L, 3349  
 Straub RH, 654  
 Strober S, 1014  
 Strong N, 2678, 2928  
 Stuart JM, 3369  
 Stuckey S, 2065  
 Sturk A, 2857  
 Stüssi E, 2073  
 Sueishi M, 2141  
 Sugai S, 2730  
 Sugiyama T, 2141  
 Sumida T, 2141  
 Sun MY, 2972  
 Sundberg E, 2598  
 Suomalainen H, 1061  
 Suzuki J, 1410  
 Suzuki N, 3259  
 Sveigaard A, 555  
 Swan DC, 2445  
 Swanson E, 5  
 Swanson H, 1309  
 Symmons DPM, 906, 2010  
 Syndercombe-Court D, 245  
 Szajnert MF, 2181  
 Szántó S, 2207  
 Szechinski J, 1744  
 Szer IS, 714  
 Szer J, 2301

# T

- Tada Y, 3259  
 Taglietti M, 1126  
 Taher A, 850, 1410  
 Tak PP, 366, 1121, 2034, 2776, 2824, 2857  
 Takada K, 995  
 Takada Y, 2730  
 Takagi M, 953  
 Takagishi K, 130  
 Takahi K, 373  
 Takanashi T, 735  
 Takaoka K, 1922  
 Takasaki Y, 2946, 3273  
 Takei S, 2539  
 Taketomi T, 1922  
 Takeuchi K, 2946  
 Takeuchi R, 1813  
 Tamaki K, 2421  
 Tamatani T, 1585  
 Tan FK, 1976, 2829, 2990  
 Tang A, 1914  
 Tang B, 3369  
 Tang SJ, 565  
 Tang X, 269  
 Tani K, 2330  
 Taniguchi K, 2878  
 Tanzer M, 2087, 3327  
 Tao X, 1735  
 Tapinos NI, 215  
 Targoff IN, 1885  
 Tarner IH, 934  
 Tarp U, 555  
 Tassies D, 3283  
 Taylor EJ, 209  
 Taylor K, 2301  
 Taylor SM, 2476  
 Teixeira A, 467  
 TeKoppele JM, 114, 3212  
 Temple MM, 3212  
 ten Cate R, 1121  
 Tennant A, 3098  
 Terada M, 1067  
 Terasawa K, 2946  
 Tesser JR, 1443  
 Testoni C, 1595, 1602  
 Tew MB, 1976, 2829  
 Thacker C, 245  
 Theander E, 1233  
 Theodore ML, 1056  
 Thibault V, 3317  
 Thomas G, 1405  
 Thome M, 2445  
 Thompson SD, 1851

Thomson W, 2402, 2716, 3304

Thornton S, 3010

Thorpe SR, 114

Thorsby E, 1614

Thyphronitis G, 215

Tijssen H, 921

Tincani A, 1019, 1126, 1399

Tissi L, 806

To T, 436

Tohidast-Akrad M, 785

Tokano Y, 1410

Tokunaga K, 1242

Tomino Y, 735

Tomita T, 373

Tonello A, 451

Torricelli F, 445

Totoritis MC, 3251

Toutou I, 2785

Tracey KJ, 2598

Tran HB, 202, 1572

Travaglino P, 232

Traynor AE, 2917

Treadwell EL, 1830, 1840

Tresp V, 1177

Trikalinos TA, 1563

Tripp CS, 1789

Tromp G, 3041

Tron F, 1196

True DG, 1698

Tsao BP, 2678, 2928

Tsarknaridis L, 238

Tsay GJ, 276

Tschopp J, 2445

Tso E, 1634

Tsokos GC, 163, 276, 1139

Tsuchiya N, 1242

Tsutsumi A, 2141

Tucker LB, 2708

Tuggle C, 1309

Türk B, 785

Türk MJ, 1947

Turnay J, 2339

## U

Udall JN Jr., 2565

Udapa JK, 3168

Uede T, 1094

Ueno A, 2578

Uesaka S, 2105

Uesugi M, 1813

Uguccioni M, 3201

Uhlig T, 1720

Uhrin Z, 1014

Ulfgren AK, 2598

Ulloa L, 2598

Ulrich-Vinther M, 2095

Umehita-Sasai M, 1094

Undlien DE, 1614

Ungethüm U, 149

Union A, 1185

Urasaki Y, 2878

Urban JPG, 3190

Ushiyama O, 3259

Uthman I, 850, 1410

Utz PJ, 885

## V

Vail TP, 420

Vaishnav AK, 1554, 2776

Valesini G, 3110

Van G, 2604

van Buchem MA, 2665

van de Laar MAFJ, 347, 1498

van de Loo FAJ, 1379, 1661

van de Putte LBA, 921

van de Stadt RJ, 848

van de Winkel GJG, 1125, 1242

van den Berg WB, 1379, 1661, 3055

van den Bergh H, 1371

van den Berselaar L, 3055

Van den Bosch F, 755, 1470

van den Hoogen FHJ, 3266

van Denderen JC, 347

van der Heijde DMFM, 319, 347, 913, 2847

van der Horst-Bruijnsma IE, 564

van der Linden MW, 1125

van der Linden S, 347, 899, 913, 2847

Van Doornum S, 862

van Eden W, 1937

van Eenennaam H, 3266

Van Ghelue M, 1270

van Heel DA, 1629

van Kooten PJS, 1937

van Kuijk AWR, 2776

Van Landeghen M, 238

van Meerwijk J, 1754

van Melkebeek J, 2893

van Osch GJVM, 976

van Riel PLCM, 921, 1691

van Roermund PM, 2893

van Venrooi WJ, 2824, 3266

van Vollenhoven RF, 1820

Vanwanseele B, 2073

Varga J, 1703, 2983

Varley AW, 1661

Varni JW, 714

Vasconcelos C, 1019, 2121

Vassiliou VA, 741

Vassilopoulos D, 585

Vaughan EM, 995

Vaughan JH, 726

Vauthier D, 1123

Vazquez E, 1255

Vazquez-Mellado J, 1885

Veale DJ, 366, 837, 2034

Veldhuis JD, 2574

Venstrom K, 1857

Verbout AJ, 2893

Verhaar JAN, 976

Verhoeven AC, 347, 899, 2847

Verthelyi D, 2219

Verzijl N, 114, 3212

Veys EM, 606, 755, 2826

Villardell-Tarrés M, 1974, 2547

Villarreal J, 1974

Vinceneux P, 277

Vincent C, 2051

Vincenti MP, 3230

Vingsbo-Lundberg C, 259

Vinje O, 986

Viola S, 2721

Violi F, 3110

Virtanen I, 953

Visser H, 357, 899

Vittecoq O, 1196

Vliet Vlieland TPM, 274

Vogelzangs JHP, 3266

Voll RE, 191

von Hunolstein C, 806

Vondracek A, 3065

Vos K, 357, 899

Vossen JM, 1121

Vossenaar ER, 2824

Voulgarelis M, 2248

Vultaggio A, 445

Vunjak-Novakovic G, 2524

## W

Wagenaar JPA, 1937

Wagner AD, 1965

Wagner CL, 1451

Wahid S, 824

Wahren-Herlenius M, 1233

Wakefield RJ, 1970, 1971, 3168

Waldenström A, 1324

Waldmann H, 1974

Walker JG, 2538

Walker JS, 802

Wallace DJ, 2545, 2678, 2928

Wallace WD, 565

Wallick JE, 100

Wallis D, 2990

Wallis G, 3386

Walport MJ, 1028

Walsh B, 1309

Walsh DA, 847

Walsmith JM, 2574

Wanders RJA, 2794

Wang A, 2990

Wang B, 1451, 1735

Wang H, 2598

Wang JP, 2225

Wang M, 3361

Wang R, 5

Wang X, 3041

Ward MM, 223

Warker VG, 163

Wasko MC, 1443

Wassenberg S, 2804

Watanabe S, 1102

Waterham HR, 2794

Watford WT, 3340

Wauben HHM, 1937

Waytz P, 1164

Weaver AL, 1443

Weber E, 663

Wechsler B, 1123

Wees S, 1164

Weinberg JB, 968

Weinblatt ME, 567, 614, 1171, 1407, 3390

Weiner SR, 2983

Weinstein A, 2410, 2983

Weisman M, 1460, 2983

Welch KE, 1460

Welsh K, 209

Welte T, 843

Wenlan L, 3099

Wernicke D, 64

Wessinghage D, 52

Westedt ML, 347

Westendorp RGJ, 3107

Westhovens R, 347

Wetzels JFM, 1691

Weyand CM, 457, 3113

Wheller SK, 824

White B, 2410, 2983

White RD, 1634

White S, 632

Whitehouse MW, 1977

Whitworth WC, 2045

Wibulswas A, 2059

Wicks IP, 862, 2301

Widmer WR, 1947

Wiesenhutter C, 2020

Wigley FM, 1873, 2410, 2983

Wiland P, 1744

Wilder RL, 1075, 2225

Wiles NJ, 2010

Wilke WS, 1309

Will R, 2301

Williams BD, 2251, 3143

Williams CJ, 3041

Williams JI, 3331

Williams NA, 1671

Williams RO, 271, 507

Wilson C, 1544

Wise RP, 2565

Wisniewski HG, 2453

Wluka AE, 2065

Woerner BM, 1789

Woessner KM, 2201

Wofsy D, 3251

Wolf JM, 1333

Wolf V, 2867

Wolfe F, 2320

Wolfson-Reichlin M, 2957

Woloszczuk W, 785

Wong KS, 1914, 2189, 2587

Wong RWS, 1003

Wong SM, 1914

Wong WK, 2983

Woo P, 2445

Wood BJ, 1056

Wood GM, 2189, 3340

Woodburn J, 3168

Woodruff TM, 2476

Wooley PH, 2514

Wordsworth BP, 75, 209, 632, 1629

Worthington J, 75, 632

Worthy T, 92

Wright JG, 3331

Wu B, 2514

Wu J, 2132

Wu W, 2087

## X

Xu JW, 3361

Xu L, 1217, 1773

Xu LC, 1947

# Y

Yagita H, 735  
Yagnik DR, 3026  
Yamada H, 379, 2219, 2946  
Yamada M, 735  
Yamada T, 1683  
Yamaguchi A, 1242  
Yamaguchi K, 2625  
Yamaguchi N, 1094  
Yamamoto H, 533, 1067  
Yamamura M, 2541, 2578  
Yamane K, 2421  
Yamanishi Y, 818  
Yamasaki S, 2625  
Yamashita T, 1585  
Yamazaki R, 3159  
Yan A, 766  
Yan XJ, 2598  
Yang H, 457, 2598  
Yang JQ, 2235  
Yang L, 3010, 3076  
Yang SY, 2514  
Yarboro CH, 995  
Yaron M, 2571  
Yasuda T, 138, 2486  
Yazici Y, 1127  
Yocum D, 1460, 2020  
Yood RA, 3103  
Yoshida H, 2235  
Yoshida T, 1813  
Yoshie O, 2878  
Yoshikawa H, 373  
Yoshizaki K, 3143, 3388

Youn J, 1109, 1202  
Young A, 2310  
Young SP, 209  
Younge B, 457  
Younger J, 1735  
Yu DTY, 606  
Yu W, 1217, 1773  
Yutani Y, 1489

# Z

Zacharek S, 1282  
Zacher J, 64  
Zack D, 2604, 3121  
Zaja F, 2029, 2252  
Zajčková K, 2828  
Zakrzewska K, 2262

Zanelli E, 899  
Zeggini E, 2402, 2716, 3304  
Zeharia A, 245  
Zeidler H, 1965, 2260  
Zeuner RA, 2219  
Zhang J, 2465  
Zhang Y, 1217, 1773  
Zhenjun L, 2730  
Zhou X, 2990  
Zink A, 2392  
Ziolkowska M, 1744  
Žofková I, 2828  
Zouali H, 1405  
Zukor D, 2087  
ZurNedden D, 647  
Zvaifler NJ, 298, 507, 3106  
Zwinderman AH, 274, 899

# SUBJECT INDEX

*Arthritis & Rheumatism*, Volume 46, Numbers 1-12, 2002

## A

- $\alpha$ -enolase, autoantibodies to, in early RA, 1196
- Acetaminophen
  - NSAIDs vs, in elderly adults, 3046
  - OA treatment with, 2831
- Acetylsalicylic acid, GCA, therapy with, 457
- Acinar glands, MMP-9 production, suppression by cepharanthine, 1585
- Acquired C1 inhibitor deficiency, associated with SLE, 2827
- Acute-phase response and arthritis development, genetic link between, 259
- ADAM gene, modulation of gene expression in chondrocytes by IL-1 and oncostatin M, 961
- Adenosine triphosphate, depletion in SLE, 175
- Adjuvant-induced arthritis
  - bone protection and osteoprotegerin therapy in rats, 1926
  - inhibition by TIMPs gene delivery, 3361
  - murine recombinant soluble IL-17R:Fc fusion protein treatment, 802
  - Mycobacterium butyricum*-induced, genetic analysis of, 1075
  - neovascularization suppressed by inhibition of IL-1 but not TNF, 2604
  - spinal adenosine receptor activation and, 3076
  - suppression by nasally administered heat-shock protein 60 peptide analog, 1937
- Adrenocorticotrophic hormone, gouty arthritis, melanocortin type 3 receptor agonists and, 2765
- Advanced glycation end products
  - glycation increases collagen stiffness in OA cartilage, 114
  - tensile properties of articular cartilage and, 3212
- African American population
  - acceptance of treatment modalities and, 2265, 2429
  - AS, HLA-B\*1403 associated with in West African population, 2968
  - willingness to consider joint replacement for hip or knee OA, 2429
- Aggrecan
  - cyclosporin A inhibition of aggrecanase-mediated proteoglycan catabolism in articular cartilage, 124
  - nerve growth inhibition by human intervertebral disc aggrecan, 2658
  - OA, regional quantification of collagen and aggrecan mRNA in, 1536
- Aggrecanase, mRNA profiling in OA, 2648
- Aging
  - advanced glycation end products and tensile properties of articular cartilage, 3212
  - matrix homeostasis in aging ankle cartilage, 2903
  - MMPs in temporomandibular and knee joints of mice, 3240
  - oxidative damage in, 2349
  - replicative aging of articular chondrocytes, 2911
- Akt, TGF $\beta$ -mediated phosphorylation of in RA, 1504
- Alefacept, PsA treatment, 2776
- Alignment, knee OA progression by disease stage, 2632
- Altered peptide ligand, nasally administered in adjuvant-induced arthritis, 1937
- Alternative medicine. *See* Complementary and alternative medicine
- American College of Rheumatology (ACR)
  - 2001 Slide Competition winners, 1160
  - aspirin and NSAIDs, 2002 ACR RA Guidelines update, 3102, 3103
  - donation of educational materials to international community, 1407
  - FM classification criteria, 10-year retrospective, 1136
  - guidelines for RA management, 2002 update, 328
  - new contact information for journal editorial office, 1628, 1964
  - presidential address, 567
- Aminopeptidase N, involvement in inflamed joints, 2330
- Amyloid, conversion of serum amyloid A into extracellular amyloid, 1905
- Amyloidosis
  - fenofibrate inhibition of, 1683
  - infliximab treatment of renal amyloidosis in RA, 2571
  - myeloma-associated amyloidosis, skeletal muscle pseudo-hypertrophy in, 2251
  - periodic fever syndromes with, *NALP3/CIAS1/PYPAF1* mutations, 2445
- Anakinra, in RA
  - combination treatment with MTX, 614
  - safety, 2838
- Angiogenesis
  - neovascularization suppressed by inhibition of IL-1 but not TNF, 2604
  - VEGF regulation by cyclosporin A in rheumatoid synovial fibroblasts, 1202
- Angiostatin, collagen-induced arthritis, gene transfer in, 793
- Animal models. *See* names of specific animals
- ANK, in calcium pyrophosphate dihydrate crystal deposition disease, 3218
- Ankle
  - joint distraction in ankle OA, 2893
  - matrix homeostasis in aging cartilage, 2903
  - neuropathic joint disease, MRI prediction of progressive joint destruction, 2814
- Ankylosing spondylitis (AS)
  - clinical trials, response criteria, 1693
  - effect of birth order or maternal age, 563
  - functional disability predicts total costs, 223
  - health-related quality of life, comparison of instruments for measuring, 3098
  - HLA-B\*1403 associated with, in West African population, 2968
  - NOD2* variants in, 1629
  - osteoprotegerin and pyridoline levels in, 3390
  - pamidronate trial for, 766
- Anti- $\alpha$ -enolase antibodies, in early RA, 1196
- Anti- $\beta_2$ -glycoprotein I, APS and, in mouse model, 1399
- Antibodies/autoantibodies. *See* names of specific antibodies
- Anticardiolipin antibody
  - antioxidants and antibody titer, 3110
  - in platelet interaction with subendothelium, 3283
- Anti-CD40 ligand antibody, in SLE, 1554
- Anti-CD154, SLE treatment, 3251
- Anti-CENP-A response, CENP-A/CENP-B-specific immune response in SSc, 1866
- Anti-c-Mpl antibody, in SLE, 2148
- Antifibroblast antibodies, in SSc, 1595, 1602
- Antifilaggrin autoantibodies
  - citrullinated RA-specific epitopes in natural filaggrin for autoantibody detection by line immunoassay, 1185
  - deimmunized recombinant rat filaggrin antibodies, ELISA detection of, 2051
- Antigen-induced monarticular arthritis, antiarthritic activity of orally active C5a antagonist, 2476
- Antigens, SLE and SS, candidate T cell epitopes of human La/SSB autoantigen, 209
- Anti-granulocyte colony-stimulating factor (G-CSF) autoantibodies, in Felty's syndrome and neutropenic SLE, 2384
- Anti-high-density lipoprotein antibodies in SLE and APS, correlation of paraoxonase to, 2686
- Anti-IL-6 receptor monoclonal antibody, in RA, 3143



- Anti-La/SSB antibodies, organ-specific binding to fetal apoptotic cells, 1572, 2247
- Anti-lipase, in SLE, 2957
- Antimalarial drugs
- cutaneous reactions to hydroxychloroquine, 3392
  - hydroxychloroquine-associated mucocutaneous hyperpigmentation, 1698
  - RA, comparison of combination therapies for, 1164
  - RA, concentration-response relationships in, 1460
  - screening for retinopathy in patients receiving hydroxychloroquine, 561
  - transplacental passage of hydroxychloroquine in humans, 1123
- Antineutrophil cytoplasmic antibodies (ANCA)
- ANCA-associated vasculitis, absence of anti-cyclic citrullinated peptide antibodies in, 849
  - ANCA-associated vasculitis, in vitro cytokine production and proliferation of T cells, 1894
  - pro-myeloperoxidase as target antigen for, 1127
  - in WG and microscopic polyangiitis, clinical and prognostic value, 278
- Antioxidants
- anticardiolipin antibody titer and, 3110
  - vitamin E and joint destruction and clinical inflammation in transgenic RA mouse model, 522
- Anti-p53 antibodies, absence of in RA and SLE in Chinese populations, 276
- Antiphospholipid antibodies, induction in mice by viral peptide, 545
- Antiphospholipid syndrome (APS)
- antiphospholipid antibodies, induction in mice by viral peptide, 545
  - $\beta_2$ -glycoprotein I, immunization and loss of tolerance in mouse model, 1399
  - $\beta_2$ -glycoprotein I, monoclonal anticardiolipin antibodies in platelet interaction with subendothelium, 3283
  - $\beta_2$ -glycoprotein I, paraoxonase activity and antibodies to high-density lipoprotein, 2686
  - clinical and immunologic manifestations, 1019
  - pregnancy, gonadotropin-releasing hormone agonists and, 2542
  - thromboembolic events after fetal loss in, 1126
  - typhoid fever and, 850
- Anti-Ro/La autoantibodies
- candidate T cell epitopes of, 209
  - subcellular redistribution of La/SSB during physiologic apoptosis, mouse study, 202
- Anti-tumor necrosis factor  $\alpha$  (anti-TNF $\alpha$ )
- histoplasmosis as complication, 2565
  - Listeria monocytogenes* infection and, 2255
  - lymphoma development and, 3151
  - PsA rechallenge, 3107
  - RA, etanercept and tenosynovitis and nodules in, 559
  - RA, high levels of osteoprotegerin and sRANKL in, 1744
  - RA, nephrotic syndrome associated with therapy, 1691
  - RA, nodule development during anti-TNF $\alpha$  therapy with etanercept, 843
  - RA, radiographic damage inhibition with minimal or no clinical improvement, 2817
  - RA, serum infliximab and clinical improvement in, 1451
  - RA, treatment with and regression of subacute cutaneous SLE, 1408
  - RA, very high-dose blockade and long-term remission, 1971
  - SAPHO syndrome, 1965
  - SpA, for enthesitis, 3396
  - SpA, infliximab vs placebo in, 755
  - SS, infliximab for primary disease, 3301
  - uveitis, treatment with, 2821
- Anti-U1 RNP antibodies, in mixed connective tissue disease, 3273
- Anxiety, FM and serotonin transporter promoter region (5-HTTLPR) polymorphism, 845
- Apoptosis
- apoptosis-specific U1-70-kd antibodies, 1264
  - collagen-induced arthritis, attenuated by Bcl-x<sub>L</sub> expression, 514
  - COX-2 inhibitors and apoptosis induction in rheumatoid synovial fibroblasts, 3159
  - IL-15 inhibition of fibroblast and endothelial cell apoptosis, 3010
  - OA, cartilage degeneration: apoptosis and cellular vitality, 1986
  - OA, induction by growth-related oncogene  $\alpha$  in chondrocytes, 3201
  - OA, TUNEL labeling in determining apoptosis in cartilage, 2260
  - SLE, impaired uptake of apoptotic cells into germinal center, 191
  - subcellular redistribution of La/SSB during physiologic apoptosis, mouse study, 202
  - Arab population, *TNFRSF1A* mutation and TRAPS, 245
  - Arm, bilateral forearm pain, chronic exertional compartment syndrome as cause of, 2245
  - Arterial wall thickening, RA, by ultrasonography, 1489
  - Arthritis & Rheumatism*, new contact information for journal office, 1628, 1964
  - Artificial neural network, as cancer predictor in inflammatory myopathies, 2547
  - Aseptic loosening, osteoprotegerin gene transfer protects against osteolysis, 2514
  - Aspirin
    - 2002 ACR RA Guidelines update, 3102, 3103
    - GCA treatment with, 3113
    - Aspirin-sensitive asthma, safety of celecoxib in, 2201
- Atherosclerosis
- RA and, 862, 1489, 1714
  - SLE, anti-lipase and dyslipidemia, 2957
  - SLE and APS, paraoxonase activity and antibodies to high-density lipoprotein and  $\beta_2$ -glycoprotein I, 2686
- Autoantibodies. *See* names of specific autoantibodies
- Autoantigens, subcellular redistribution of La/SSB during physiologic apoptosis, mouse study, 202
- Autoimmunity
- antiphospholipid antibodies, induction in mice by viral peptide, 545
  - cell death, autoantigen cleavage and, 1699
  - IL-1 and, 533
  - JRA and familial autoimmunity, 1851
  - SLE, proliferating cell nuclear antigen and autoimmune response, 2946
  - SSc, CENP-A/CENP-B-specific immune response in, 1866
- Autologous stem cell transplantation
- JIA, decrease in synovial cellularity and cytokine expression following, 1121
  - SLE, 1580
- Autosomal-dominant recurrent fever, *TNFRSF1A* mutation in family with, 1061
- Avascular necrosis of femoral head in Fabry's disease, 1922
- Azathioprine, diffuse proliferative lupus glomerulonephritis, sequential oral cyclophosphamide and azathioprine, 1003
- B**
- Bacteria. *See* names of specific bacteria
- B cells
- collagen-induced arthritis and RA shared B cell epitopes in, 2339
  - RA, B cell-ablative therapy, 1984
  - RA, B cell blockade in, 2029
  - SLE, CD154-CD40 interactions mediate plasma cell differentiation in, 1417
  - SLE, depletion, 2673
  - SLE, epitope spreading in, 1430
  - SLE, RP105-lacking B cells in, 3259
  - SS, in salivary glands, 2160
- Bcl-3 gene, transcription of MMP-1 gene and, 3230
- Bcl-x<sub>L</sub> protein, collagen-induced arthritis attenuated by expression of, 514

$\beta_2$ -glycoprotein I immunization and loss of tolerance in mouse model, 1399

monoclonal anticardiolipin antibodies in platelet interaction with subendothelium and, 3283

Biodegradable nanoparticles, oral tolerance induction by poly(lactico-glycolic acid) nanoparticles entrapping type II collagen, 1109

**Biomarkers**

- fetal risk of congenital heart block, 1233
- OA, progression of cartilage degeneration, 2549
- OA, whole-genome scan for hand OA, 946
- RA, joint damage prediction in early disease by bone and joint markers, 2847
- urea as passive transport marker, 420

Biau syndrome, *CARD15* mutations in familial granulomatosis, 3041

Blood monocytes, CD14+, CD16 monocytes and joint inflammation in RA, 2578

*BMP2* gene, mutations and pulmonary hypertension and connective tissue disease, 2829

Body cell mass, cachexia in RA not due to decreased growth hormone secretion, 2574

**Bone**

- adjuvant-induced arthritis, bone protection by osteoprotegerin therapy in rats, 1926
- AS, osteoprotegerin and pyridoline levels in, 3390
- bone marrow mesenchymal progenitor cells, 3349
- Fabry's disease, avascular necrosis of femoral head, 1922
- OA, osteoblasts and leukotriene B<sub>4</sub>, 1804
- OA, resorption in progressive knee disease, 3178
- RA, osteoprotegerin as antiosteoclast factor in, 3121

**Bone erosion**

- collagen-induced arthritis, osteopontin expression at erosion sites, 1094
- RANK expression and inflammation in collagen-induced arthritis, 3055

**Bone mass, fractures and OA, 1**

**Bone mineral density (BMD)**

- knee OA, BMD and fracture in, 92
- quantitative computed tomography to predict vertebral fractures in postmenopausal women, 1292
- RA, bone loss in, 1720

**Bone morphogenetic proteins, cartilage differentiation and protection, 149**

**Bone protection**

- adjuvant-induced arthritis, bone protection by osteoprotegerin therapy in rats, 1926
- RA, osteoprotegerin as antiosteoclast factor in, 3121

Brachial arteries, assessment of vascular function in SSc, 1324

Brain damage, in neuropsychiatric SLE, 2665

Brain injury, cell death induction as mechanism of autoantibody production, 3290

Breastfeeding, SLE risk and, 1830

Breast implants, rheumatic diseases and, 2545

Breast milk, neonatal lupus, immunoglobulin G antibodies reactive with SSA/Ro-SSB/La complex in breast milk, 269

## C

C1 inhibitor deficiency, associated with SLE, 2827

C5a antagonists, orally active, antiarthritic activity, 2476

Cachexia in RA not due to decreased growth hormone secretion, 2574

**Caffeine**

- intolerance to and RA, 3104
- RA risk factor, 83

Calcinosis, dialysis-associated uremic tumoral calcinosis, 1416

Calcium pyrophosphate dihydrate crystal deposition disease, cartilage intermediate-layer protein and ANK in articular cartilage in, 3218

Cancer, neural network as cancer predictor in inflammatory myopathies, 2547

Capillaries, PM and DM, IL-1 $\alpha$  expression in, 1044

Capitate, osteoid osteoma of, 2808

*CARD15* mutations

- in familial granulomatosis syndromes, 3041
- in SpA, *CARD15/NOD2* analyses in, 1405

Cardiac myocytes, subcellular redistribution of La/SSB during physiologic apoptosis, mouse study, 202

**Cardiovascular disease**

- accelerated atherosclerosis and RA, 862, 1489, 1714
- mortality in early inflammatory polyarthritis, 2010
- paraonase activity and antibodies to high-density lipoprotein and  $\beta_2$ -glycoprotein I in SLE and APS, 2686

Carpal tunnel syndrome, sonographic criteria for diagnosis of, 1914

**Cartilage**

- advanced glycation end products and tensile properties of, 3212
- ankle, matrix homeostasis in aging cartilage, 2903
- bone morphogenetic proteins promote cartilage differentiation and protection, 149
- calcium pyrophosphate dihydrate crystal deposition disease, cartilage intermediate-layer protein and ANK in, 3218
- cyclosporin A inhibition of proteoglycan catabolism in articular cartilage, 124
- cytokine-induced production of proinflammatory mediators in, 968
- enzyme treatment and integrative repair of, 976
- fibronectin induction of collagen degradation through IL-1-mediated pathway, 138
- functional replacement of oxygen by other oxidants in joints, 3190
- gene expression profile of cultured human chondrocytes, 404
- insulin-like growth factor binding proteins in, 2358
- knee, progressive thinning in absence of normal joint loading and movement, 2073
- knee OA, change in tibial cartilage volume in, 2065
- knee osteonecrosis, cartilage damage determination by joint fluid analysis, 1813
- matrix homeostasis in aging ankle cartilage, 2903
- MMPs in temporomandibular and knee joints during growth, maturation, and aging of mice, 3240
- modulation of MMP and ADAM gene expression in chondrocytes by IL-1 and oncostatin M, 961
- OA, biomarkers for progression of degeneration, 2549
- OA, cartilage degeneration: apoptosis and cellular vitality, 1986
- OA, cathepsin K and cartilage degeneration, 953
- OA, change in tibial cartilage volume in knee, 2065
- OA, collagenase and aggrecanase expression in chondrocytes, 2648
- OA, degradation modulated by COX-2-dependent prostaglandin E<sub>2</sub>, 1789
- OA, glycation increases collagen stiffness in, 114
- OA, inhibition of insulin-like growth factor binding protein 5 proteolysis, 694
- OA, n-3 fatty acids and human cartilage, 1544
- OA, oxidative damage: nitrotyrosine in, 2349
- OA, regional quantification of collagen and aggrecan mRNA in, 1536
- OA, TUNEL labeling in determining apoptosis in, 2260
- tissue-engineered composites for osteochondral repair, 2524

Cartilage intermediate-layer protein, in calcium pyrophosphate dihydrate crystal deposition disease, 3218

Cartilage loss, in OA, risk factors for progressive cartilage loss, 2884

Cartilage repair, enzyme treatment and, 976

**Cathepsin**

- OA and RA, cathepsin K and S expression in synovium, 663
- OA, cathepsin K and cartilage degeneration, 953

CCR4+ T lymphocytes, lupus nephritis, selective accumulation in, 735

CD4+, CD57+ T cells, in RA, 379

- CD4+ lymphocytes  
 heat-labile enterotoxin B subunit prevents autoimmune arthritis by induction of CD4+ T cells, 1671  
 MHC class II tetramers for direct analysis, 5  
 RA, profound lymphopenia following CD4 monoclonal antibody therapy, morbidity and, 1973
- CD11a, demethylation of *ITGAL* regulatory sequences in SLE, 1282
- CD13/aminopeptidase N-induced lymphocyte involvement in inflamed joints in RA, 2330
- CD14+, CD16 monocytes, joint inflammation in RA, 2578
- CD16, in phagocytosis, bacterial killing, and responses to immune complexes, 1351
- CD27, B cell subsets in SS, 2160
- CD34-selected vs hematopoietic stem cell transplantation in RA, 2301
- CD44, splice variants in fibroblast-like synoviocytes of RA, 2059
- CD154-CD40 interactions mediate plasma cell differentiation in SLE, 1417
- CD163, macrophage subpopulations in synovium in RA, 1210
- Celecoxib  
 apoptosis induction in rheumatoid synovial fibroblasts by, 3159  
 safety in aspirin-sensitive asthma, 2201
- Cell adhesion, in collagen-induced arthritis, antagonism by fibronectin peptides, 1102
- Cell death  $\alpha 5 \beta 1$  integrin and chondrocyte survival, 1528  
 autoantibody production induced by cell death following brain injury, 3290  
 autoantigen cleavage, autoimmunity, and, 1699  
 nitric oxide-mediated chondrocyte cell death with additional reactive oxygen species, 394
- Centromeric protein, in SS  
 CENP-A/CENP-B-specific immune response, 1866  
 granzyme B-generated autoantigen fragments, 1873
- Cepharanthine, suppression of MMP-9 production by, 1585
- Ceramide trihexoside, in Fabry's disease with avascular necrosis of femoral head, 1922
- Cevimeline, for dry mouth and dry eyes in SS, 748
- Charcot joint, MRI prediction of progressive joint destruction, 2814
- Chemokines  
 OA, apoptosis induction by growth-related oncogene  $\alpha$ , 3201  
 RA, migration of CX3CR1+ T cells in synovium, 2878  
 SS, T cell-attracting chemokines in, 2730
- Chest pain, unrecognized SAPHO as rare cause of, 566
- Children  
 childhood-onset disease, predicting damage in, 436  
 chronic infantile neurologic, cutaneous, articular syndrome, *CIAS1* mutations, 3340  
 neonatal-onset multisystem inflammatory disease, *CIAS1* mutations, 3340  
 Pediatric Quality of Life Inventory, 714  
 SLE, thrombotic thrombocytopenic purpura in childhood and, 1410  
*See also* Juvenile dermatomyositis; Juvenile idiopathic arthritis; Juvenile rheumatoid arthritis; Neonatal lupus
- Chinese population  
 hip OA, prevalence in Chinese vs US subjects, 1773  
 knee OA, prevalence of lateral knee OA in Chinese vs US subjects, 1217  
 RA and SLE, absence of anti-p53 antibodies in, 276
- Chinese traditional medicine, *Tripterygium wilfordii* hook F in RA, 1735
- Chlamydia, reactive arthritis diagnosis and, 319
- Chlamydia pneumoniae*, temporal arteritis and, 1056
- 2-Chloro-2'-deoxyadenosine, in SS treatment, 2248
- Chondrocytes  
 $\alpha 5 \beta 1$  integrin and survival of, 1528  
 Bcl-3 gene and transcription of MMP1 gene, 3230  
 bone morphogenetic proteins promote cartilage differentiation and protection, 149
- Chondrocytes (*cont'd*)  
 chondroprotective effect of TNF $\alpha$ -stimulated gene 6 protein, 2207  
 collagenase and aggrecanase expression in, 2648  
 functional replacement of oxygen by other oxidants in articular cartilage, 3190  
 gene expression profile of cultured human chondrocytes, 404  
 green tea inhibits nitric oxide production in, 2079  
 integrin signaling and MMP-13, 2368  
 light-activated gene transduction in, 2095  
 modulation of MMP and ADAM gene expression by IL-1 and oncostatin M, 961  
 nitric oxide-mediated chondrocyte cell death with additional reactive oxygen species, 394  
 nitric oxide-mediated up-regulation of IL-1-converting enzyme and IL-18, 2637  
 OA, apoptosis induction by growth-related oncogene  $\alpha$ , 3201  
 OA, collagenase and aggrecanase expression in, 2648  
 OA, exogenous expression of telomerase for expansion of, 683  
 OA, regional quantification of collagen and aggrecan mRNA in, 1536  
 replicative aging of, 2911  
 stromal cell-derived factor 1 and CXC chemokine receptor 4 in, 130  
 Chondroitin sulfates, in normal synovial fluid, age and sex effects on, 2105
- Chronic infantile neurologic, cutaneous, articular syndrome, *CIAS1* mutations, 3340
- CIAS1* mutations  
 chronic infantile neurologic, cutaneous, articular syndrome, 3340  
 periodic fever syndromes and, 2445
- Cigarette smoking. *See* Smoking
- Ciprofloxacin, MMP-3 expression in tendon-derived cells and, 3034
- Citrullinated peptides  
 ANCA-associated vasculitis, absence of anti-cyclic citrullinated peptide antibodies in, 849  
 deimmunized recombinant rat filaggrin antibodies, ELISA detection of, 2051  
 RA, intracellular citrullinated proteins in RA synovial tissue, 2824  
 RA-specific epitopes in natural filaggrin for autoantibody detection by line immunoassay, 1185
- c-Jun, halofuginone inhibition of *COL1A2* promoter activity, 2748
- c-Jun N-terminal kinase, in collagen-induced arthritis, 818
- Coagulation  
 cell-derived microparticles in synovial fluid of inflamed arthritis joints and, 2857  
 RA and, 2268
- Coffee, as RA risk factor, 83
- Cognitive function, in FM, 1980
- COL1A1* gene, polymorphism and osteoporosis, 2828
- COL1A2* gene, halofuginone inhibition of promoter activity, 2748
- Collagen  
 fibronectin-induced degradation of type II collagen through IL-1-mediated pathway, 138  
 halofuginone inhibition of *COL1A2* promoter activity, 2748  
 knee OA, type II collagen synthesis and degradation, 2613  
 matrix homeostasis in aging ankle cartilage, 2903  
 OA, cleavage sites and denaturation, MMP-1 and MMP-13 and, 2087  
 OA, glycation increases collagen stiffness in cartilage, 114  
 OA, regional quantification of collagen and aggrecan mRNA in, 1536  
 oral tolerance induction by poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen, 1109  
 RA, joint damage prediction in early disease by bone and joint markers, 2847  
 recombinant type IX collagen in murine collagen-induced arthritis, 1086  
 relapsing polychondritis, type II collagen peptide-specific T cell clones, 238

- Collagenase**  
 fibronectin-induced type II collagen degradation through IL-1-mediated pathway, 138  
 for integrative cartilage repair, 976  
 mRNA profiling in OA, 2648  
 OA, collagen cleavage sites and denaturation, MMP-1 and MMP-13 and, 2087  
 RA, stimulation by collagen matrix in synovial fibroblasts, mouse model, 64
- Collagen-induced arthritis**  
 angiostatin gene transfer in, 793  
 antagonism of cell adhesion by fibronectin peptides, 1102  
 attenuated by Bcl-x<sub>L</sub> expression, 514  
 C3-Tat/HIV-regulated IL-1Ra gene therapy, 1661  
 c-Jun N-terminal kinase, role in, 818  
 complement inhibition in, 3065  
 heat labile enterotoxin B subunit prevents autoimmune arthritis by induction of CD4+ T cells, 1671  
 IL-1 and, mouse models, 533  
 oral tolerance induction by poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen, 1109  
 osteopontin expression at sites of bone erosion, 1094  
 peptide-induced suppression of, 3369  
 quantitative trait loci regions in congenic rats modulate experimental arthritis, 2225  
 RANK expression and inflammation in, 3055  
 recombinant type IX collagen in, 1086  
 shared B cell epitopes, 2339  
 therapeutic effect of vasoactive intestinal peptide in, 271  
 TNF-dependent infiltration of mesenchymal cells, 507  
 TSG-6 transgene and susceptibility, 2453
- Color Doppler ultrasound, in detection of finger joint vascularization in RA, 647**
- Combination therapy**  
 FIN-RACo trial, 894  
 proliferative lupus nephritis, renal flares following pulse immunosuppressive therapy, 995  
 RA, COBRA combination therapy for early disease, long-term benefits of, 347  
 RA, comparison of combination therapies for, 1164  
 RA, delay to therapy and remission induction in early disease, 894  
 RA, IL-1Ra and MTX, 614
- Complement inhibition, in collagen-induced arthritis, 3065**
- Complement proteins, local production in RA synovium, 934**
- Complementary and alternative medicine, *Tripterygium wilfordii* hook F in RA, 1735**
- Complementary DNA array, gene expression in RA, 52**
- Congenital fascial dystrophy, with limitation of joint mobility, 1978**
- Congenital heart block**  
 distinguishing congenital from acquired form, 561  
 fetal risk, serologic marker for, 1233
- Corticosteroids**  
 JRA, intraarticular corticosteroids for coxitis in, 1620  
 SLE, prasterone (DHEA) and corticosteroid requirements in, 1820
- Corticotropin releasing hormone, familial and sporadic RA and corticotropin-releasing hormone genomic haplotype, 75**
- Costimulatory T cell blockade, in RA, 1470**
- Costs. See Medical costs; Pharmacoeconomics**
- Coxitis, intraarticular corticosteroids for JRA, 1620**
- CpG-induced arthritis, reduction by suppressive oligodeoxynucleotides, 2219**
- Crohn's disease**  
 anti-TNF treatment and lymphoma development, 3151  
 CARD15 mutations in, 3041
- Cryoglobulinemia, rituximab treatment, 2252**
- Crystal-induced arthritis, mimicking RA, 2816**
- Crystalline silica, SLE risk and, 1840**
- C-terminal crosslinking telopeptide of type II collagen (CTX-II), in RA, joint damage prediction in early disease, 21**
- CX3C chemokine receptor 1, in RA, migration of CXCR1+ T cells in synovium, 2878**
- CXC chemokine receptor 4, stimulation of MMP-3 release from chondrocytes by interaction of stromal cell-derived factor 1 and, 130**
- CXCL9, T cell-attracting chemokines in SS salivary gland lesions, 2730**
- CXCL10, T cell-attracting chemokines in SS salivary gland lesions, 2730**
- CXCL12**  
 hypoxia-induced production by synovial fibroblasts, 2587  
 induces monocyte localization to synovium, 824
- Cyclooxygenase-2 (COX-2) inhibitors**  
 apoptosis induction in rheumatoid synovial fibroblasts by, 3159  
 celecoxib, safety in aspirin-sensitive asthma, 2201  
 leukotriene B<sub>4</sub> and OA osteoblasts, 1804  
 nimesulide inhibits peroxisome proliferator-activated receptor-induced COX-2 expression, 494
- Cyclooxygenase-2 (COX-2) protein, OA cartilage degradation modulated by COX-2-dependent prostaglandin E<sub>2</sub>, 1789**
- Cyclophosphamide**  
 diffuse proliferative lupus glomerulonephritis, sequential oral cyclophosphamide and azathioprine, 1003  
 lupus nephritis treatment: Euro-Lupus Nephritis Trial, 2121  
 proliferative lupus nephritis, renal flares following pulse therapy, 995  
 RA, high doses with stem cell rescue, 837
- Cyclosporin A**  
 proteoglycan catabolism in articular cartilage, 124  
 RA, regulation of synovial cytokine production, 42  
 RA, VEGF regulation in synovial fibroblasts, 1202
- Cysteine-rich secretory protein 3 gene, in SS, 215**
- Cytokines**  
 anti-proteinase 3- and antitylperoxidase-associated vasculitis and, 1894  
 JIA, decrease in cytokine expression after autologous stem cell transplantation, 1121  
 RA, cyclosporine regulation of synovial cytokine production, 42

## D

- Dactylitis, in SpA, fast spin echo-T2 sequences with fat saturation, 2964**
- Dehydroepiandrosterone, in SLE**  
 mild-to-moderate disease, 2924  
 prasterone and corticosteroid requirements, 1820
- Dermatomyositis (DM)**  
 IL-1 $\alpha$  and MHC class I expression in, 1044  
 juvenile, immune response targets in, 3015  
 juvenile, magnesium abnormalities of skeletal muscle in, 475
- Dialysis-associated uremic tumoral calcinosis, 1416**
- Diffuse proliferative lupus glomerulonephritis**  
 sequential oral cyclophosphamide and azathioprine, 1003  
 total lymphoid irradiation for, 1014
- Digital vascular disease in SSc, smoking as risk factor for, 3312**
- Disability**  
 AS, functional disability predicts total costs, 223  
 knee OA, avoidance of activity and disability in, 1784
- Disc innervation, nerve growth inhibition by human disc aggrecan, 2658**
- Disease activity**  
 ACR RA Guidelines for management of, 328  
 lupus nephritis, up-regulation of IL-18 with, 3083  
 RA, CD4+, CD57+ T cells in, 379  
 RA, elevated levels of platelet microparticles and, 1498  
 SSc with Raynaud's phenomenon, 2410



Disease-modifying antirheumatic drugs (DMARDs), in RA  
 ACR RA Guidelines for management of, 2002 update, 328  
 combination therapy for early disease, long-term benefits of, 347  
 comparison of combination therapies for, 1164  
 delay to therapy and remission induction in early disease, 894  
 early treatment, 283  
*See also names of individual drugs*  
 Disease progression  
 knee OA, varus and valgus misalignment and, 2632  
 oligoarticular JRA, early pattern of joint involvement predicts  
 disease progression, 2708  
 RA, modeling, 2310  
 DNA, demethylation changes in SLE, 1282  
 DNA microarrays  
 gene expression profile of cultured human chondrocytes, 404  
 gene expression profiles, 874  
 guidelines for use, 859  
 proteomics technologies, 885  
 DNASE1 mutation, SLE and, 1974, 3109  
 Dog studies, in OA  
 nitric oxide-mediated up-regulation of chondrocyte IL-1-converting  
 enzyme and IL-18, 2637  
 regional quantification of collagen and aggrecan mRNA in, 1536  
 Doppler ultrasound, detection of finger joint vascularization in RA,  
 647  
 D-penicillamine, predictors and outcomes of SSc renal crisis, 2836,  
 2983  
 Dutch-type periodic fever, lack of isoprenoids raises IL-1 $\beta$ , 2794  
 Dynamic strength training, in RA, effect on functional capacity, 274  
 Dyslipidemia, in SLE, 2957

## E

Economics. *See* Medical costs; Pharmacoeconomics  
 Education, effect on need and willingness to undergo total joint  
 arthroplasty and, 3331  
 Elderly adults. *See* Older adults  
 Endothelial cells  
 activation caused by antiphospholipid antibodies induced by viral  
 peptides, 545  
 IL-15 inhibition of apoptosis, 3010  
 Endothelium, assessment of vascular function in SSc, 1324  
 Engineered cartilage, for osteochondral repair, 2524  
 Enterotoxin B, heat-labile subunit prevents autoimmune arthritis by  
 induction of CD4+ T cells, 1671  
 Enthesopathy  
 inflammatory heel pain in SpA, response to infliximab shown by  
 ultrasound, 840  
 plantar fasciitis, biomechanical factors and HLA-B27 in MRI-  
 determined bone changes, 489  
 Enzyme-linked immunosorbent assay (ELISA), RA diagnosis with  
 deiminated recombinant rat flaggrin antibodies, 2051  
 Epidural lipomatosis, in SLE, 1291  
 Epigallocatechin-3-gallate, nitric oxide production in chondrocytes  
 inhibited by green tea, 2079  
 Epitope spreading, in SLE, 1430  
 Epstein-Barr virus (EBV), autoantibody to LSm4 and LSm complex,  
 726  
 Erosion, RA, rheumatoid factor as predictor of increasing severity of,  
 906  
 Errata, 282, 1406, 1690, 2247, 2830  
 Estrogen, SLE risk and, 1830  
 Estrogen replacement therapy, severity of OA and, 1956  
 Etanercept  
 histoplasmosis as complication of therapy, 2565  
 lymphoma development and, 3151  
 RA, effect on tenosynovitis and nodules in, 559  
 RA, nodule development during anti-TNF $\alpha$  therapy, 843

Etanercept (*cont'd*)  
 RA, two-year radiographic and clinical outcomes, 1443  
 Still's disease, treatment with, 1171  
 Ethnic differences  
 acceptance of treatment modalities and, 2265, 2429  
 NIAMS conference report, 2280  
 TNF receptor genes, single-nucleotide polymorphisms in, 2045  
 willingness to consider joint replacement of hip or knee OA, 2429  
 Exercise in FM, growth hormone response to, 1344  
 Exertional compartment syndrome, as cause of bilateral forearm pain,  
 2245  
 Extracellular matrix  
 $\alpha$ 5 $\beta$ 1 integrin and chondrocyte survival, 1528  
 RA, expression of MMP inducer in, 373  
 Eyes  
 hydroxychloroquine, screening for retinopathy, 561  
 uveitis management, 309

## F

F $_2$ -isoprostanes, in SSc and Raynaud's phenomenon, 1319  
 Fabry's disease, avascular necrosis of femoral head in, 1922  
 Familial cold urticaria, NALP3/CIAS1/PYPAF1 mutations in, 2445  
 Familial granulomatosis, CARD15 mutations in, 3041  
 Familiality  
 granulomatosis, CARD15 mutations in, 3041  
 JRA and familial autoimmunity, 1851  
 OA, linkage on chromosome 2q and hand and knee OA, 3386  
 RA, corticotropin-releasing hormone genomic haplotype, 75  
 RA, TNF receptor II in, 2039  
 SLE clinical features, 2678  
 SLE, increased renal disease in familial-male disease, 428  
 SLE, stratification of pedigrees to detect SLE linkage, 2937  
 SLE, susceptibility genes at 1q23 and 16q12, 2928  
 Familial Mediterranean fever, reduced MEFV mRNA expression in,  
 2785  
 Fascia  
 congenital fascial dystrophy with limitation of joint mobility, 1978  
 exertional compartment syndrome as cause of bilateral forearm  
 pain, 2245  
 macrophagic myofasciitis, HLA-DRB1\*01 and, 2535  
 monocytic fasciitis in TRAPS, 2189  
 Fast spin echo-T2 sequences, dactylitis of SpA, 2964  
 Fatty acids, OA, n-3 fatty acids and human cartilage, 1544  
 Fc receptors  
 neutrophil Fc $\gamma$  receptor IIIb (CD16) in phagocytosis, bacterial  
 killing, and responses to immune complexes, 1351  
 RA, Fc $\gamma$  receptor IIIA polymorphism, 556  
 SLE, defective Fc-mediated immune complex clearance in, 1028  
 SLE, Fc $\gamma$  receptor gene polymorphisms, 1125, 1242, 1563  
 SLE, Fc $\gamma$  receptor IIIA in, 2132  
 SLE and lupus nephritis, Fc $\gamma$  receptor IIa polymorphism and  
 susceptibility to, 1563  
 Felty's syndrome, anti-G-CSF autoantibodies in, 2384  
 Fenofibrate, amyloidosis inhibition by, 1683  
 Fetus  
 anti-La/SSB antibodies, organ-specific binding to fetal apoptotic  
 cells, 1572, 2247  
 congenital heart block risk, serologic marker for, 1233  
 gene expression profile of cultured human chondrocytes, 404  
 hydroxychloroquine, transplacental passage in humans, 1123  
 neonatal lupus, biomarkers for fetal risk of congenital heart block,  
 1233  
 neonatal lupus, long-term followup, 2377  
 neonatal lupus, organ-specific binding of anti-La/SSB antibodies to  
 fetal apoptotic cells, 1572, 2247  
 neonatal lupus syndrome, subcellular redistribution of La/SSB dur-  
 ing physiologic apoptosis, mouse study, 202

## Fetus (cont'd)

SSc, pathogenic role of long-term fetal microchimerism in, 445  
Fibrillin, TGF $\beta$  induces fibroblast fibrillin-1 matrix formation, 3000  
Fibrin, RA and, 2268

Fibroblast-like synoviocytes, CD44 splice variants in RA, 2059

## Fibroblasts

Bcl-3 gene and transcription of MMP1 gene, 3230  
COX-2 inhibitors and apoptosis induction in, 3159  
halofuginone inhibition of *COL1A2* promoter activity, 2748  
IL-15 inhibition of apoptosis, 3010  
RA, collagenase 3 stimulation by collagen matrix in synovial fibroblasts, 64  
RA, FLIP in, 1512  
RA, retroviruses from synovial fibroblasts, 2811  
RA, TGF $\beta$ -mediated phosphorylation of Akt, 1504  
RA, VEGF regulation by cyclosporin A in synovial fibroblasts, 1202  
SSc, antifibroblast antibodies in, 1595, 1602  
SSc, parvovirus B19 infection of cultured skin fibroblasts, 2262  
SSc, *SPARC* polymorphisms and, 2990  
SSc, TGF $\beta$  receptor transcriptional activities in fibroblasts, 2421  
stromal cell-derived factor 1 (CXCL12) and VEGF production, hypoxia-induced, 2587  
TGF $\beta$  induces fibrillin-1 matrix formation, 3000

## Fibromyalgia (FM)

ACR classification criteria, 10-year retrospective, 1136  
augmented pain processing in, 1333  
cognitive function in, 1980  
dysautonomic nature of, 1415  
growth hormone response to exercise in, 1344  
rheumatologists, value of to FM patients, 3390  
serotonin transporter promoter region (5-HTTLPR) polymorphism, anxiety-related personality traits and, 845  
sibutramine treatment, 2545  
somatization in, 564

## Fibronectin

collagen degradation by collagenase through IL-1-mediated pathway induced by, 138  
collagen-induced arthritis, antagonism by fibronectin peptides, 1102  
RA, regulation by Wnt signaling in synoviocytes, 2867

Fibrosis, SSc and Smads, 1703

## Filaggrin

citruinated RA-specific epitopes in natural filaggrin for autoantibody detection by line immunoassay, 1185  
deimmunized recombinant rat filaggrin antibodies, ELISA detection, 2051

## Finger

dactylitis of SpA, fast spin echo-T2 sequences with fat saturation, 2964  
RA, laser-based imaging of joint inflammation, 1177  
SSc, granzyme B-generated autoantigen fragments following ischemic digital loss, 1873

Flare. See Disease flare

FLIP, in RA, 1512

Fluoroquinolone, myalgia induced by, investigated with <sup>31</sup>P MRS and in vitro contracture tests, 774

Fluoroquinolones, MMP-3 expression in tendon-derived cells and ciprofloxacin, 3034

Folate receptor, imaging of activated macrophages in rat with adjuvant-induced arthritis, 1947

Folic acid, treatment in RA, with MTX and folic acid supplementation, 1413

## Foot

heel pain in SpA, response to infliximab shown by ultrasound, 840  
neuropathic joint disease, MRI prediction of progressive joint destruction, 2814  
plantar fasciitis, biomechanical factors and HLA-B27 in MRI bone changes, 489

## Foot (cont'd)

RA, minimal clinically important difference in joint damage by 2 scoring methods, 913  
RA, subtalar and midtarsal joint architecture by MRI, 3168  
Forearm, bilateral pain, chronic exertional compartment syndrome as cause of, 2245  
Fractures, in OA  
BMD and knee fracture, 92  
bone mass and, 1  
Functional capacity in RA, dynamic strength training and, 274  
Functional disability in AS, total costs predicted by, 223  
Functional status  
neuropsychiatric SLE, in patients with, 2665  
SSc and Raynaud's phenomenon, in patients with, 2410

## G

Gastropathy, acetaminophen vs NSAIDs in elderly adults, 3046

Gastroprotective measures, underuse with NSAIDs, 2195

## Gender

effects of on chondroitin sulfate in normal synovial fluid, 2105  
influence of HLA-DRB1 shared epitope on manifestations of RA in men and women, 1481

## Gene therapy

adjuvant-induced arthritis, TIMPs, 3361  
collagen-induced arthritis, C3-Tat/HIV-regulated IL-1Ra, 1661  
light-activated gene transduction in chondrocytes, 2095  
viral IL-10 gene therapy for osteolysis, 1298

## Genetics

ADAM gene, modulation of expression in chondrocytes by IL-1 and oncostatin M, 961  
arthritis in MRL/lpr mice, 1067  
AS, *NOD2* variants in, 1629  
autosomal-dominant recurrent fever, *TNFRSF1A* mutation in family with, 1061  
Bcl-3 gene and transcription of MMP-1 gene, 3230  
bone morphogenetic protein receptor type II mutations and pulmonary hypertension and connective tissue disease, 2829  
*CARD15* mutations in familial granulomatosis syndromes, 3041  
*COL1A1* polymorphism and osteoporosis, 2828  
collagen-induced arthritis, angiostatin gene transfer in, 793  
collagen-induced arthritis, attenuated by Bcl-x<sub>L</sub> expression, 514  
collagen-induced arthritis, quantitative trait loci regions in congenic rats modulate experimental arthritis, 2225  
collagen-induced arthritis, shared B cell epitopes, 2339  
cultured human chondrocytes, gene expression profile of, 404  
familial Mediterranean fever, reduced MEFV mRNA expression in, 2785  
gene expression profiles and arthritis research, 874  
halofuginone inhibition of *COL1A2* promoter activity, 2748  
JIA, HLA class I region susceptibility gene, 1614  
JIA, sacroiliitis in, 986  
JRA, familial autoimmunity, 1851  
juvenile DM, immune response targets in, 3015  
juvenile idiopathic oligoarthritis, linkage of HLA loci in, 2716  
juvenile idiopathic oligoarthritis, single-nucleotide polymorphism-tagged TNF haplotypes in, 3304  
light-activated gene transduction in chondrocytes, 2095  
link between acute-phase response and arthritis development, 259  
lupus nephritis, T cell receptor V $\beta$  gene in, 2141  
macrophage migration inhibitory factor gene, mutation screening of, 2402  
macrophagic myofasciitis, HLA-DRB1\*01 and, 2535  
mixed connective tissue disease, new conformational epitope, 3273  
*Mycobacterium butyricum* adjuvant-induced arthritis, 1075  
myopathy, Mestizo phenotypes and genotypes, 1885  
*NALP3/CIAS1/PYPAFI* mutations and periodic fever syndromes, 2445

## Genetics (cont'd)

- neonatal-onset multisystem inflammatory disease, *CIAS1* mutations, 3340
- nimesulide inhibits peroxisome proliferator-activated receptor-induced COX-2 expression, 494
- OA, apoptosis induction by growth-related oncogene  $\alpha$ , 3201
- OA, finer linkage mapping of an OA locus, 1780
- OA, IL-1 gene cluster and susceptibility to knee OA, 1519
- OA, linkage on chromosome 2q and hand and knee OA, 3386
- OA, whole-genome scan for hand OA, 946
- osteoporosis, *COL1A1* polymorphism and, 2828
- periodic fever syndromes and *NALP3/CIAS1/PYPAF1* mutations, 2445
- RA, CD44 splice variants in fibroblast-like synoviocytes, 2059
- RA, citrullinated RA-specific epitopes in natural filaggrin for autoantibody detection by line immunoassay, 1185
- RA, corticotropin-releasing hormone genomic haplotype in familial and sporadic RA, 75
- RA, Fc $\gamma$  receptor IIIA polymorphism and, 556
- RA, gene expression by complementary DNA array and RNA arbitrarily primed PCR, 52
- RA, heat-shock protein 73 and HLA-DRB1 alleles, 929
- RA, HLA-DRB1 shared epitope and sex interaction, 1481
- RA, HLA-DRB1 shared epitope genotype associations in, 2320
- RA, mannose-binding lectin genotypes and outcomes, 555
- RA, MMP-3 and HLA-DRB1 gene polymorphisms in, 1754
- RA, shared B cell epitopes, 2339
- RA, shared epitope hypothesis, 921
- RA, susceptibility genes, call for global collaboration, 582
- RA, *TNFR2* gene, 2039
- RA, whole-genome scan of susceptibility loci, 632
- SLE, demethylation of *ITGAL* regulatory sequences in, 1282
- SLE, *DNASE1* mutation and, 1974, 3109
- SLE, familiarity of clinical features, 2678
- SLE, Fc $\gamma$  receptor gene polymorphisms, 1125, 1242, 1563
- SLE, Fc $\gamma$  receptor IIIA in, 2132
- SLE, recombination activating genes 1 and 2, 1255
- SLE, stratification of pedigrees to detect SLE linkage, 2937
- SLE, susceptibility genes at 1q23 and 16q12, 2928
- SpA, *CARD15/NOD2* analyses in, 1405
- SpA, HLA-B\*2709 subtype confers susceptibility, 553
- SpA, *NOD2* variants in, 1629
- SS, C57BL/6 mouse model, 1390
- SS, cysteine-rich secretory protein 3 gene in, 215
- SSc, dysregulation of signaling pathway in, 1857, 2830
- SSc, immunodominant epitope on RNA polymerase III, 2742
- SSc, *SPARC* polymorphisms and, 2990
- TNF receptor genes, single-nucleotide polymorphisms in, 2045
- TNF receptor II and IL-6 gene polymorphisms, hypertension with RA and, 3096
- TRAPS, *TNFRSF1A* mutation, 245, 2181
- See also Gene transfer; Mutations; Polymorphisms
- Gene transduction, light-activated gene transduction in chondrocytes, 2095
- Gene transfer
  - IL-10 and monosodium urate monohydrate crystal-induced inflammation, 2504
  - IL-12 gene transfer and chronic destructive arthritis, 1379
  - osteoprotegerin gene transfer protects against osteolysis, 2514
  - See also Genetics; Mutations; Polymorphisms
- Germinal centers, impaired uptake of apoptotic cells in SLE, 191
- Giant cell arteritis (GCA)
  - acetylsalicylic acid therapy, 457
  - aspirin treatment, 3113
  - MTX treatment, 1309
  - parvovirus DNA, PCR detection, 3099

## Glucocorticoids

- osteoporosis and, 3115, 3136
- RA, 2553
- RA, ACR Guidelines for management of, 2002 update, 328
- Glucosamine, oral, effect on cartilage and meniscus, 2495
- Glucosyl-galactosyl-pyridinoline, in RA, joint damage prediction in early disease, 21
- Glutathione S-transferase M1, in RA, polymorphism and, 640
- Glycation, advanced glycation end products increase collagen stiffness in articular cartilage, 114
- Gonadotropin-releasing hormone agonists, to prevent multiple gestations in SLE and APS, 2542
- Gout
  - disposal of monosodium urate monohydrate crystals by macrophages, 3026
- gouty tophi in pancreatic pseudocyst, 565
- monosodium urate monohydrate crystal-induced inflammation in vivo, 1643
- Gouty arthritis, melanocortin type 3 receptor agonists and, 2765
- Granulocyte colony-stimulating factor (G-CSF), anti-G-CSF autoantibodies in Felty's syndrome and neutropenic SLE, 2384
- Granulomatoses, *CARD15* mutations in, 3041
- Granzyme B autoantigens, in SSc, 1873
- Greek population with SS, long-term risk of mortality and lymphoproliferative disease, 741
- Green tea, nitric oxide production in chondrocytes inhibited by, 2079
- Group B streptococci-induced arthritis, beneficial effect of IL-12 on, 806
- Growth hormone
  - cachexia in RA not due to, 2574
  - exercise in FM and, 1344
- Growth-related oncogene  $\alpha$ , apoptosis induction in OA chondrocytes, 3201

## H

- Halofuginone, inhibition of *COL1A2* promoter activity, 2748
- Hand
  - carpal tunnel syndrome, sonographic criteria, 1914
  - OA, linkage on chromosome 2q and hand and knee OA, 3386
  - OA, whole-genome scan for, 946
  - RA, minimal clinically important difference in joint damage by 2 scoring methods, 913
  - RA, MTX therapy and radiographic healing and sustained remission, 2804
- Health care costs. See Medical costs; Pharmacoeconomics
- Heart block, distinguishing congenital from acquired form, 561
- Heat-shock protein
  - adjuvant-induced arthritis, suppression by nasally administered heat-shock protein 60 peptide analog, 1937
  - RA, HLA-DRB1 alleles and heat-shock protein 73, 929
- Heel pain, in SpA, response to infliximab shown by ultrasound, 840
- Hematopoietic stem cells, plasticity of, 855
- Hematopoietic stem cell transplantation
  - for RA, CD34-selected vs, 2301
  - for severe and refractory SLE, 2917
- Henoch-Schönlein purpura, ACR 2001 Slide Competition winners, 1160
- Hepatitis C
  - type II mixed cryoglobulinemia, rituximab treatment, 2252
  - vasculitis and, 585
- Hepatitis C-related systemic vasculitis, IFN $\alpha$  and ribavirin treatment, 3317
- High-density lipoprotein, in SLE and APS, correlation of paraoxonase to antibodies to high-density lipoprotein, 2686
- High mobility group box chromosomal protein 1, proinflammatory mediator in synovitis, 2598

## Hip

- JRA, intraarticular corticosteroids for coxitis in, 1620
- OA, finer linkage mapping of an OA locus, 1780
- OA, increased circulating MMP-3 and MMP-9 in rapidly destructive disease, 2625
- OA, prevalence in Chinese vs US subjects, 1773
- OA, triamcinolone for, 2546
- SpA, TNF $\alpha$  blockade for enthesitis, 3396
- Hip replacement, in OA
  - complications, 2436
  - ethnic/racial differences in willingness to consider, 2429
  - risk factors for, 675
  - timing of total joint replacement affects outcomes, 3327
- Histiocytes, lupus-related hemophagocytic syndrome, 2537
- Histones, T cell autoimmunity to in normal immune system and SLE, 1270
- Histoplasmosis, as a complication of anti-TNF $\alpha$  therapy, 2565
- HLA
  - AS, HLA-B\*1403 in West African population, 2968
  - class II tetramers for direct analysis of antigen-specific CD4+ T cells, 5
  - HLA-B27, expression of cell-surface homodimers, 2972
  - HLA-B27, nuclear factor  $\kappa$ B activation in monocytes modulated by, 2172
  - JIA, HLA class I region susceptibility gene, 1614
  - JIA, sacroiliitis in, 986
  - juvenile idiopathic oligoarthritis, linkage of HLA loci in, 2716
  - juvenile idiopathic oligoarthritis, proinflammatory response to self HLA epitopes, 2721
  - plantar fasciitis, MRI-determined bone changes and HLA-B27, 489
  - RA, class II antigens and joint damage, 899
  - SpA, HLA-B\*2709 subtype confers susceptibility to, 553
- HLA-DRB1 alleles
  - juvenile idiopathic oligoarthritis, linkage of HLA loci in, 2716
  - macrophagic myofasciitis and, 2535
  - RA, heat-shock protein 73 and, 929
  - RA, HLA-DRB1 genotype associations in, 2230
  - RA, polymorphism in, 1754
  - RA, shared epitope-sex interactions in, 1480
  - shared epitope hypothesis, 921
- hLSm4 and LSm complex, autoantibody to, 726
- Homing peptides, synovium-specific, 2109
- Homodimers, cell-surface expression of HLA-B27 homodimers, 2972
- Hormones, SLE risk and, 1830
- Hospital, complications of total hip replacement surgery, 2437
- Hyaluronic acid, in OA, intraarticular hyaluronate injections in knee chondrocalcinosis, 847
- Hydroxychloroquine
  - cutaneous reactions to, 3392
  - mucocutaneous hyperpigmentation associated with, 1698
  - RA, comparison of combination therapies for, 1164
  - RA, concentration-response relationships in, 1460
  - screening for antimalarial retinopathy, 561
  - transplacental passage in humans, 1123
- Hylan, severe adverse reactions, 2543
- Hyperimmunoglobulinemia D and periodic fever syndrome, lack of isoprenoids raises IL-1 $\beta$ , 2794
- Hyperpigmentation, hydroxychloroquine-associated mucocutaneous, 1698
- Hypoxia
  - cytokine-induced production of proinflammatory mediators in cartilage and, 968
  - stromal cell-derived factor 1 (CXCL12) and VEGF production, 2587

## I

- IDEC-131, SLE treatment with anti-CD154 treatment, 3251
- Idiopathic inflammatory myopathy
  - Mestizo phenotypes and genotypes, 1885
  - neural network as cancer predictor in, 2547
- Idiopathic thrombocytopenic purpura, B cell-ablative therapy for, 1984
- Imaging
  - ACR 2001 Slide Competition winners, 1160
  - acute-phase response and arthritis development, genetic link between, 259
  - adjuvant-induced arthritis, bone protection and osteoprotegerin therapy in rats, 1926
  - adjuvant-induced arthritis, murine recombinant soluble IL-17R:Fc fusion protein treatment, 802
  - amyloidosis, fenofibrate inhibition of, 1683
  - antigen-induced monarticular arthritis, antiarthritic activity of orally active C5a antagonist, 2476
  - bone morphogenetic proteins promote cartilage differentiation and protection, 149
  - carpal tunnel syndrome, sonographic criteria for diagnosis of, 1914
  - cartilage, enzyme treatment and integrative repair of, 976
  - Charcot joint, MRI prediction of progressive joint destruction, 2814
  - chondrocytes, gene expression profile of cultured human chondrocytes, 404
  - collagen-induced arthritis, angiostatin gene transfer in, 793
  - collagen-induced arthritis, antagonism of cell adhesion by fibronectin peptides, 1102
  - collagen-induced arthritis, C3-Tat/HIV-regulated IL-1Ra gene therapy, 1661
  - collagen-induced arthritis, IL-1 and, mouse models, 533
  - collagen-induced arthritis, oral tolerance induction by poly(lactico-glycolic acid) nanoparticles entrapping type II collagen, 1109
  - collagen-induced arthritis, osteopontin expression at sites of bone erosion, 1094
  - collagen-induced arthritis, RANK expression and inflammation in, 3055
  - collagen-induced arthritis, TNF-dependent infiltration of mesenchymal cells, 507
  - collagen-induced arthritis, TSG-6 transgene and susceptibility, 2453
  - congenital fascial dystrophy with limitation of joint mobility, 1978
  - CpG-induced arthritis, reduction by suppressive oligodeoxynucleotides, 2219
  - crystal-induced arthritis mimicking RA, 2816
  - dactylitis of SpA, fast spin echo-T2 sequences, 2964
  - dialysis-associated uremic tumoral calcinosis, 1416
  - engineered cartilage for osteochondral repair, 2524
  - exertional compartment syndrome as cause of bilateral forearm pain, 2245
  - FM, MRI evidence of augmented pain processing in, 1333
  - gout, monosodium urate monohydrate crystal-induced inflammation in vivo, 1643
  - gouty arthritis, melanocortin type 3 receptor agonists and, 2765
  - gouty tophi in pancreatic pseudocyst, 565
  - halofuginone inhibition of *COL1A2* promoter activity, 2748
  - high mobility group box chromosomal protein 1 as proinflammatory mediator in synovitis, 2598
  - hydroxychloroquine-associated mucocutaneous hyperpigmentation, 1698
  - IL-12 gene transfer and chronic destructive arthritis, 1379
  - IL-15 inhibition of fibroblast and endothelial cell apoptosis, 3010
  - intervertebral disc, nerve growth inhibition by human disc aggrecan, 2658
  - JIA, decrease in synovial cellularity and cytokine expression after autologous stem cell transplantation, 1121
  - JRA, intraarticular corticosteroids for coxitis in, 1620
  - juvenile DM, immune response targets in, 3015



# Imaging (cont'd)

- knee, cartilage damage determination by joint fluid analysis in osteonecrotic knee, 1813
- knee, progressive thinning of knee cartilage in absence of normal joint loading and movement, 2073
- knee, trabecular architecture using high-resolution MRI, 385
- knee OA, progressive cartilage loss, MRI study of risk factors, 2884
- lectin-like oxidized LDL receptor 1 in zymosan-induced arthritis, 2486
- light-activated gene transduction in chondrocytes, 2095
- lupus nephritis, T cell receptor V $\beta$  gene in, 2141
- lupus nephritis, up-regulation of IL-18 with disease activity, 3083
- lupus-related hemophagocytic syndrome, 2537
- macrophages, folate-targeted imaging in rats, 1947
- monocytic fasciitis in TRAPS, 2189
- monosodium urate monohydrate crystals, safe disposal by differentiated macrophages, 3026
- MRI, progressive thinning of knee cartilage in absence of normal joint loading and movement, 2073
- neonatal lupus, organ-specific binding of anti-La/SSB antibodies to fetal apoptotic cells, 1572, 2247
- neovascularization suppressed by inhibition of IL-1 but not TNF, 2604
- neuropathic joint disease, MRI prediction of progressive joint destruction, 2814
- OA,  $\alpha$ 5 $\beta$ 1 integrin and chondrocyte survival, 1528
- OA, BMD and fracture in knee OA, 92
- OA, cathepsin K and cartilage degeneration, 953
- OA, cathepsin K and S expression in, 663
- OA, change in tibial cartilage volume in knee by MRI, 2065
- OA, cleavage sites and denaturation, MMP-1 and MMP-13 and, 2087
- OA, degradation modulated by COX-2-dependent prostaglandin E<sub>2</sub>, 1789
- OA, inhibition of insulin-like growth factor binding protein 5 proteolysis, 694
- OA, knee pain reduces joint space width in anteroposterior radiographs, 1223
- OA, mesenchymal stem cells in advanced disease, 704
- OA, nitrotyrosine in, 2349
- OA, reproducibility of semiflexed MTP view in knee OA, 109
- OA, trabecular architecture of knee using high-resolution MRI, 385
- osteoid osteoma of capitate, 2808
- osteolysis, osteoprotegerin gene transfer protects against, 2514
- plantar fasciitis, biomechanical factors and HLA-B27 in MRI bone changes, 489
- PM and DM, IL-1 $\alpha$  and MHC class I expression in, 1044
- PsA, T cell-targeted therapy with alefacept, 2776
- pulmonary hypertension in autoimmune rheumatic diseases, 1997
- quantitative computed tomography to predict vertebral fractures in postmenopausal women, 1292
- RA, arterial intima-media thickness detected in ultrasonography, 1489
- RA, atherosclerosis evidence by carotid ultrasound, 1714
- RA, cathepsin K and S expression in, 663
- RA, CD13/aminopeptidase N-induced lymphocyte involvement in inflamed joints, 2330
- RA, CD44 splice variants in fibroblast-like synoviocytes, 2059
- RA, color Doppler ultrasound for detection of finger joint vascularization, 647
- RA, complement protein production in synovium, 934
- RA, complementary DNA array and RNA arbitrarily primed PCR for gene expression in, 52
- RA, expression of extracellular MMP inducer and enhancement of MMP production in, 373
- RA, FLICP in, 1512
- RA, high-dose cyclophosphamide with stem cell rescue, 837

# Imaging (cont'd)

- RA, high-resolution ultrasound for target joints in, 1969
- RA, intracellular citrullinated proteins specific for, 2824
- RA, laser-based imaging of finger joint inflammation, 1177
- RA, macrophage subpopulations in synovium, 1210
- RA, migration of CX3CR1+ T cells in synovium, 2878
- RA, MRI assessment of leflunomide and MTX for, 366
- RA, MTX therapy and radiographic healing and sustained remission, 2804
- RA, rheumatoid factor as predictor of increasing severity of erosions, 906
- RA, stimulation by collagen matrix in synovial fibroblasts, mouse model, 64
- RA, subtalar and midtarsal joint architecture by MRI, 3168
- RA, synovial tissue from knee joint compared with small joint, 2034
- RA, TNF $\alpha$ -mediated joint destruction inhibited by osteoprotegerin, 785
- RA, very high-dose anti-TNF $\alpha$  blockade and long-term remission, 1971
- RA, vitamin E and joint destruction and clinical inflammation in transgenic RA mouse model, 522
- reactive amyloidosis, conversion of serum amyloid A into extracellular amyloid, 1905
- SAPHO, as rare cause of chronic anterior chest pain, 566
- SAPHO, sustained response to anti-TNF $\alpha$ , 1965
- SLE, autologous stem cell transplantation in refractory disease with pulmonary impairment, 1580
- SLE, epidural lipomatosis in, 1291
- SLE, impaired uptake of apoptotic cells into tingible body macrophages in germinal centers, 191
- SLE, neuropathy in, 1228
- SLE, nuclear lamin B1 autoantibodies and thromboprotection, 2695
- SpA, fast spin echo-T2 sequences in dactylitis, 2964
- SpA, TNF $\alpha$  blockade for enthesitis, 3396
- SS, B cell subsets in, 2160
- SS, C57BL/6 mouse model, 1390
- SS, cysteine-rich secretory protein 3 gene, 215
- SS, MMP-9 suppression by cepharanthine, 1585
- SS, T cell-attracting chemokines in salivary gland lesions, 2730
- SSc, antifibroblast antibodies in, 1595, 1602
- SSc, male offspring T cells reactive against maternal MHC, 445
- SSc, TGF $\beta$  induces fibroblast fibrillin-1 matrix formation, 3000
- stromal cell-derived factor 1 (CXCL12) and monocyte localization to synovium, 824
- stromal cell-derived factor 1 (CXCL12) and VEGF, hypoxia-induced production in synovial fibroblasts, 2587
- synovitis, photodynamic therapy for, 1371
- synovium-specific homing peptides, 2109
- Takayasu arteritis, MRI in, 1634
- TNF $\alpha$ -stimulated gene 6 protein, chondroprotective effect of, 2207
- tongue myositis and macroglossia in polymyositis, 2762
- tristetraprolin, function, expression, and subcellular distribution of, 1362
- uveitis, management of, 309
- vasculitis, hepatitis C virus infection and, 585
- vertebral fractures, quantitative computed tomography to predict in postmenopausal women, 1292
- wrist, osteoid osteoma of capitate, 2808
- Immune complex
  - neutrophil Fc $\gamma$  receptor IIIb (CD16) in response to, 1351
  - SLE, defective Fc-mediated immune complex clearance in, 1028
- Immunity
  - autoimmune T cells in healthy subjects and SLE, 1270
  - diffuse proliferative lupus glomerulonephritis, sequential oral cyclophosphamide and azathioprine, 1003
  - sexual dimorphism in innate immune response, 250

- Immunoglobulin G, in neonatal lupus, antibodies reactive with SSA/Ro-SSB/La complex in breast milk, 269
- Immunologic laboratory tests, likelihood ratios and, 2547
- Immunosuppression
- lupus nephritis, Euro-Lupus Nephritis Trial of cyclophosphamide, 2121
  - lupus nephritis, total lymphoid irradiation for, 1014
  - proliferative lupus nephritis, renal flares following pulse therapy, 995
- In memoriam, LeRoy, E. Carwile
- Infants. *See* Children; Neonatal lupus; Neonatal-onset multisystem inflammatory disease
- Infection
- anti-TNF $\alpha$  and *Listeria monocytogenes* infection, 2255
  - LSm4 autoantibodies following EBV infection, 726
  - frequency of in RA, 2287
  - predictors of in RA, 2294
  - SSc, parvovirus B19 infection of cultured skin fibroblasts, 2262
  - vasculitis, hepatitis C virus infection and, 585
- Inflammation
- adjuvant-induced arthritis, murine recombinant soluble IL-17R:Fc fusion protein treatment, 802
  - Bcl-3 gene and transcription of MMP-1 gene, 3230
  - cell-derived microparticles in synovial fluid of inflamed arthritic joints and, 2857
  - collagen-induced arthritis, c-Jun N-terminal kinase, 818
  - collagen-induced arthritis, RANK expression and, 3055
  - genetic link between acute-phase response and arthritis development, 259
  - juvenile idiopathic oligoarthritis, proinflammatory response to self HLA epitopes, 2721
  - monosodium urate monohydrate crystal-induced inflammation in vivo, 1643
  - NK cells in inflamed joints, 1763
  - OA, n-3 fatty acids and human cartilage, 1544
  - peroxisome proliferator-activated receptor  $\gamma$  and, 598
  - RA, CD14+CD16 monocytes and joint inflammation, 2578
  - RA, vitamin E and transgenic mouse model of, 522
  - reactive arthritis and RA, steroid hormones, IL-6, and TNF in early disease, 654
  - viral IL-10 gene inhibition of, 1298
- Inflammatory polyarthritis, mortality in early disease, 2010
- Infliximab
- histoplasmosis as complication, 2565
  - lymphoma development and, 3151
  - RA, bullous skin lesions following infusion, 2257
  - RA, renal amyloidosis treated with, 2571
  - RA, serum infliximab and clinical improvement in, 1451
  - SpA, infliximab vs placebo in, 755
  - SpA, response of inflammatory heel pain shown by ultrasound, 840
  - SS, to restore normal aquaporin 5 distribution in salivary glands, 2249
  - SS primary disease, 3301
  - uveitis treatment, 2821
- Innate immunity
- RA and, 299
  - sexual dimorphism in, 250
- Insulin-like growth factor 1, OA improvement and, 694
- Insulin-like growth factor binding proteins
- inhibition of proteolysis in OA, 694
  - in uncultured cartilage, 2358
- Integrins  $\alpha 5 \beta 1$  integrin and chondrocyte survival, 1528
- chondrocyte integrin signaling and MMP-13, 2368
- Interferon (IFN)
- group B streptococci-induced arthritis, beneficial effect on mediated by IFN $\gamma$ , 806
  - hepatitis C virus-related systemic vasculitis treatment, 3317
- Interferon (IFN) (*cont'd*)
- SS, T cell-attracting chemokines in salivary gland lesions, 2730
- Interferon- $\gamma$ -inducible 10-kd protein, T cell-attracting chemokines in SS salivary gland lesions, 2730
- Interleukin-1 (IL-1)
- Bcl-3 gene and transcription of MMP-1 gene, 3230
  - collagen-induced arthritis, C3-Tat/HIV-regulated IL-1Ra gene therapy, 1661
  - fibronectin-induced type II collagen degradation through IL-1-mediated pathway, 138
  - modulation of MMP and ADAM gene expression in chondrocytes by, 961
  - neovascularization suppressed by inhibition of IL-1 but not TNF, 2604
  - OA, IL-1 gene cluster and susceptibility to knee OA, 1519
  - RA, as treatment target, 574, 1690
  - RA, mouse models, 533
- Interleukin-1 $\alpha$  (IL-1 $\alpha$ ), expression in PM and DM, 1044
- Interleukin-1 $\beta$  (IL-1 $\beta$ )
- hyperimmunoglobulinemia D and periodic fever syndrome, lack of isoprenoids raises IL-1 $\beta$ , 2794
  - MMP-3 expression in tendon-derived cells enhanced by ciprofloxacin, 3034
  - nitrotyrosine in aging and OA cartilage, 2349
- Interleukin-1-converting enzyme, in OA, nitric oxide-mediated up-regulation of chondrocyte IL-1-converting enzyme and IL-18, 2637
- Interleukin-1 receptor antagonist (IL-1Ra), in RA combination treatment with MTX, 614
- safety, 2838
- Interleukin-6 (IL-6)
- RA, anti-IL-6 receptor monoclonal antibody in, 3143
  - RA, hypertension with RA and gene polymorphisms, 3096
  - RA and reactive arthritis, steroid hormones, IL-6, and TNF in early disease, 654
  - Still's disease, monoclonal anti-IL-6 receptor antibody for treatment, 3388
- Interleukin-10 (IL-10)
- adjuvant-induced arthritis, suppression by IL-10-driven regulatory cells induced by heat-shock protein 60 peptide analog, 1937
  - group B streptococci-induced arthritis, beneficial effect on mediated by, 806
  - IL-10 gene promoter and Fc $\gamma$  receptor IIa polymorphism as risk factor for SLE, 1125
  - monosodium urate monohydrate crystal-induced inflammation and, 2504
  - osteolysis, viral IL-10 gene therapy for, 1298
  - RA, cyclosporine regulation of synovocyte cytokine production, 42
- Interleukin-12 (IL-12)
- gene transfer and chronic destructive arthritis, 1379
  - group B streptococci-induced arthritis, beneficial effect on, 806
- Interleukin-15 (IL-15)
- inhibition of fibroblast and endothelial cell apoptosis by, 3010
  - RA, cyclosporine regulation of synovocyte cytokine production, 42
- Interleukin-17 (IL-17), adjuvant-induced arthritis, murine recombinant soluble IL-17R:Fc fusion protein treatment, 802
- Interleukin-18 (IL-18)
- in lupus nephritis, up-regulation with disease activity, 3083
  - OA, nitric oxide-mediated up-regulation of chondrocyte IL-1-converting enzyme and IL-18, 2637
  - SLE, 1410
  - systemic JIA, 2539
- Intervertebral disc aggrecan, nerve growth inhibition by, 2658
- Intravenous immunoglobulin infusions, in chronic refractory PM, 467
- In vitro contracture tests, fluoroquinolone-induced myalgia investigated with, 774
- Iron deficiency, inflammatory arthritis and, 847

Irrigation, needle tidal, for OA, 100  
 Isoprenoids, in hyperimmunoglobulinemia D and periodic fever syndrome, lack of raises IL-1 $\beta$ , 2794  
 Italian population  
   SpA, HLA-B\*2709 subtype confers susceptibility to, 553  
   SSc, reproductive factors and risk of, 451  
*ITGAL* gene, DNA demethylation changes in SLE, 1282

## J

Japanese population with SLE, Fc $\gamma$  receptor gene polymorphisms, 1242  
 Joint  
   ACR RA Guidelines for management of joint protection, 328  
   progressive thinning of knee cartilage in absence of normal joint loading and movement, 2073  
 Joint architecture  
   subtalar and midtarsal joint architecture by MRI, 3168  
   trabecular architecture of knee by MRI, 385  
 Joint damage  
   adjuvant-induced arthritis, murine recombinant soluble IL-17R:Fc fusion protein treatment, 802  
   collagen-induced arthritis, c-Jun N-terminal kinase, 818  
   glucosamine, effect on cartilage and meniscus, 2495  
   knee osteonecrosis, cartilage damage determination by joint fluid analysis, 1813  
   OA, cartilage degeneration: apoptosis and cellular vitality, 1986  
   OA, type II collagen synthesis and degradation, 2613  
   RA, anti-TNF $\alpha$  treatment and radiographic damage inhibition with minimal or no clinical improvement, 2817  
   RA, color Doppler ultrasound to detect finger joint vascularization in, 647  
   RA, expression of extracellular MMP inducer and enhancement of MMP production in, 373  
   RA, high-resolution ultrasound for target joints in, 1969  
   RA, HLA class II antigens and, 899  
   RA, minimal clinically important difference by 2 scoring methods, 913  
   RA, synovial tissue from knee joint compared with small joint, 2034  
 Joint destruction  
   neuropathic joint disease, MRI prediction of, 2814  
   osteoprotegerin inhibits TNF $\alpha$ -mediated joint destruction, 785  
   RA, HLA class II antigens and, 899  
   RA, joint damage prediction in early disease by bone and joint markers, 2847  
   RA, prediction in early RA by molecular markers, 21  
   RA, vitamin E and transgenic mouse model of, 522  
 Joint distraction, ankle OA treatment, 2893  
 Joint fluid. *See* Synovial fluid  
 Joint lavage, urea as passive transport marker, 420  
 Joint prosthesis, osteoprotegerin gene transfer protects against osteolysis, 2514  
 Joint replacement  
   education and income and need and willingness to undergo, 3331  
   hip replacement in OA, complications, 2436  
   hip replacement in OA, risk factors for, 675  
   knee or hip OA, ethnic/racial differences in willingness to consider, 2429  
   knee or hip OA, nonrandom evolution of end-stage OA of lower limbs, 3185  
   knee or hip OA, timing affects clinical outcomes, 3327  
 Joint space width, in OA, knee pain reduces joint space width in anteroposterior radiographs, 1223  
 Juvenile DM  
   immune response targets in, 3015  
   magnesium abnormalities of skeletal muscle in, 475

Juvenile idiopathic arthritis (JIA)  
   autologous stem cell transplantation, decrease in synovial cellularity and cytokine expression following, 1121  
   HLA class I region susceptibility gene, 1614  
   long-term outcomes in, 2392  
   macrophage migration inhibitory factor gene polymorphism and, 2402  
   macrophage migration inhibitory factor in, 232  
   oligoarthritis, linkage of HLA loci in, 2716  
   oligoarthritis, proinflammatory response to self HLA epitopes, 2721  
   oligoarthritis, single-nucleotide polymorphism-tagged TNF haplotypes in, 3304  
   sacroiliitis in, 986  
   systemic disease, IL-18 and, 2539  
 Juvenile rheumatoid arthritis (JRA)  
   ACR 2001 Slide Competition winners, 1160  
   familial autoimmunity and, 1851  
   IL-15 inhibition of fibroblast and endothelial cell apoptosis, 3010  
   intraarticular corticosteroids for coxitis in, 1620  
   oligoarticular, early joint involvement predicts disease progression, 2708  
   Still's disease, etanercept treatment, 1171

## K

Keratoconjunctivitis sicca, in SS, cevimeline therapy, 748  
 Kidneys  
   lupus nephritis, diffuse proliferative lupus glomerulonephritis, sequential oral cyclophosphamide and azathioprine, 1003  
   lupus nephritis, Euro-Lupus Nephritis Trial for cyclophosphamide, 2121  
   lupus nephritis, selective accumulation of CCR4+ T lymphocytes in, 735  
   lupus nephritis, T cell receptor V $\beta$  gene in, 2141  
   lupus nephritis, total lymphoid irradiation for, 1014  
   proliferative lupus nephritis, choosing treatment, 1981  
   proliferative lupus nephritis, renal flares following pulse immunosuppressive therapy, 995  
   RA, infliximab treatment of renal amyloidosis, 2571  
   RA, nephrotic syndrome associated with anti-TNF $\alpha$  therapy, 1691  
   SLE, increased renal disease in familial-male SLE, 428  
   SSc, predictors and outcomes of renal crisis, 2836, 2983  
 Knee  
   MMPs in articular cartilage during growth, maturation, and aging of mice, 3240  
   OA, avoidance of activity and disability, 1784  
   OA, BMD and fracture in knee OA, 92  
   OA, change in tibial cartilage volume in, 2065  
   OA, estrogen replacement therapy and OA severity, 1956  
   OA, IL-1 gene cluster and susceptibility to knee OA, 1519  
   OA, increased bone resorption in, 3178  
   OA, intraarticular hyaluronate injections in chondrocalcinosis, 847  
   OA, linkage on chromosome 2q and hand and knee OA, 3386  
   OA, prevalence of lateral knee OA in Chinese vs US subjects, 1217  
   OA, progressive cartilage loss, MRI study of risk factors, 2884  
   OA, reproducibility of semiflexed MTP view, 109  
   OA, tidal irrigation for, 100  
   OA, trabecular architecture using high-resolution MRI, 385  
   OA, type II collagen synthesis and degradation, 2613  
   OA, varus and valgus misalignment and disease progression by disease stage, 2632  
   osteonecrosis, cartilage damage determination by joint fluid analysis, 1813  
   progressive thinning of cartilage in absence of normal joint loading and movement, 2073  
   RA, synovial tissue from knee joint compared with small joint, 2034  
 Knee replacement  
   OA, ethnic/racial differences in willingness to consider, 2429

## Knee replacement (cont'd)

- OA, timing of total joint replacement affects outcomes, 3327

## L

### La antigen

- candidate T cell epitopes of human La/SSB autoantigen, 209
- subcellular redistribution of La/SSB during physiologic apoptosis, mouse study, 202

### Labial salivary gland biopsy, microchimerism in SSc and SS, 1039

### Laboratory tests, likelihood ratios and, 2547

- Larsen/Scott scoring method, in RA, minimal clinically important difference by, 913

### Laser-based imaging, in RA, finger joint inflammation, 1177

### Lavage, urea as passive transport marker, 420

### Lectin-like oxidized LDL receptor 1, in zymosan-induced arthritis, 2486

### Leflunomide, in RA, MRI assessment of treatment with, 366

### LeRoy, E. Carwile, in memoriam, 2564

### Leukotriene B<sub>4</sub>, OA osteoblasts and, 1804

### Licofelone, in OA, leukotriene B<sub>4</sub> and, 1804

### Likelihood ratios, immunologic laboratory tests and, 2547

### Line immunoassay, citrullinated RA-specific epitopes in natural filagrin for autoantibody detection by line immunoassay, 1185

### Lipoprotein lipase, in SLE, anti-lipase and dyslipidemia in, 2957

### 5-lipoxygenase inhibition

- OA osteoblasts, leukotriene B<sub>4</sub> and, 1804

- SSc, Lyprinol trial, 1977

### Lip salivary gland biopsy. See Labial salivary gland biopsy

### Listeria monocytogenes infection, anti-TNF $\alpha$ and, 2255

### Low-density lipoprotein, lectin-like oxidized LDL receptor 1 in zymosan-induced arthritis, 2486

### Lower limbs, nonrandom evolution of end-stage OA of, 3185

### LSm4, autoantibodies to following EBV infection, 726

### Lungs. See Pulmonary function; Pulmonary hypertension

### Lupus nephritis

- cyclophosphamide therapy for, 2121
- diffuse proliferative lupus glomerulonephritis, sequential oral cyclophosphamide and azathioprine, 1003

- Fc $\gamma$  receptor IIa polymorphism and susceptibility to, 1563

- IL-18, up-regulation of with disease activity, 3083

- immunosuppressive therapy: Euro-Lupus Nephritis Trial of cyclophosphamide, 2121

- proliferative lupus nephritis, choosing treatment, 1981

- renal flares following pulse immunosuppressive therapy, 995

- selective accumulation of CCR4+ T lymphocytes in, 735

- T cell receptor V $\beta$  gene in, 2141

- total lymphoid irradiation for, 1014

### Lupus-related hemophagocytic syndrome, 2537

### Lyme disease, vaccination for, economics of, 1439, 1651

### Lymphocytes, RA, CD13/aminopeptidase N-induced lymphocyte involvement in inflamed joints, 2330

### Lymphoma, anti-TNF treatment and development of, 3151

### Lymphopenia, RA, profound lymphopenia following CD4 monoclonal antibody therapy, morbidity and, 1973

### Lymphoproliferative disease, in SS, long-term risk of, 741

### Lyprinol, in SSc, trial of, 1977

## M

### Macroglossia, and tongue myositis in polymyositis, 2762

### Macrophage migration inhibitory factor gene, mutation screening of, 2402

### Macrophages

- disposal of monosodium urate monohydrate crystals by, 3026

- folate-targeted imaging in rats, 1947

- JIA, migration inhibitory factor in, 232

- RA, macrophage subpopulations in synovium, 1210

### Macrophages (cont'd)

- SLE, impaired uptake of apoptotic cells into tingible body macrophages in germinal centers, 191

### Macrophagic myofasciitis, HLA-DRB1\*01 and, 2535

### Magnesium, DM and juvenile DM, abnormalities of in skeletal muscle, 475

### Magnetic resonance imaging (MRI)

- FM, augmented pain processing in, 1333

- knee, progressive thinning of knee cartilage in absence of normal joint loading and movement, 2073

- neuropathic joint disease, prediction of progressive joint destruction by, 2814

- OA, change in tibial cartilage volume in knee, 2065

- OA, risk factors for progressive cartilage loss, 2884

- OA, trabecular architecture of knee using high-resolution MRI, 385
- plantar fasciitis, biomechanical factors and HLA-B27 in bone changes, 489

- RA, comparative assessment of leflunomide and MTX by dynamic enhanced MRI, 366

- RA, subtalar and midtarsal joint architecture, 3168

- Takayasu arteritis, 1634

- wrist, osteoid osteoma of capitate, 2808

### Magnetic resonance spectroscopy

- DM and juvenile DM, magnesium abnormalities of skeletal muscle in, 475

- fluoroquinolone-induced myalgia investigated with <sup>31</sup>P magnetic resonance spectroscopy, 774

### Magnetization transfer imaging, neuropsychiatric SLE, global brain damage in, 2665

### Major histocompatibility complex (MHC)

- CD+ T cells analyzed using MHC class II tetramers, 5

- PM and DM, MHC class I expression, 1044

- PsA, in endogenous MHC class II-deficient mice, 2465

- SSc, male offspring T cells reactive against maternal MHC, 445

### Malignancy

- lymphoma development and anti-TNF treatment, 3151

- neural network as cancer predictor in inflammatory myopathies, 2547

### Mannose-binding lectin genotypes, RA outcomes and, 555

### Matrix metalloproteinase (MMP)

- modulation in chondrocytes by IL-1 and oncostatin M, 961

- RA, enhancement of production of in, 373

- in temporomandibular and knee joints of mice during growth, maturation, and aging, 3240

- as therapeutic targets, 13

### Matrix metalloproteinase 1 (MMP-1)

- OA, collagen degradation and, 2087

- RA, collagenase 3 stimulation by collagen matrix in synovial fibroblasts, mouse model, 64

### Matrix metalloproteinase 3 (MMP-3)

- ciprofloxacin enhancement of expression in tendon-derived cells, 3034

- hip OA, increased circulating MMP-3 and MMP-9 in rapidly destructive disease, 2625

- RA, MMP-3 gene polymorphism in, 1754

- RA, regulation by Wnt signaling in synovocytes, 2867

- stimulation of release from chondrocytes by interaction of stromal cell-derived factor 1 and CXCR4 chemokine receptor 4, 130

### Matrix metalloproteinase 9 (MMP-9)

- hip OA, increased circulating MMP-3 and MMP-9 in rapidly destructive disease, 2625

- suppression by cepharanthine, 1585

### Matrix metalloproteinase 13 (MMP-13)

- chondrocyte integrin signaling and, 2368

- OA, collagen degradation and, 2087

- OA, collagenase expression in chondrocytes, 2648



- Matrix metalloproteinase 13 (MMP-13) (*cont'd*)  
 RA, collagenase 3 stimulation by collagen matrix in synovial fibroblasts, mouse model, 64
- McEwen, Dr. O. Currier, 100th birthday tributes, 1162
- Mediators, cytokine-induced production of proinflammatory mediators in cartilage, 968
- Medical costs  
 AS, functional disability predicts total costs, 223  
 Lyme disease, vaccination for, 1439, 1651  
 RA, modeling disease progression, 2310
- MEFV gene, reduced mRNA expression in familial Mediterranean fever, 2785
- Melanocortin type 3 receptor, gouty arthritis, melanocortin type 3 receptor agonists and, 2765
- Menopause  
 OA, estrogen replacement therapy and OA severity, 1956  
 SLE risk and, 1830
- Mesenchymal cells, collagen-induced arthritis, TNF-dependent infiltration of, 507
- Mesenchymal progenitor cells, isolation and characterization of, 3349
- Mesenchymal stem cells, in advanced OA, 704
- Messenger RNA (mRNA)  
 familial Mediterranean fever, reduced MEFV expression, 2785  
 OA, collagenase and aggrecanase expression in chondrocytes, 2648  
 OA, regional quantification of collagen and aggrecan mRNA in, 1536
- Mestizo population, myopathy phenotypes and genotypes, 1885
- Metatarsophalangeal (MTP) joint, knee OA, reproducibility of semi-flexed joint view, 109
- Methotrexate (MTX)  
 GCA treatment, 1309  
 RA, COBRA combination therapy for early disease, long-term benefits of, 347  
 RA, combination treatment with anakinra, 614  
 RA, comparison of combination therapies for, 1164  
 RA, folic acid and folinic acid supplementation with, 1413  
 RA, MRI assessment of treatment with, 366  
 RA, radiographic healing and sustained remission, 2804  
 RA, two-year radiographic and clinical outcomes, 1443  
 SSc treatment, early diffuse disease, 845
- Methylprednisolone, proliferative lupus nephritis, renal flares following pulse therapy, 995
- Microarray analysis  
 gene expression profile of cultured human chondrocytes, 404  
 gene expression profiles and arthritis research, 874  
 guidelines for studies, 859  
 proteomics technologies, 885
- Microchimerism  
 pregnancy and, 291  
 SS, labial salivary glands, 1039  
 SSc, 445, 1039, 2538
- Microparticles, in inflamed arthritis joints, 2857
- Microscopic polyangiitis, ANCA, clinical and prognostic value of, 278
- Microvascular endothelium, synovium-specific homing peptides, 2109
- Midtarsal joint, joint architecture by MRI, 3168
- Migration inhibitory factor, in JIA, 232
- Mitochondria, SLE, hypopolarization of in, 175
- Mixed connective tissue disease, anti-U1 RNP antibodies in, 3273
- Mixed cryoglobulinemia, rituximab treatment, 2252
- Molecular markers, RA, predicting joint destruction in early disease, 21
- Monarticular arthritis, antiarthritic activity of orally active C5a antagonist, 2476
- Monkey studies, estrogen replacement therapy and OA severity, 1956
- Monoclonal antibodies  
 anticardiolipin antibodies in platelet interaction with subendothelium, 3283
- Monoclonal antibodies (*cont'd*)  
 RA, anti-IL-6 receptor monoclonal antibody in, 3143  
 RA, profound lymphopenia following CD4 monoclonal antibody therapy, 1973  
 SLE, anti-CD154 treatment, 3251  
 Still's disease, monoclonal anti-IL-6 receptor antibody for treatment, 3388
- Monoclonal gammopathy, crystal-induced arthritis mimicking RA, 2816
- Monocytes  
 HLA-B27 modulates NF- $\kappa$ B activation in, 2172  
 RA, CD14+, CD16+ blood monocytes and joint inflammation, 2578  
 stromal cell-derived factor 1 (CXCL12) and monocyte localization to synovium, 824
- Monocytic fasciitis, in TRAPS, 2189
- Monosodium urate monohydrate crystals  
 disposal by differentiated macrophages, 3026  
 gouty arthritis, melanocortin type 3 receptor agonists and, 2765  
 IL-10 and inflammation induced by, 2504  
 inflammation induced by in vivo, 1643
- Morbidity  
 total lymphoid irradiation for lupus nephritis, 1014  
*See also Outcomes*
- Mortality  
 inflammatory polyarthritis early disease, 2010  
 RA, 40-year trends in Rochester, MN, 625, 3107  
 RA, accelerated atherosclerosis and, 862  
 SS, long-term risk of, 741  
*See also Outcomes*
- Mouse models  
 adjuvant-induced arthritis, murine recombinant soluble IL-17R:Fc fusion protein treatment, 802  
 amyloidosis, fenofibrate inhibition of, 1683  
 antiphospholipid antibodies, induction in mice by viral peptide, 545  
 $\beta_2$ -glycoprotein I immunization and loss of tolerance, 1399  
 chondroprotective effect of TNF $\alpha$ -stimulated gene 6 protein in, 2207  
 collagen-induced arthritis, angiostatin gene transfer in, 793  
 collagen-induced arthritis, antagonism of cell adhesion by fibronectin peptides, 1102  
 collagen-induced arthritis, attenuated by Bcl-x<sub>L</sub> expression, 514  
 collagen-induced arthritis, c-Jun N-terminal kinase, role of in, 818  
 collagen-induced arthritis, complement inhibition in, 3065  
 collagen-induced arthritis, immunogenicity of recombinant type IX collagen in, 1086  
 collagen-induced arthritis, osteopontin expression at sites of bone erosion, 1094  
 collagen-induced arthritis, peptide-induced suppression of, 3369  
 collagen-induced arthritis, shared B cell epitopes, 2339  
 collagen-induced arthritis, TNF-dependent infiltration of mesenchymal cells, 507  
 collagen-induced arthritis, TSG-6 transgene and susceptibility, 2453  
 genetic basis of arthritis in MRL/lpr mice, 1067  
 group B streptococci-induced arthritis, beneficial effect of IL-12 mediated by IFN $\gamma$  and IL-10, 806  
 heat-labile enterotoxin B subunit prevents autoimmune arthritis by induction of CD4+ T cells, 1671  
 IL-1 and autoimmune arthritis, 533  
 IL-10 and monosodium urate monohydrate crystal-induced inflammation, 2504  
 IL-12 gene transfer and chronic destructive arthritis, 1379  
 lupus nephritis, up-regulation of IL-18 with disease activity, 3083  
 MMPs in temporomandibular and knee joints during growth, maturation, and aging, 3240  
 neonatal lupus, organ-specific binding of anti-La/SSB antibodies to fetal apoptotic cells, 1572, 2247  
 osteolysis, osteoprotegerin gene transfer protects against, 2514

# Mouse models (*cont'd*)

- PsA, in endogenous MHC class II-deficient mice, 2465
- RA, collagenase 3 stimulation by collagen matrix, 64
- RA, shared B cell epitopes, 2339
- RA, vitamin E and joint destruction and clinical inflammation in transgenic mouse, 522
- SLE, pristane and, 2235
- SS, C57BL/6 mouse model, 1390
- SSc, intravenous immunoglobulin therapy for skin fibrosis, 1689
- stromal cell-derived factor 1 (CXCL12) and monocyte localization to synovium, 824
- subcellular redistribution of La/SSB during physiologic apoptosis, 202
- synovium-specific homing peptides, 2109
- Muckle-Wells syndrome, *NALP3/CIAS1/PYPAF1* mutations in, 2445
- Muscles
  - DM and juvenile DM, magnesium abnormalities in, 475
  - fluoroquinolone-induced myalgia investigated with <sup>31</sup>P magnetic resonance spectroscopy and in vitro contracture tests, 774
  - knee OA, avoidance of activity and disability in, 1784
  - myeloma-associated amyloidosis, skeletal muscle pseudo-hypertrophy in, 2251
  - PM and DM, MHC class I expression in type II muscle fibers, 1044
- Mutations
  - autosomal-dominant recurrent fever, *TNFRSF1A* mutation in family with, 1061
  - bone morphogenetic protein receptor type II and pulmonary hypertension and connective tissue disease, 2829
  - CARD15* mutations in familial granulomatosis syndromes, 3041
  - macrophage migration inhibitory factor gene, mutation screening of, 2402
  - NALP3/CIAS1/PYPAF1* mutations and periodic fever syndromes, 2445
  - neonatal-onset multisystem inflammatory disease, *CIAS1* mutations, 3340
  - SLE, *DNASE1* mutation and, 1974, 3109
  - SpA, *CARD15/NO2* analyses in, 1405
  - TRAPS, *TNFRSF1A* mutation, 245, 2181
  - See also* Genetics; Gene transfer; Polymorphisms
- Myalgia, fluoroquinolone-induced, investigated with <sup>31</sup>P magnetic resonance spectroscopy and in vitro contracture tests, 774
- Mycobacterium butyricum* adjuvant-induced arthritis, genetic analysis of, 1075
- Myeloma
  - myeloma-associated amyloidosis, skeletal muscle pseudo-hypertrophy in, 2251
  - POEMS syndrome, osteosclerotic myeloma associated with, 1968
- Myeloperoxidase, ANCA-associated vasculitis, 1894
- Myosin, immune response targets in juvenile DM, 3015
- Myositis
  - in Mesoamerican Mestizos, phenotypes and genotypes, 1885
  - tongue myositis in polymyositis, 2762

# N

- Nanoparticles, oral tolerance induction by poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen, 1109
- Native American population, rheumatoid factor in Pima Indians, 1729
- Natural killer cells (NK cells), in inflamed joints, 1763
- Needle tidal irrigation, for OA, 100
- Neonatal lupus
  - congenital heart block, biomarkers for fetal risk of, 1233
  - immunoglobulin G antibodies reactive with SSA/Ro-SSB/La complex in breast milk, 269
  - long-term followup, 2377
  - organ-specific binding of anti-La/SSB antibodies to fetal apoptotic cells, 1572, 2247

# Neonatal lupus (*cont'd*)

- subcellular redistribution of La/SSB during physiologic apoptosis, mouse study, 202
- Neonatal-onset multisystem inflammatory disease, *CIAS1* mutations, 3340
- Nephritis, lupus. *See* Lupus nephritis
- Nephritis flare, proliferative lupus nephritis, renal flares following pulse immunosuppressive therapy, 995
- Nephropathy, nephrotic syndrome associated with RA therapy, 1691
- Nerve growth, inhibition by human intervertebral disc aggrecan, 2658
- Neural network, as cancer predictor in inflammatory myopathies, 2547
- Neuropathic joint disease, MRI prediction of progressive joint destruction, 2814
- Neuropathy, in SLE, 1228
- Neuropsychiatric SLE, global brain damage and clinical functioning, 2665
- Neutropenia, anti-G-CSF autoantibodies in Felty's syndrome and neutropenic SLE, 2384
- Neutrophil Fcγ receptor IIIb (CD16), in phagocytosis, bacterial killing, and responses to immune complexes, 1351
- Nimesulide, peroxisome proliferator-activated receptor-induced COX-2 expression inhibited by, 494
- N*-iminoethyl-L-lysine, inhibits chondrocyte IL-1-converting enzyme and IL-18, 2637
- N*-iminoethyl-[L4]-lysine inhibits chondrocyte IL-1-converting enzyme and IL-18, 2637
- Nitric oxide
  - chondrocyte survival and, 394
  - cytokine-induced production of proinflammatory mediators in cartilage, 968
  - production of in chondrocytes inhibited by green tea, 2079
  - up-regulation of chondrocyte IL-1-converting enzyme and IL-18, 2637
- Nitrotyrosine, in aging and OA cartilage, 2349
- NOD2* variants, spondylarthritis and, 1629
- Nodules in RA, etanercept and, 559, 843
- Nonsteroidal antiinflammatory drugs (NSAIDs)
  - acetaminophen vs NSAIDs in elderly adults, 3046
  - RA, ACR Guidelines for management of, 2002 update, 328, 3102, 3103
  - underuse of gastroprotective measures, 2195
- Norwegian population, JIA, HLA class I region susceptibility gene, 1614
- Nuclear factor κB (NF-κB)
  - Bcl-3 gene and transcription of MMP1 gene, 3230
  - HLA-B27 modulates activation of in monocytes, 2172
  - RA, NF-κB pathway in TNFα production in, 31
  - SS, MMP-9 suppression by cepharanthine, 1585
- Nuclear lamin B1 autoantibodies, thromboprotection in SLE, 2695
- Nucleosomes, T cell autoimmunity to in normal immune system and SLE, 1270

# O

- Occupational exposure, SLE risk and crystalline silica, 1840
- Older adults, acetaminophen vs traditional NSAIDs in, 3046
- Oligoarthritis
  - juvenile idiopathic oligoarthritis, linkage of HLA loci in, 2716
  - juvenile idiopathic oligoarthritis, proinflammatory response to self HLA epitopes, 2721
  - juvenile idiopathic oligoarthritis, single-nucleotide polymorphism-tagged TNF haplotypes in, 3304
  - oligoarticular JRA, early joint involvement predicts disease progression, 2708
- Oligodeoxynucleotides, reduction of CpG-induced arthritis by, 2219
- Oncostatin M, modulation of MMP and ADAM gene expression in chondrocytes by, 961

Oral tolerance induction, by poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen, 1109

**Osteoarthritis (OA)**  
 $\alpha 5 \beta 1$  integrin and chondrocyte survival, 1528  
 acetaminophen treatment, 2831  
 ankle, joint distraction in severe disease, 2893  
 apoptosis induction by growth-related oncogene  $\alpha$  in chondrocytes, 3201  
 BMD and fracture in knee OA, 92  
 bone mass, fractures and, 1  
 cartilage degeneration: apoptosis and cellular vitality, 1986  
 cartilage degeneration, biomarkers for progression of, 2549  
 cartilage degradation modulated by COX-2-dependent prostaglandin  $E_2$ , 1789  
 cathepsin K and cartilage degeneration, 953  
 cathepsin K and S expression in synovium, 663  
 chondrocytes, stromal cell-derived factor 1 and CXC chemokine receptor 4 in, 130  
 collagen degradation, MMP-1 and MMP-13 and, 2087  
 end-stage OA of lower limbs, 3185  
 estrogen replacement therapy and OA severity, monkey model, 1956  
 ethnic health disparities in, NIAMS conference report, 2280  
 exogenous expression of telomerase for expansion of chondrocytes, 683  
 FLIP in, 1512  
 glycation increases collagen stiffness in cartilage, 114  
 hand, linkage on chromosome 2q of hand and knee OA, 3386  
 hip, finer linkage mapping of an OA locus, 1780  
 hip, increased circulating MMP-3 and MMP-9 in rapidly destructive disease, 2625  
 hip, prevalence of hip OA in Chinese vs US subjects, 1773  
 hip, timing of total joint replacement affects outcomes, 3327  
 hip, triamcinolone for, 2546  
 IL-1 gene cluster and susceptibility to knee OA, 1519  
 inhibition of insulin-like growth factor binding protein 5 proteolysis, 694  
 insulin-like growth factor binding proteins in cartilage, 2358  
 intraarticular hyaluronate injections in knee chondrocalcinosis, 847  
 joint distraction, 2893  
 joint replacement, ethnic/racial differences in willingness to consider, 2429  
 joint replacement, timing of knee or hip replacement affects outcomes, 3327  
 knee, avoidance of activity and disability in, 1784  
 knee, change in tibial cartilage volume in, 2065  
 knee, increased bone resorption in, 3178  
 knee, linkage on chromosome 2q of hand and knee OA, 3386  
 knee, pain reduces joint space width in anteroposterior radiographs, 1223  
 knee, prevalence of lateral knee OA in Chinese vs US subjects, 1217  
 knee, progressive cartilage loss, MRI study of risk factors, 2884  
 knee, type II collagen synthesis and degradation, 2613  
 knee, varus and valgus misalignment and disease progression by disease stage, 2632  
 leukotriene  $B_4$  in osteoblasts, 1804  
 mesenchymal stem cells in advanced disease, 704  
 MMPs as therapeutic targets, 13  
 n-3 fatty acids and human cartilage, 1544  
 nitric oxide-mediated chondrocyte cell death with additional reactive oxygen species, 394  
 nitric oxide-mediated up-regulation of chondrocyte IL-1-converting enzyme and IL-18, 2637  
 oral glucosamine and cartilage and meniscus, 2495  
 oxidative damage and, 2349  
 T cells and pathogenesis, 3112  
 tidal irrigation as treatment, 100  
 total hip replacement, complications, 2436

**Osteoarthritis (OA) (cont'd)**  
 total hip replacement, risk factors for, 675  
 TUNEL labeling in determining apoptosis in cartilage, 2260

**Osteoblasts, OA, leukotriene  $B_4$  in, 1804**

**Osteochondral repair, tissue-engineered composites for, 2524**

**Osteoclasts, TNF $\alpha$ -mediated joint destruction inhibited by osteoprotegerin, 785**

**Osteoid osteoma, of the capitate, 2808**

**Osteolysis**  
 osteoprotegerin gene transfer protects against, 2514  
 viral IL-10 gene inhibition of in response to titanium particles, 1298

**Osteonecrosis, knee, cartilage damage determination by joint fluid analysis, 1813**

**Osteopenia, quantitative computed tomography to predict vertebral fractures in postmenopausal women, 1292**

**Osteopontin, expression of at sites of bone erosion in collagen-induced arthritis, 1094**

**Osteoporosis**  
 COL1A1 polymorphism and, 2828  
 glucocorticoid-induced, 3115, 3136  
 OA, bone mass, and fractures, 1  
 vertebral fractures, quantitative computed tomography to predict in postmenopausal women, 1292

**Osteoprotegerin**  
 adjuvant-induced arthritis, bone protection by osteoprotegerin therapy in rats, 1926  
 AS, increased level in, 3390  
 gene transfer protects against osteolysis, 2514  
 in RA, as antiosteoclast factor for protecting bone, 3121  
 in RA, high levels of after anti-TNF $\alpha$  treatment, 1744  
 TNF $\alpha$ -mediated joint destruction inhibited by, 785

**Osteosclerotic myeloma, POEMS syndrome and, 1968**

**Outcomes**  
 JIA, long-term outcomes, 2392  
 knee or hip OA, timing of total joint replacement, 3327  
 RA, mannose-binding lectin genotypes and, 555  
 SSc renal crisis, 2836, 2983  
 SSc with Raynaud's phenomenon, outcomes measures for disease activity and functional status, 2410  
 See also Morbidity; Mortality

**Oxidative damage, in aging and OA cartilage, 2349**

**Oxidized ATP, inflammatory pain relieved by, 3378**

## P

**Pain**  
 bilateral forearm pain, chronic exertional compartment syndrome as cause of, 2245  
 FM, augmented pain processing in, 1333  
 heel pain in SpA, response to infliximab shown by ultrasound, 840  
 inflammatory pain relieved by oxidized ATP, 3378  
 OA, knee pain reduces joint space width in anteroposterior radiographs, 1223  
 somatization and chronic widespread pain, 1129  
 unrecognized SAPHO as rare cause of chronic anterior chest pain, 566

**Pamidronate, AS, trial for, 766**

**Pannus, neovascularization suppressed by inhibition of IL-1 but not TNF, 2604**

**Paraoxonase, SLE and APS, correlation with antibodies to high-density lipoprotein and  $\beta_2$ -glycoprotein I, 2686**

**Parvovirus B19**  
 infection of cultured skin fibroblasts in SSc, 2262  
 PCR detection in GCA, 3099

**Pathogens. See names of specific pathogens**

**Pauciarticular juvenile rheumatoid arthritis (JRA), early joint involvement predicts disease progression, 2708**

**Pediatric Quality of Life Inventory, 714**

- Pediatrics. *See* Children; Juvenile dermatomyositis; Juvenile idiopathic arthritis; Juvenile rheumatoid arthritis; Neonatal lupus
- Peptides
- citrullinated, ANCA-associated vasculitis, absence of anti-cyclic citrullinated peptide antibodies in, 849
  - citrullinated, deiminated recombinant rat filaggrin antibodies, ELISA detection, 2051
  - citrullinated, RA-specific epitopes in natural filaggrin for autoantibody detection by line immunoassay, 1185
  - collagen-induced arthritis, antagonism by fibronectin peptides, 1102
  - collagen-induced arthritis, peptide-induced suppression of, 3369
  - synovium-specific homing peptides, 2109
  - viral peptides, antiphospholipid antibodies induced in mice by, 545
- Periodic fever syndromes. *See* Recurrent fever syndromes
- Peripheral neuropathy, in SLE, 1228
- Peroxisome proliferator-activated receptor
- inflammation and, 598
  - nimesulide, COX-2 expression inhibited by, 494
- Peroxisome proliferator-activated receptor  $\gamma$  agonists, potential for treating inflammation, 598
- Phagocytosis, neutrophil Fc $\gamma$  receptor IIIb (CD16) in phagocytosis, 1351
- Pharmacoeconomics, RA, modeling disease progression, 2310
- Phosphatidylinositol 3-kinase
- RA, TGF $\beta$ -mediated phosphorylation of Akt, 1504
  - RA, TNF $\alpha$  production in and, 31
- Photodynamic therapy, for synovitis, 1371
- Pima Indians, rheumatoid factor in, 1729
- Plantar fasciitis, biomechanical factors and HLA-B27 in MRI bone changes, 489
- Plasma cells, CD154-CD40 interactions mediate plasma cell differentiation in SLE, 1417
- Plasma dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes (POEMS syndrome), osteosclerotic myeloma associated with, 1968
- Plasminogen activator/plasmin system, RA and, 2268
- Plasticity, of stem cells, 855
- Platelet-derived microparticles, RA, elevated levels of and disease activity, 1498
- Platelets, monoclonal anticardiolipin antibodies in platelet interaction with subendothelium,  $\beta_2$ -glycoprotein I and, 3283
- Poetry, "On My Knees," 2264
- Polyarthritis, crystal-induced arthritis mimicking RA, 2816
- Poly(lactic-co-glycolic acid), oral tolerance induction by poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen, 1109
- Polymerase chain reaction (PCR)
- GCA, parvovirus DNA in, 3099
  - RA, RNA arbitrarily primed-PCR for gene expression, 52
  - Whipple's disease, testing for, 1130
- Polymorphisms
- AS, *NOD2* variants, 1629
  - COL1A1* gene, osteoporosis and, 2828
  - juvenile idiopathic oligoarthritis, single-nucleotide polymorphism-tagged TNF haplotypes in, 3304
  - macrophage migration inhibitory factor gene, mutation screening of, 2402
  - OA, IL-1 gene cluster and susceptibility to knee OA, 1519
  - osteoporosis and *COL1A1* Sp1 polymorphism, 2828
  - RA, Fc $\gamma$  receptor IIIA polymorphism and, 556
  - RA, glutathione S-transferase M1 polymorphism and, 640
  - RA, MMP-3 and HLA-DRB1 gene polymorphisms in, 1754
  - serotonin transporter promoter region (5-HTTLPR) polymorphism, FM and anxiety-related personality traits, 845
  - SLE, Fc $\gamma$  receptor gene polymorphisms, 1125, 1242, 1563
  - SLE, Fc $\gamma$  receptor IIa polymorphism and, 1125, 1563
  - SpA, *NOD2* variants, 1629
  - SSc, *SPARC* polymorphisms, 2990
- Polymorphisms (*cont'd*)
- TNF receptor genes, single-nucleotide polymorphisms, 2045
  - TNF receptor II and IL-6 gene polymorphisms, hypertension with RA and, 3096
- See also* Genetics; Gene transfer; Mutations
- Polymyositis (PM)
- IL-1 $\alpha$  and MHC class I expression in, 1044
  - intravenous immunoglobulin infusions in chronic, refractory disease, 467
  - macroglossia and tongue myositis in, 2762
- Polyneuropathy, POEMS syndrome, osteosclerotic myeloma associated with, 1968
- Polyphenols, nitric oxide production in chondrocytes inhibited by green tea, 2079
- Polysaturated fatty acids, OA, n-3 fatty acids and human cartilage, 1544
- Prasterone, SLE, effect on corticosteroid requirements in, 1820
- Predictors
- AS, functional disability predicts total costs, 223
  - Charcot joint, MRI prediction of progressive joint destruction, 2814
  - JIA, sacroiliitis in, 986
  - neural network as cancer predictor in inflammatory myopathies, 2547
  - neuropathic joint disease, MRI prediction of progressive joint destruction, 2814
  - OA, progression of joint damage, 2613
  - oligoarticular JRA, early pattern of joint involvement predicts disease progression, 2708
  - RA, early arthritis: new prognostic criteria, 286
  - RA, infection in, 2294
  - RA, joint damage prediction by molecular markers, 21
  - RA, joint damage prediction in early disease by bone and joint markers, 2847
  - RA, prediction of persistent erosive arthritis, 357
  - RA, rheumatoid factor as predictor of increasing severity of, 906
  - SLE, predicting damage in childhood SLE, 436
  - SS, long-term risk of mortality and lymphoproliferative disease, 741
  - SSc renal crisis, 2836, 2983
  - vertebral fractures, quantitative computed tomography to predict, 1292
- Prednisolone, COBRA combination therapy for early RA, long-term benefits of, 347
- Pregnancy
- APS, gonadotropin-releasing hormone agonists and, 2542
  - APS, thromboembolic events after fetal loss in, 1126
  - gonadotropin-releasing hormone agonists and, 2542
  - microchimerism in autoimmune disease, 291
  - SLE, gonadotropin-releasing hormone agonists and, 2542
  - SSc, 291, 451
- Pristane
- genetic link between acute-phase response and arthritis development, 259
  - SLE pathogenesis in mice, 2235
- Prolactin, SLE risk and, 1830
- Proliferating cell nuclear antigen, SLE, autoimmune response to, 2946
- Proliferative lupus glomerulonephritis
- sequential oral cyclophosphamide and azathioprine for, 1003
  - total lymphoid irradiation for, 1014
- Proliferative lupus nephritis
- renal flares following pulse immunosuppressive therapy, 995
  - treatment for, 1981
- Pro-myeloperoxidase, as target antigen for ANCA, 1127
- Prostaglandin E $_2$
- cytokine-induced production of proinflammatory mediators in cartilage, 968
  - OA cartilage degradation modulated by COX-2-dependent prostaglandin E $_2$ , 1789



Prosthetic joints, osteoprotegerin gene transfer protects against osteolysis, 2514  
 Proteinase 3, ANCA-associated vasculitis, 1894  
 Proteinuria, renal amyloidosis treated with infliximab, 2571  
 Proteinuric flare, proliferative lupus nephritis, renal flares following pulse immunosuppressive therapy, 995  
 Proteoglycan  
   catabolism in articular cartilage, cyclosporin A inhibition of, 124  
   OA, cartilage degradation modulated by COX-2-dependent prostaglandin E<sub>2</sub>, 1789  
 Proteolysis, OA, inhibition of insulin-like growth factor binding protein 5 proteolysis, 694  
 Protoporphyrin IX, photodynamic therapy for synovitis, 1371  
 Pseudocysts, gouty tophi in pancreatic pseudocyst, 565  
 Psoriatic arthritis (PsA)  
   alefacept treatment, 2776  
   anti-TNF $\alpha$  rechallenge, 3107  
   in endogenous MHC class II-deficient mice, 2465  
 Pulmonary function, SLE, autologous stem cell transplantation in refractory disease with pulmonary impairment, 1580  
 Pulmonary hypertension  
   in autoimmune rheumatic diseases, update, 1997  
   bone morphogenetic protein receptor type II mutations and, 2829  
 PYP $AF1$  mutations, periodic fever syndromes and, 2445  
 Pyridinoline, decreased level in AS, 3390

## Q

Quality of life  
   health-related quality of life in AS, 3098  
   Pediatric Quality of Life Inventory, 714  
 Quantitative computed tomography, to predict vertebral fractures in postmenopausal women, 1292  
 Questionnaires  
   AS, functional disability predicts total costs in, 223  
   AS, health-related quality of life, 3098  
   Pediatric Quality of Life Inventory, 714

## R

Rabbit models  
   glucosamine, effect on cartilage and meniscus, 2495  
   hylan, severe adverse reactions, 2543  
   tissue-engineered composites for osteochondral repair, 2524  
 Racial differences  
   acceptance of treatment modalities and, 2265, 2429  
   NIAMS conference report, 2280  
   TNF receptor genes, single-nucleotide polymorphisms in, 2045  
   willingness to consider joint replacement for joint or hip OA, 2429  
 Radiography  
   JIA, sacroiliitis in, 986  
   OA, BMD and knee fracture, 92  
   OA, knee pain reduces joint space width, 1223  
   OA, reproducibility of semiflexed MTP view in knee OA, 109  
   OA, whole-genome scan for hand OA, 946  
   RA, minimal clinically important difference in joint damage by 2 scoring methods, 913  
   RA, MTX and etanercept therapy and two-year radiographic and clinical outcomes, 1443  
   RA, MTX therapy and radiographic healing and sustained remission, 2804  
   RA, rheumatoid factor as predictor of increasing severity of erosions, 906  
   Randomized clinical trials, secular changes in quality of published trials, 779  
 Rat models  
   adjuvant-induced arthritis, bone protection by osteoprotegerin therapy, 1926

Rat models (cont'd)  
   adjuvant-induced arthritis, murine recombinant soluble IL-17R:Fc fusion protein treatment in rats, 802  
   adjuvant-induced arthritis, spinal adenosine receptor activation and, 3076  
   antiarthritic activity of orally active C5a antagonist, 2476  
   deiminated recombinant rat filaggrin antibodies, ELISA detection, 2051  
   folate-targeted imaging in rats, 1947  
   genetic link between acute-phase response and arthritis development, 259  
   high mobility group box chromosomal protein 1 as proinflammatory mediator in synovitis, 2598  
   inflammatory pain relieved by oxidized ATP, 3378  
   lectin-like oxidized low-density lipoprotein receptor 1 in zymosan-induced arthritis, 2486  
   monosodium urate monohydrate crystal-induced inflammation, 1643  
   *Mycobacterium butyricum* adjuvant-induced arthritis, genetic analysis of, 1075  
   neovascularization suppressed by inhibition of IL-1 but not TNF, 2604  
   quantitative trait loci regions modulate experimental arthritis, 2225  
 Raynaud's phenomenon  
   disease activity and functional status in SSc with, 2410  
   F<sub>2</sub>-isoprostanes in, 1319  
 Reactive amyloidosis  
   conversion of serum amyloid A into extracellular amyloid, 1905  
   infliximab treatment of renal amyloidosis, 2571  
 Reactive arthritis  
   diagnosis of, 319  
   HLA-B27 modulates NF- $\kappa$ B activation in monocytes, 2172  
   steroid hormones, IL-6, and TNF in early disease, 654  
   synovial lymphocyte responses to antigen stimulation, 2259  
 Reactive oxygen species  
   nitric oxide-mediated chondrocyte cell death, 394  
   RA, vitamin E and joint destruction and clinical inflammation in, 522  
 Receptor activator of NF- $\kappa$ B (RANK), expression and inflammation in collagen-induced arthritis, 3055  
 Receptor activator of NF- $\kappa$ B ligand (RANKL), high levels of after anti-TNF $\alpha$  RA treatment, 1744  
 Recombination activating genes 1 and 2, in SLE, 1255  
 Recurrent fever syndromes  
   familial Mediterranean fever, reduced MEFV mRNA expression in, 2785  
   hyperimmunoglobulinemia D and periodic fever syndrome, lack of isoprenoids raises IL-1 $\beta$ , 2794  
   NALP3/CIAS1/PYPAF1 mutations in, 2445  
   TNFRSF1A mutation in family with autosomal-dominant recurrent fever, 1061  
   TRAPS, frequency, clinical signs, and genotypic features of, 2181  
   TRAPS, monocytic fasciitis as clinical feature of, 2189  
   TRAPS, TNFRSF1A mutation, 245, 2181  
 Relapsing polychondritis, type II collagen peptide-specific T cell clones in, 238  
 Renal amyloidosis, infliximab treatment, 2571  
 Renal disease. See Kidneys  
 Renal flares in proliferative lupus nephritis following pulse immunosuppressive therapy, 995  
 Reoxygenation, cytokine-induced production of proinflammatory mediators in cartilage and, 968  
 Replicative aging, of articular chondrocytes, 2911  
 Reproductive factors, SSc and, 291, 451  
 Retroviruses, from synovial fibroblasts and synovial fluid cells in RA, 2811  
 Reverse transcriptase, autoimmune diseases and, 1412

## Rheumatic diseases

- pulmonary hypertension in, update, 1997
- silicone breast implants and, 2545
- Rheumatoid arthritis (RA)
  - 40-year trends in incidence and mortality in Rochester, MN, 625, 3107
  - ACR Guidelines for management of, 2002 update, 328
  - ANCA-associated vasculitis differential diagnosis, absence of anti-cyclic citrullinated peptide antibodies, 849
  - anti-IL-6 receptor monoclonal antibody in, 3143
  - anti-p53 antibodies, absence of in Chinese populations, 276
  - anti-TNF treatment and lymphoma development, 3151
  - anti-TNF $\alpha$  treatment, high levels of osteoprotegerin and sRANKL, 1744
  - anti-TNF $\alpha$  treatment, radiographic damage inhibition with minimal or no clinical improvement, 2817
  - anti-TNF $\alpha$  treatment, regression of subacute cutaneous SLE and, 1408
  - anti-TNF $\alpha$  treatment, very high-dose blockade and long-term remission, 1971
  - atherosclerosis and, 862, 1489, 1714
  - autoantibodies to  $\alpha$ -enolase in early disease, 1196
  - B cell-ablative therapy, 1984
  - B cell blockade for, 2029
  - bone loss in, 1720
  - cachexia not due to decreased growth hormone secretion, 2574
  - caffeine intolerance and susceptibility, 3104
  - cathepsin K and S expression in synovium, 663
  - CD13/aminopeptidase N and lymphocyte involvement in inflamed joints, 2330
  - CD14+, CD16+ blood monocytes and joint inflammation, 2578
  - CD34-selected vs hematopoietic stem cell transplantation, 2301
  - CD44 splice variants in fibroblast-like synoviocytes, 2059
  - chondrocytes, stromal cell-derived factor 1 and CXC chemokine receptor 4 in, 130
  - citrullinated peptides in synovial tissue, 2824
  - citrullinated RA-specific epitopes in natural filaggrin for autoantibody detection by line immunoassay, 1185
  - coagulation and plasminogen activator/plasmin system in, 2268
  - COBRA combination therapy for early disease, long-term benefits of, 347
  - coffee, tea, and caffeine consumption as risk factors, 83
  - collagenase 3 stimulation by collagen matrix, mouse model, 64
  - combination therapies for, comparison of, 1164
  - complement proteins in synovium, 934
  - complementary DNA array and RNA arbitrarily primed-PCR for gene expression in, 52
  - contrast ultrasound for detection of finger joint vascularization in, 647
  - corticotropin-releasing hormone genomic haplotype in familial and sporadic RA, 75
  - costimulatory T cell blockade in, 1470
  - criteria for early RA, 1155
  - crystal-induced arthritis mimicking RA, 2816
  - cyclophosphamide with stem cell rescue for, 837
  - cyclosporine regulation of synovial cytokine production, 42
  - decline in incidence, 579
  - delay to therapy and remission induction in early disease, 894
  - diagnosis using ELISA detection of deiminated recombinant rat filaggrin antibodies, 2051
  - disease activity, CD4+, CD57+ T cells in, 379
  - disease progression, modeling in, 2310
  - dynamic strength training, effect on functional capacity, 274
  - early arthritis: criteria for, 1155
  - early arthritis: new prognostic criteria, 286
  - early diagnosis of, 357, 1155
  - early treatment of, 283, 1443

## Rheumatoid arthritis (RA) (cont'd)

- etanercept therapy, effect on tenosynovitis and nodules, 559
- etanercept therapy, nodule development with, 843
- etanercept therapy, two-year radiographic and clinical outcomes, 1443
- expression of extracellular MMP inducer and enhancement of MMP production in, 373
- Fc $\gamma$  receptor IIIA polymorphism and, 556
- Felty's syndrome, anti-G-CSF autoantibodies in, 2384
- finger joint inflammation, laser-based imaging, 1177
- FLIP in, 1512
- gene expression profiles, 874
- glucocorticoid-induced osteoporosis, 3136
- glucocorticoids and, 2553
- heat-shock protein 73 and HLA-DRB1 alleles and, 929
- hematopoietic stem cell transplantation vs CD34-selected, 2301
- high-resolution ultrasound for target joints in, 1969
- HLA class II antigens and joint damage, 899
- HLA-DRB1 shared epitope and sex interaction, 1481
- HLA-DRB1 shared epitope genotype associations in, 2320
- hydroxychloroquine concentration-response relationships in, 1460
- hydroxychloroquine in combination therapies, 1164
- IL-1 and, mouse models, 533
- IL-1 as treatment target, 574, 1690
- IL-15 inhibition of fibroblast and endothelial cell apoptosis, 3010
- infection, predictors of, 2294
- infection frequency in, 2287
- infliximab, bullous skin lesions following infusion, 2257
- infliximab treatment of renal amyloidosis, 2571
- iron deficiency and, 847
- joint damage prediction by molecular markers, 21
- joint damage prediction in early disease by bone and joint markers, 2847
- knee joints vs small joints in, 2034
- lectin-like oxidized low-density lipoprotein receptor 1 in zymosan-induced arthritis, 2486
- lymphoma development and anti-TNF treatment, 3151
- macrophage subpopulations in synovium, 1210
- mannose-binding lectin genotypes and outcome, 555
- migration of CX3CR1+ T cells in synovium, 2878
- minimal clinically important difference in joint damage by two scoring methods, 913
- MMP-3 and HLA-DRB1 gene polymorphisms in, 1754
- MMPs as therapeutic targets, 13
- modeling disease progression in, 2310
- MRI assessment of leflunomide and MTX for, 366
- MTX therapy, folic acid and folinic acid supplementation with, 1413
- MTX therapy, radiographic healing and sustained remission, 2804
- MTX therapy, two-year radiographic and clinical outcomes, 1443
- Mycobacterium butyricum* adjuvant-induced arthritis genetic analysis, RA susceptibility loci and, 1075
- nephrotic syndrome associated with anti-TNF $\alpha$  therapy, 1691
- nitric oxide-mediated chondrocyte cell death with additional reactive oxygen species, 394
- onset following somatostatinoma, 277
- osteoprotegerin and sRANKL, high levels following anti-TNF $\alpha$  treatment, 1744
- platelet microparticles and disease activity, 1498
- prediction of persistent erosive arthritis, 357
- profound lymphopenia following CD4 monoclonal antibody therapy, morbidity and, 1973
- quantitative trait loci regions in congenic rats modulate experimental arthritis, 2225
- retroviruses from synovial fibroblasts and synovial fluid cells, 2811
- rheumatoid factor as predictor of increasing severity of erosions, 906
- rheumatoid factor in Pima Indians, 1729

## Rheumatoid arthritis (RA) (cont'd)

- self-reported RA and SLE, stratification of pedigrees to detect SLE linkage, 2937
  - serum infliximab and clinical improvement in, 1451
  - shared B cell epitopes, 2339
  - shared epitope hypothesis, 921
  - smoking and glutathione S-transferase M1 polymorphism and, 640
  - steroid hormones, IL-6, and TNF in early disease, 654
  - stromal cell-derived factor 1 (CXCL12) and VEGF production, hypoxia-induced, 2587
  - subtalar and midtarsal joint architecture by MRI, 3168
  - susceptibility genes, call for global collaboration, 582
  - synovial lymphocyte responses to antigen stimulation, 2259
  - synovium-specific homing peptides, 2109
  - T cell-independent mechanisms in, 298
  - T cells in synovitis, 3105
  - tacrolimus efficacy in, 2020
  - TGF $\beta$ -mediated phosphorylation of Akt, 1504
  - TNF receptor II and, 2039
  - TNF receptor II and IL-6 gene polymorphisms, hypertension with RA and, 3096
  - TNF $\alpha$ -mediated joint destruction inhibited by osteoprotegerin, 785
  - TNF $\alpha$  production, phosphatidylinositol 3-kinase and NF- $\kappa$ B pathways in, 31
  - Tripterygium wilfordii* hook F in, 1735
  - urgent care and, 851
  - VEGF regulation by cyclosporin A in synovial fibroblasts, 1202
  - vitamin E in transgenic mouse models of, 522
  - whole-genome scan of susceptibility loci, 632
  - Wnt signaling in synoviocytes, 2867
- ## Rheumatoid factor
- in Pima Indians, 1729
  - as predictor of erosions in RA, 906
- ## Rheumatology
- ACR donation of educational materials to international community, 1407
  - FM, value of rheumatologists to FM patients, 3390
  - quality of published randomized clinical trials, 779
  - Ribavirin, hepatitis C virus-related systemic vasculitis treatment, 3317
- ## Rituximab
- cryoglobulinemia treatment, 2252
  - SLE, B lymphocyte depletion, 2673
- ## RNA arbitrarily primed-PCR, RA, gene expression in, 52
- ## RNA polymerase
- polymerase III transcription, autoimmune diseases and, 1412
  - SSc, immunodominant epitope on RNA polymerase III, 2742
- ## RNase MRP/RNase P proteins, SSc, 3266

## S

Sacroiliitis, in JIA, 986

## Salivary glands

- SS, B cell subsets in, 2160
  - SS, infliximab to restore normal aquaporin 5 distribution in, 2249
  - SS, MMP-9 production in acinar cells suppressed by cepharanthine, 1585
  - SS, T cell-attracting chemokines, 2730
  - SSc and SS, microchimerism in labial salivary gland biopsy, 1039
- ## Scleroderma. See Systemic sclerosis
- ## Self epitopes
- juvenile DM, immune response targets in, 3015
  - juvenile idiopathic oligoarthritis, proinflammatory response to self HLA epitopes, 2721
  - self-reported RA and SLE, stratification of pedigrees to detect SLE linkage, 2937

Semiflexed MTP view, knee OA, reproducibility of, 109

Sensorineural deafness, *NALP3/CLAS1/PYPAF1* mutations in, 2445

September 11th, reflections on, 1133

Serotonin transporter promoter region (5-HTTLPR) polymorphism, FM and anxiety-related personality traits, 845

Serum amyloid A, conversion into extracellular amyloid, 1905

Sexual dimorphism, in innate immune response, 250

Shared epitope hypothesis, 921

RA, HLA-DRB1 shared epitope genotype associations in, 2320

RA, shared epitope-sex interactions in, 1480

Sharp/van der Heijde scoring method, RA, minimal clinically important difference by, 913

Sibutramine, for FM, 2545

Signal transduction, SLE, abnormal T cell signal transduction in, 1139

Silica, SLE risk and crystalline silica, 1840

Silicone breast implants, rheumatic diseases and, 2545

Simulation, RA disease progression, 2310

Single-nucleotide polymorphisms

juvenile idiopathic oligoarthritis, single-nucleotide polymorphism-

tagged TNF haplotypes in, 3304

in TNF receptor genes, 2045

Sjögren's syndrome (SS)

B cell subsets in, 2160

CS7BL/6 mouse model, 1390

candidate T cell epitopes of human La/SSB autoantigen, 209

cevimeline for dry mouth and dry eyes, 748

2-chloro-2'-deoxyadenosine treatment, 2248

classification of, 741

cysteine-rich secretory protein 3 gene in, 215

infliximab to restore normal aquaporin 5 distribution in salivary glands, 2249

infliximab treatment of primary disease, 3301

long-term risk of mortality and lymphoproliferative disease, 741

microchimerism in labial salivary glands, 1039

MMP-9 production, suppression in salivary gland acinar cells by cepharanthine, 1585

T cell-attracting chemokines in, 2730

Skeletal muscles, pseudo-hypertrophy in myeloma-associated amyloidosis, 2251

## Skin

fibrosis: SSc and Smads, 1703

hydroxychloroquine, associated mucocutaneous hyperpigmentation associated with, 1698

hydroxychloroquine, cutaneous reactions to, 3392

SSc, intravenous immunoglobulin therapy for skin fibrosis, 1689

*SLER1* gene, stratification of pedigrees to detect SLE linkage, 2937

Smad signaling pathway, SSc and, 1703

Smallest detectable difference, RA, comparison with minimal clinically important difference in joint damage, 913

## Smoking

RA, disease severity and, 640

SSc, smoking as risk factor for digital vascular disease in, 3312

Socioeconomic status, need and willingness to undergo total joint arthroplasty and, 3331

## Somatization

chronic widespread pain and, 1129

in FM, 564

Somatostatinoma, RA following treatment, 277

Spanish population, *DNASE1* mutation and SLE, 1974

*SPARC* polymorphisms, in SSc, 2990

Spinal adenosine receptor, adjuvant-induced arthritis and, 3076

Spinal cord injury, thinning of knee cartilage in absence of normal joint loading and movement, 2073

Spine, quantitative computed tomography to predict vertebral fractures, 1292

## Spondylarthropathy (SpA)

CARD15/NO2 analyses in, 1405

dactylitis, fast spin echo-T2 sequences with fat saturation, 2964

HLA-B\*2709 subtype confers susceptibility to, 553

### Spondylarthropathy (SpA) (cont'd)

- HLA-B27, expression of cell-surface homodimers, 2972
- inflammatory heel pain, response to infliximab shown by ultrasound, 840
- infliximab treatment for uveitis, 2821
- infliximab vs placebo in, 755
- NOD2 variants in, 1629
- plantar fasciitis, biomechanical factors and HLA-B27 in MRI-determined bone changes, 489
- research cutting edge, 606
- TNF $\alpha$  blockade for enthesitis, 3396

Spontaneous osteonecrosis, knee, cartilage damage determination by joint fluid analysis, 1813

### Stem cells

- mesenchymal stem cells in advanced OA, 704
- plasticity of, 855

### Stem cell transplantation

- JIA, decrease in synovial cellularity and cytokine expression after autologous stem cell transplantation in, 1121
- plasticity of hematopoietic stem cells, 855
- RA, CD34-selected vs hematopoietic stem cell transplantation, 2301
- RA, high-dose cyclophosphamide, 837
- SLE, autologous stem cell transplantation in refractory SLE, 1580
- SLE, hematopoietic stem cell transplantation for severe and refractory disease, 2917

Steroid hormones, in early reactive arthritis and RA, 654

Stiff skin syndrome, with limitation of joint mobility, 1978

### Still's disease

- etanercept treatment, 1171
- lupus-related hemophagocytic syndrome presentation similar to, 2537
- monoclonal anti-IL-6 receptor antibody for treatment, 3388

### Streptococci

- Group B streptococci-induced arthritis, beneficial effect of IL-12 on, 806

IL-12 gene transfer and chronic destructive arthritis, 1379

*Streptococcus pyogenes* M5 protein, immune response targets in juvenile DM, 3015

### Stromal cell-derived factor 1

- CXCL12 induces monocyte localization to synovium, 824
- hypoxia-induced production of CXCL12 by synovial fibroblasts, 2587

stimulation of MMP-3 release from chondrocytes by interaction of CXC chemokine receptor 4 and, 130

T cell-attracting chemokines in SS salivary gland lesions, 2730

Stromelysin 1, RA, MMP-3 gene polymorphism in, 1754

Subtalar joint, joint architecture by MRI, 3168

### Sulfasalazine, for RA

- COBRA combination therapy for early disease, long-term benefits of, 347

comparison of combination therapies for, 1164

Suppressive oligodeoxynucleotides, reduction of CpG-induced arthritis by, 2219

### Susceptibility

CARD15 mutations in familial granulomatosis syndromes, 3041

collagen-induced arthritis, TSG-6 transgene and, 2453

JIA, HLA class I region susceptibility gene, 1614

OA, finer linkage mapping of an OA locus, 1780

OA, IL-1 gene cluster and susceptibility to knee OA, 1519

RA, caffeine intolerance and, 3104

RA, *Mycobacterium butyricum* adjuvant-induced arthritis genetic analysis and susceptibility loci, 1075

RA, susceptibility genes, 582

RA, whole-genome scan of susceptibility loci, 632

shared epitope hypothesis, 921

SLE and lupus nephritis, Fc $\gamma$  receptor IIa polymorphism and, 1563

SLE, stratification of pedigrees to detect SLE linkage, 2937

### Susceptibility (cont'd)

SLE, susceptibility genes at 1q23 and 16q12, 2928

SpA, HLA-B\*2709 subtype confers susceptibility, 553

SSc, SPARC polymorphisms and, 2990

Sweet's syndrome, ACR 2001 Slide Competition winners, 1160

Synovial fibroblasts. *See* Fibroblasts

### Synovial fluid

chondroitin sulfates in normal fluid, 2105

knee osteonecrosis, cartilage damage determination by joint fluid analysis, 1813

microparticles in inflamed arthritis joints, 2857

OA, inhibition of insulin-like growth factor binding protein 5 proteolysis in, 694

RA, retroviruses from, 2811

urea as passive transport marker, 420

### Synovial tissue

intracellular citrullinated proteins specific for RA, 2824

JIA, decrease in synovial cellularity after autologous stem cell transplantation, 1121

OA and RA, cathepsin K and S expression in, 663

RA, collagenase 3 stimulation by collagen matrix, 64

RA, complement protein production, 934

RA, expression of extracellular MMP inducer and enhancement of MMP production in, 373

RA, FLIP in, 1512

RA, knee joints vs small joints in, 2034

RA, macrophage subpopulations in synovium, 1210

RA, phosphatidylinositol 3-kinase and NF- $\kappa$ B pathways in TNF $\alpha$  production, 31

RA, TGF $\beta$ -mediated phosphorylation of Akt, 1504

Synoviocytes, in RA

CD44 splice variants, 2059

cyclosporine regulation of cytokine production, 42

Wnt signaling in, 2867

### Synovitis

high mobility group box chromosomal protein 1 proinflammatory mediator in, 2598

protoporphyrin IX photodynamic therapy for, 1371

T cells and, 3105

Synovitis, acne pustulosis, hyperostosis, osteitis (SAPHO)

as rare cause of chronic anterior chest pain, 566

sustained response to anti-TNF $\alpha$ , 1965

### Synovium

COX-2 inhibitors and apoptosis induction in rheumatoid fibroblasts, 3159

IL-15 inhibition of fibroblast and endothelial cell apoptosis, 3010

RA, migration of CX3CR1+ T cells in, 2878

RA, retroviruses from synovial fibroblasts, 2811

RA, stromal cell-derived factor 1 (CXCL12) and VEGF, hypoxia-induced production by synovial fibroblasts, 2587

RA, VEGF regulation by cyclosporin A in synovial fibroblasts, 1202

stromal cell-derived factor 1 (CXCL12) and monocyte localization to, 824

synovial lymphocyte responses to antigen stimulation, 2259

synovium-specific homing peptides, 2109

Systemic lupus erythematosus (SLE)

abnormal T cell signal transduction in, 1139

acquired C1 inhibitor deficiency associated with, separate disease entity?, 2827

anti-CD40 ligand antibody in, 1554

anti-CD154 treatment, 3251

anti-c-Mpl antibody in, 2148

anti-G-CSF autoantibodies in neutropenic SLE, 2384

anti-lipoprotein lipase and dyslipidemia in, 2957

anti-p53 antibodies, absence of in Chinese populations, 276

anti-TNF $\alpha$  RA treatment and regression of subacute cutaneous lupus, 1408



# Systemic lupus erythematosus (SLE) (cont'd)

- autologous stem cell transplantation in refractory disease with pulmonary impairment, 1580
- B cell-ablative therapy for, 1984
- B lymphocyte depletion in, 2673
- candidate T cell epitopes of human La/SSB autoantigen, 209
- CD154-CD40 interactions mediate plasma cell differentiation, 1417
- crystalline silica exposure and risk of, 1840
- defective Fc-mediated immune complex clearance in, 1028
- dehydroepiandrosterone treatment, 1820, 2924
- diffuse proliferative lupus glomerulonephritis, sequential oral cyclophosphamide and azathioprine, 1003
- DNA demethylation changes in, 1282
- DNASE1 mutation and, 1974, 3109
- epidural lipomatosis in, 1291
- epitope spreading in, 1430
- ethnic health disparities in, NIAMS conference report, 2280
- familiality of clinical features, 2678
- Fcγ receptor gene polymorphisms, 1242
- Fcγ receptor IIa polymorphism and, 1125, 1563
- Fcγ receptor IIIa in, 2132
- hematopoietic stem cell transplantation for severe and refractory disease, 2917
- hormonal and reproductive risk factors for, 1830
- hydroxychloroquine, cutaneous reactions to, 3392
- hydroxychloroquine, screening for antimalarial retinopathy, 561
- hydroxychloroquine, transplacental passage of in humans, 1123
- IL-18 in, 1410
- impaired uptake of apoptotic cells in, 191
- increased renal disease in familial male SLE, 428
- lupus nephritis, Fcγ receptor IIa polymorphism and susceptibility to, 1563
- lupus nephritis, immunosuppressive therapy: Euro-Lupus Nephritis Trial of cyclophosphamide, 2121
- lupus nephritis, selective accumulation of CCR4+ T lymphocytes in, 735
- lupus nephritis, T cell receptor Vβ gene in, 2141
- lupus nephritis, total lymphoid irradiation for, 1014
- lupus nephritis, up-regulation of IL-18 with disease activity, 3083
- lupus-related hemophagocytic syndrome, 2537
- mitochondrial hypopolarization and ATP depletion in, 175
- neonatal lupus, fetal risk of congenital heart block, 1233
- neonatal lupus, immunoglobulin G antibodies reactive with SSA/Ro-SSB/La complex in breast milk, 269
- neonatal lupus, long-term followup, 2377
- neonatal lupus, organ-specific binding of anti-La/SSB antibodies to fetal apoptotic cells, 1572, 2247
- neonatal lupus syndrome, subcellular redistribution of La/SSB during physiologic apoptosis, mouse study, 202
- neuropathy in, 1228
- neuropsychiatric, global brain damage and clinical functioning, 2665
- nuclear lamin B1 autoantibodies and thromboprotection, 2695
- para-oxonase activity and antibodies to high-density lipoprotein and β<sub>2</sub>-glycoprotein I, 2686
- prasterone (DHEA) and corticosteroid requirements in, 1820
- pregnancy, gonadotropin-releasing hormone agonists and, 2542
- pristine and pathogenesis of in mice, 2235
- proliferating cell nuclear antigen in, autoimmune response to, 2946
- proliferative lupus nephritis, choosing treatment, 1981
- proliferative lupus nephritis, renal flares following pulse immunosuppressive therapy, 995
- pulmonary hypertension in, 1997
- recombination activating genes 1 and 2 in, 1255
- regression, in RA treated with anti-TNFα, 1408
- RP105-lacking B cells and, 3259
- stratification of pedigrees to detect SLE linkage, 2937
- susceptibility genes at 1q23 and 16q12, 2928

# Systemic lupus erythematosus (SLE) (cont'd)

- T cell receptor ζ chain abnormalities in, 163
  - thrombotic thrombocytopenic purpura in childhood and, 1410
- ## Systemic sclerosis (SSc)
- antifibroblast antibodies in, 1595, 1602
  - assessment of vascular function in, 1324
  - CENP-A/CENP-B-specific immune response in, 1866
  - congenital fascial dystrophy with limitation of joint mobility, 1978
  - disease activity and functional status in SSc with Raynaud's phenomenon, 2410
  - F<sub>2</sub>-isoprostanes in, 1319
  - failure to detect antinucleosome antibodies in, 280
  - granzyme B-generated autoantigen fragments in, 1873
  - immunodominant epitope on RNA polymerase III, 2742
  - intravenous immunoglobulin therapy for skin fibrosis, 1689
  - Lyprinol trial, 1977
  - microchimerism in, 445, 1039, 2538
  - MTX for treatment of early diffuse SSc, 845
  - parvovirus B19 infection of cultured skin fibroblasts, 2262
  - pregnancy and, 291
  - pulmonary hypertension in, 1997
  - renal crisis, predictors and outcomes, 2836, 2983
  - reproductive factors and risk of, 451
  - Smads and, 1703
  - smoking as risk factor for digital vascular disease in, 3312
  - SPARC polymorphisms, 2990
  - TGFβ, induction of fibrillin fibrillogenesis by, 3000
  - TGFβ receptor transcriptional activities in fibroblasts, 2421
  - TGFβ signaling dysregulation in, 1857, 2830
  - Th/To autoantigen, 3266
  - topotecan and development of, 844

## T

- T cell activation, SLE, epitope spreading in, 1430
  - T cell receptors, SLE, ζ chain abnormalities in, 163
- ## T cells
- antigen-responsive immune, in healthy subjects and SLE, 1270
  - anti-proteinase 3- and antimyeloperoxidase-associated vasculitis and, 1894
  - autoimmune, in healthy subjects and SLE, 1270
  - CD4+, MHC class II tetramers for direct analysis, 5
  - childhood-onset disease, predicting damage in, 436
  - chronic rheumatoid synovitis and, 298
  - heat-labile enterotoxin B subunit prevents autoimmune arthritis by induction of CD4+ T cells, 1671
  - juvenile DM, immune response targets in, 3015
  - lupus nephritis, selective accumulation of CCR4+ T lymphocytes in, 735
  - lupus nephritis, T cell receptor Vβ gene in, 2141
  - OA pathogenesis and, 3112
  - PsA, T cell-targeted therapy with alefacept, 2776
  - RA, CD4+, CD57+ T cells in, 379
  - RA, costimulatory T cell blockade in, 1470
  - RA, IL-1 and, 533
  - RA, migration of CX3CR1+ T cells in synovium, 2878
  - RA, phosphatidylinositol 3-kinase and NF-κB pathways in TNFα production, 31
  - RA, synovitis, 3105
  - relapsing polychondritis, type II collagen peptide-specific T cell clones, 238
  - in rheumatoid synovitis, 3105
  - SLE, abnormal T cell signal transduction in, 1139
  - SLE and SS, candidate T cell epitopes of human La/SSB autoantigen, 209
  - SS, T cell-attracting chemokines in, 2730
  - SSc, male offspring T cells in, 445
  - SSc, pathogenic role of long-term fetal microchimerism in, 445

- Tacrolimus, in RA unsuccessfully treated with MTX, 2020
- Takayasu arteritis, 1634
- Tat protein, collagen-induced arthritis, C3-Tat/HIV-regulated IL-1RA gene therapy, 1661
- Tea, as RA risk factor, 83
- Telomerase, exogenous expression of, for expansion of OA chondrocytes, 683
- Temporal arteritis, *Chlamydia pneumoniae* and, 1056
- Temporomandibular joint, MMPs in articular cartilage during growth, maturation, and aging of mice, 3240
- Tendinopathy, MMP-3 expression in tendon-derived cells and ciprofloxacin, 3034
- Tenosynovitis, RA, etanercept and, 559
- Tensile strength, of cartilage, advanced glycation end products and, 3212
- Thiazolidinediones, peroxisome proliferator-activated receptor  $\gamma$  agonists for treating inflammation, 598
- Thrombocytopenia, anti-c-Mpl antibody in SLE, 2148
- Thrombopoietin receptor, anti-c-Mpl antibody in SLE, 2148
- Thrombosis
- APS, thromboembolic events after fetal loss in, 1126
  - caused by antiphospholipid antibodies induced in mice by viral peptides, 545
  - SLE, nuclear lamin B1 autoantibodies and thromboprotection, 2695
- Thrombotic thrombocytopenic purpura, SLE and, in childhood, 1410
- Th/To autoantigen, in SSc, 3266
- Tidal irrigation, for OA, 100
- Time trends, RA, 40-year trends in incidence and mortality in Rochester, MN, 625
- Tingible body macrophages, SLE, impaired uptake of apoptotic cells into, 191
- Tissue inhibitor of metalloproteinases 4 (TIMP-4), adjuvant-induced arthritis, inhibition by TIMP-4 gene delivery, 3361
- Titanium, viral IL-10 gene inhibition of osteolysis in response to, 1298
- TNFR2* gene, RA and, 2039
- TNFRSF1A* mutation
- in autosomal-dominant recurrent fever, 1061
  - in TRAPS, 245, 2181
- Tongue, macroglossia and tongue myositis in polymyositis, 2762
- Tophi, gouty tophi in pancreatic pseudocyst, 565
- Topotecan, SSc development and, 844
- Total joint replacement, in OA
- complications, 2436
  - education and income and need and willingness to undergo, 3331
  - nonrandom evolution of end-stage OA of lower limbs, 3185
  - risk factors for, 675
  - timing of affects outcomes, 3327
- Total lymphoid irradiation, for lupus nephritis, 1014
- Trabecular bone structure, knee OA, using high-resolution MRI, 385
- Transforming growth factor  $\beta$  (TGF $\beta$ )
- RA, TGF $\beta$ -mediated phosphorylation of Akt, 1504
  - SSc, dysregulation of signaling pathway in, 1857, 2830
  - SSc, induction of fibrillin fibrillogenesis by, 3000
- Transforming growth factor  $\beta$  receptors, transcriptional activities in SSc fibroblasts, 2421
- Triamcinolone
- for hip OA, 2546
  - JRA, intraarticular corticosteroids for coxitis in, 1620
- Tripterygium wilfordii* hook F, in RA, 1735
- Tristetraprolin, function, expression, and subcellular distribution of, 1362
- Tropheryma whippelii*, PCR for testing for, 1130
- TSG-6 protein, chondroprotective effect of, 2207
- TSG-6 transgene, susceptibility to collagen-induced arthritis and, 2453
- Tumor necrosis factor  $\alpha$  (TNF $\alpha$ )
- collagen-induced arthritis, TNF-dependent infiltration of mesenchymal cells, 507
  - Tumor necrosis factor  $\alpha$  (TNF $\alpha$ ) (*cont'd*)
  - joint destruction inhibited by osteoprotegerin, 785
  - neovascularization suppressed by inhibition of IL-1 but not TNF, 2604
  - RA, cyclosporine regulation of synovocyte cytokine production, 42
  - RA, TNF $\alpha$  production, phosphatidylinositol 3-kinase and NF- $\kappa$ B pathways in, 31
  - reactive arthritis and RA, steroid hormones, IL-6, and TNF in early disease, 654
  - sexual dimorphism in innate immune response, 250
- Tumor necrosis factor receptor-associated periodic syndrome (TRAPS)
- in Arab population, 245
  - frequency, clinical signs, and genotypic features of, 2181
  - monocytic fasciitis as clinical feature of, 2189
  - TNFRSF1A* mutation, 245, 2181
- Tumor necrosis factor receptor genes, single-nucleotide polymorphisms, 2045
- Tumor necrosis factor receptor I (TNF receptor I), autosomal-dominant recurrent fever, *TNFRSF1A* mutation in family with, 1061
- Tumor necrosis factor receptor II (TNF receptor II)
- familial but not sporadic RA, 2039
  - hypertension with RA and gene polymorphisms, 3096
- TUNEL labeling, in determining apoptosis in OA cartilage, 2260
- Type II collagen
- collagen-induced arthritis, peptide-induced suppression of, 3369
  - fibronectin-induced degradation of through IL-1-mediated pathway, 138
  - knee OA, synthesis and degradation, 2613
  - matrix homeostasis in aging ankle cartilage, 2903
  - OA, collagen degradation, MMP-1 and MMP-13 and, 2087
  - OA, regional quantification of collagen and aggrecan mRNA in, 1536
  - oral tolerance induction by poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen, 1109
  - relapsing polychondritis, type II collagen peptide-specific T cell clones in, 238
- Type II mixed cryoglobulinemia, rituximab treatment, 2252
- Typhoid fever, APS and, 850

## U

- U1-70 kd antibodies, apoptosis-specific, 1264
- Ultrasound
- carpal tunnel syndrome, sonographic criteria for diagnosis of, 1914
  - inflammatory heel pain in SpA, response to infliximab shown by, 840
  - RA, arterial intima-media thickness detected by, 1489
  - RA, atherosclerosis in, 1714
  - RA, color Doppler ultrasound to detect finger joint vascularization in, 647
  - RA, high-resolution ultrasound for target joints in, 1969
- Ultraviolet light, light-activated gene transduction in chondrocytes, 2095
- Urate crystals. *See* Monosodium urate monohydrate crystals
- Urea, as passive transport marker, 420
- Uric acid, gouty tophi in pancreatic pseudocyst, 565
- Uveitis
- anti-TNF $\alpha$  treatment with infliximab, 2821
  - management of, 309

## V

- Vaccination, for Lyme disease, economics of, 1439, 1651
- Valgus/varus misalignment, knee OA progression by disease stage, 2632
- Vascular disease, SSc, smoking as risk factor for digital vascular disease in, 3312

Vascular endothelial growth factor (VEGF)

- hypoxia-induced production by synovial fibroblasts, 2587
- regulation by cyclosporin A in synovial fibroblasts, 1202

Vascular function, in SSc, 1324

Vascularization

- RA, color Doppler ultrasound to detect finger joint vascularization, 647
- suppressed by inhibition of IL-1 but not TNF, 2604

Vasculitis

- ANCA-associated vasculitis, absence of anti-cyclic citrullinated peptide antibodies in, 849
- ANCA-associated vasculitis, cytokine and T cell response to proteinase 3 and myeloperoxidase in, 1894
- GCA, acetylsalicylic acid therapy for, 457
- hepatitis C infection and, 585
- hepatitis C-related systemic vasculitis, IFN $\alpha$  and ribavirin treatment, 3317
- Takayasu arteritis, 1634
- temporal arteritis and *Chlamydia pneumoniae*, 1056
- type II mixed cryoglobulinemia, rituximab treatment, 2252

Vasoactive intestinal peptide, collagen-induced arthritis, therapeutic effect in, 271

Vertebral fractures, quantitative computed tomography to predict, in postmenopausal women, 1292

Viral peptides, antiphospholipid antibodies induced in mice by, 545

Vitamin E, RA, joint destruction and clinical inflammation in, 522

W

Wegener's granulomatosis (WG), clinical and prognostic value of ANCA in, 278

West African population, HLA-B\*1403 associated with AS, 2968

Whipple's disease, PCR for testing for, 1130

Whole-genome scan

hand OA, 946

RA, susceptibility loci, 632

Wnt signaling, RA synoviocytes, regulation of fibronectin and metalloproteinase expression by, 2867

Wound healing, fibrosis: SSc and Smads, 1703

Wrist

osteoid osteoma of capitate, 2808

RA, MTX therapy and radiographic healing and sustained remission, 2804

X

Xerostomia, in SS, cevimeline therapy, 748

Z

Zinc-finger proteins, tristetraprolin, function, expression, and subcellular distribution of, 1362

Zymosan-induced arthritis, lectin-like oxidized low-density lipoprotein receptor 1 in, 2486